<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">94794</article-id><article-id pub-id-type="doi">10.7554/eLife.94794</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.94794.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>Cell-autonomous and non-cell-autonomous effects of Arginase 2 on cardiac aging</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Potenza</surname><given-names>Duilio M</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2442-9154</contrib-id><email>duilio.potenza@unifr.ch</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Cheng</surname><given-names>Xin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Ajalbert</surname><given-names>Guillaume</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Brenna</surname><given-names>Andrea</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8542-9855</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Giraud</surname><given-names>Marie-Noelle</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Frobert</surname><given-names>Aurelien</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Cook</surname><given-names>Stephane</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Mertz</surname><given-names>Kirsten D</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Yang</surname><given-names>Zhihong</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4133-5099</contrib-id><email>zhihong.yang@unifr.ch</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Ming</surname><given-names>Xiu-Fen</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5848-4496</contrib-id><email>xiu-fen.ming@unifr.ch</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/022fs9h90</institution-id><institution>Laboratory of Cardiovascular and Aging Research, University of Fribourg</institution></institution-wrap><addr-line><named-content content-type="city">Fribourg</named-content></addr-line><country>Switzerland</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/022fs9h90</institution-id><institution>Cardiology, Department of Endocrinology, Metabolism, and Cardiovascular System, Faculty of Science and Medicine, University of Fribourg</institution></institution-wrap><addr-line><named-content content-type="city">Fribourg</named-content></addr-line><country>Switzerland</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00rm7zs53</institution-id><institution>Institute for Pathology, Cantonal Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Baar</named-content></addr-line><country>Switzerland</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Radisic</surname><given-names>Milica</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03dbr7087</institution-id><institution>University of Toronto</institution></institution-wrap><addr-line><named-content content-type="city">Toronto</named-content></addr-line><country>Canada</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Bhargava</surname><given-names>Balram</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0492wrx28</institution-id><institution>Indian Council of Medical Research</institution></institution-wrap><addr-line><named-content content-type="city">New Delhi</named-content></addr-line><country>India</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>04</day><month>11</month><year>2025</year></pub-date><volume>13</volume><elocation-id>RP94794</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2024-01-17"><day>17</day><month>01</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2024-01-20"><day>20</day><month>01</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.01.17.576017"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-04-02"><day>02</day><month>04</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.94794.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-06-16"><day>16</day><month>06</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.94794.2"/></event></pub-history><permissions><copyright-statement>© 2024, Potenza et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Potenza et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-94794-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-94794-figures-v1.pdf"/><related-article related-article-type="commentary" ext-link-type="doi" xlink:href="10.7554/eLife.107882" id="ra1"/><abstract><p>Aging is a predominant risk factor for heart disease. Aging heart reveals low-grade chronic inflammation, cell apoptosis, cardiac fibrosis, and increased vulnerability to ischemic injury. The underlying molecular mechanisms responsible for cardiac aging and its susceptibility to injury are not fully understood. Although literature reports a role for mitochondrial Arginase 2 (ARG2) in heart failure, contradictory results are reported. How ARG2 participates in cardiac aging is still unknown. In this study, we demonstrate that <italic>Arg2</italic> is not expressed in cardiomyocytes from aged mice and humans but is upregulated in non-myocyte cells, including macrophages, fibroblasts, and endothelial cells. Mice with genetic deficiency of <italic>Arg2</italic> (<italic>Arg2<sup>-/-</sup></italic>) are protected from age-associated cardiac inflammation, myocyte apoptosis, interstitial and perivascular fibrosis, endothelial-mesenchymal transition (EndMT), and susceptibility to ischemic injury. Further experiments show that ARG2 mediates IL-1β release from macrophages of old mice, contributing to the cardiac aging phenotype. In addition, ARG2 enhances mitochondrial reactive oxygen species (mtROS) and activates cardiac fibroblasts that is inhibited by inhibition of mtROS. Thus, our study demonstrates a non-cell-autonomous effect of ARG2 on cardiomyocytes, fibroblasts, and endothelial cells mediated by IL-1β from aging macrophages as well as a cell-autonomous effect of ARG2 through mtROS in fibroblasts contributing to cardiac aging phenotype.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>Aging</kwd><kwd>arginase</kwd><kwd>heart</kwd><kwd>inflammtion</kwd><kwd>fibrosis</kwd><kwd>macrophages</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd><kwd>Rat</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00yjd3n13</institution-id><institution>Swiss National Science Foundation</institution></institution-wrap></funding-source><award-id>31003A_179261/1</award-id><principal-award-recipient><name><surname>Yang</surname><given-names>Zhihong</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01k789405</institution-id><institution>Swiss Heart Foundation</institution></institution-wrap></funding-source><award-id>FF19033</award-id><principal-award-recipient><name><surname>Ming</surname><given-names>Xiu-Fen</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Arginase 2 in macrophages promotes cardiac aging phenotype via paracrine release of IL-1β.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p> Aging is a predominant risk factor for cardiovascular disease (CVD; <xref ref-type="bibr" rid="bib56">Moturi et al., 2022</xref>). Cardiac aging is accompanied by low-grade chronic inflammation termed ‘inflammaging’ (<xref ref-type="bibr" rid="bib11">Cevenini et al., 2013</xref>), which is linked to gradual development of cardiac fibrosis and heart failure, whereby macrophages, cardiac fibroblasts, and endothelial cells play critical roles in age-associated cardiac remodeling and dysfunction (<xref ref-type="bibr" rid="bib1">Abdellatif et al., 2023</xref>; <xref ref-type="bibr" rid="bib50">Meschiari et al., 2017</xref>). Studies in experimental animal models and in humans provide evidence demonstrating that aging heart is more vulnerable to stressors such as ischemia/reperfusion injury and myocardial infarction and exhibits less efficient reparative capability after injury as compared to the heart of young individuals (<xref ref-type="bibr" rid="bib9">Bujak et al., 2008</xref>; <xref ref-type="bibr" rid="bib48">Mariani et al., 2000</xref>). Even in the heart of apparently healthy individuals of old age, chronic inflammation, cardiomyocyte senescence, cell apoptosis, interstitial/perivascular tissue fibrosis, endothelial dysfunctio,n and endothelial-mesenchymal transition (EndMT), and cardiac dysfunction either with preserved or reduced ejection fraction rate are observed (<xref ref-type="bibr" rid="bib1">Abdellatif et al., 2023</xref>; <xref ref-type="bibr" rid="bib64">Ruiz-Meana et al., 2020</xref>). Despite the intensive investigation in the past, the underlying causative cellular and molecular mechanisms responsible for the cardiac aging phenotype and the susceptibility of aging heart to injurious stressors are not fully elucidated yet. Moreover, most preclinical studies preferentially use relatively juvenile animal models that hardly recapitulate clinical scenarios. It is therefore critical to investigate mechanisms of cardiac aging phenotype with a naturally advanced aging animal model.</p><p> Research in the past years suggests a wide range of functions of the enzyme arginase, including the cytosolic isoenzyme Arginase 1 (ARG1) and the mitochondrial isoenzyme Arginase 2 (ARG2) in organismal aging as well as age-related organ structural remodeling and functional changes (<xref ref-type="bibr" rid="bib10">Caldwell et al., 2015</xref>; <xref ref-type="bibr" rid="bib39">Li et al., 2022</xref>). These functions of arginase have been implicated in cardiac and vascular aging (<xref ref-type="bibr" rid="bib82">Yepuri et al., 2012</xref>) and cardiac ischemia/reperfusion injury in rodents (<xref ref-type="bibr" rid="bib35">Jung et al., 2010</xref>). ARG1, originally found in hepatocytes, plays a crucial role in the urea cycle in the liver to remove ammonia from the blood (<xref ref-type="bibr" rid="bib66">Sin et al., 2015</xref>), whereas ARG2 is inducible in many cell types under pathological conditions, contributing to chronic tissue inflammation and remodeling (<xref ref-type="bibr" rid="bib55">Moretto et al., 2019</xref>). Both enzymes are able to catalyze the divalent cation-dependent hydrolysis of L-arginine (<xref ref-type="bibr" rid="bib54">Ming and Yang, 2013</xref>). Studies in the literature, including our own, demonstrate that ARG2 is involved in the aging process and promotes organ inflammation and fibrosis, and inhibition of arginase or genetic ablation of <italic>Arg2</italic> slows down the aging process and protects against age-associated organ degeneration such as lung (<xref ref-type="bibr" rid="bib86">Zhu et al., 2023</xref>), pancreas (<xref ref-type="bibr" rid="bib78">Xiong et al., 2017b</xref>), and heart (<xref ref-type="bibr" rid="bib77">Xiong et al., 2017a</xref>). However, controversial results on expression of arginase and its isoforms at the cellular levels in the heart are reported. While some studies linked ARG1 to the cardiac ischemia/reperfusion injury (<xref ref-type="bibr" rid="bib35">Jung et al., 2010</xref>), others suggest a role of ARG2 in this context (<xref ref-type="bibr" rid="bib25">Heusch et al., 2010</xref>). Even protective functions of ARG2 are suggested in some studies, based on correlation of ARG2 levels with cardiac injury or systemic administration of ARG2 in rat models (<xref ref-type="bibr" rid="bib29">Huang et al., 2018</xref>; <xref ref-type="bibr" rid="bib44">Lu et al., 2012</xref>). Importantly, cellular localization of arginase and its isoenzyme in the heart, that is expression of arginase in cardiomyocytes and non-cardiomyocytes hase not been systematically analyzed and confirmed. Finally, whether and how ARG2 participates in cardiac aging and whether it is through cell-autonomous and/or paracrine effects are not known.</p><p>Therefore, our current study is aimed at investigating which cell types in the heart express arginase and what enzymatic isoforms. How arginase and this isoenzyme in these cells influence the cardiac aging process and enhance susceptibility of the aging heart to ischemia/reperfusion injury.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Increased <italic>Arg2</italic> expression in aging heart</title><p>In heart from young (3–4 months in age) and old (22–24 months in age) mice, an age-associated increase in <italic>Arg2</italic> expression in both wt male and female mice is observed (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). This age-associated increase in <italic>Arg2</italic> expression is more pronounced in females than in males (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). In contrast to <italic>Arg2</italic>, <italic>Arg1</italic> mRNA expression is very low in the heart (with very high Ct values, data not shown), and no age-dependent changes of <italic>Arg1</italic> gene expression are observed in wt and in <italic>Arg2<sup>-/-</sup></italic> mice of either gender (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A and B</xref>), suggesting a specific enhancement of ARG2 in aging heart. Further experiments are thus focused on ARG2 and female mice. We made efforts to analyze ARG2 protein levels by immunoblotting in the heart tissues. However, immunoblotting is not sensitive enough to detect ARG2 protein in the heart tissue of either young or old animals. Therefore, further experiments are performed to detect ARG2 protein at the cellular level with confocal microscopic immunofluorescence staining as described in later sections.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Age-associated increase in Arg2 levels in mouse heart.</title><p>(<bold>A</bold>) <italic>Arg2</italic> mRNA levels of male and female young (3–4 months) and old (20–22 months) wild type (wt) heart tissues analyzed by qRT-PCR. <italic>Rps12</italic> served as the reference (n=8–9 animals per group); (<bold>B</bold>) Representative histological images of heart interstitial and perivascular fibrosis in young and old wt and <italic>Arg2<sup>-/-</sup></italic> female mice. Fibrosis is shown by the blue-colored Trichrome Masson’s staining. Scale bar = 50 µm. (n=5–7 mice per group); (<bold>C</bold>) Quantification of total fibrotic area in cardiac tissue (% of total area); (<bold>D</bold>) Hydroxyproline content of mouse heart from young and old wt and <italic>Arg2<sup>-/-</sup></italic> female mice. (n=4 mice in each group); (<bold>E</bold>) Representative confocal images showing immunofluorescence staining of PDGF-Rα (green, fibroblasts marker) in young and old wt and <italic>Arg2<sup>-/-</sup></italic> heart tissue. DAPI (blue) is used to stain nuclei. Scale bar = 50 µm; (<bold>F</bold>) Relative PDGF-Rα signal quantification of confocal images (n=4 per each group). (<bold>G</bold>) Representative confocal images showing immunofluorescence staining of p16 (green, senescent marker) in young and old wt and <italic>Arg2<sup>-/-</sup></italic> heart tissue. DAPI (blue) is used to stain nuclei. Scale bar = 50 µm; (<bold>H</bold>) Percentage of p16<sup>+</sup> nuclei in the four groups (n=4). The values shown are mean ± SD. Data are presented as the fold change to the young-<italic>wt</italic> group, except for panel <bold>D</bold>. *p≤0.05, **p≤0.01, ***p≤0.005, ****p≤0.001 between the indicated groups. wt, wild-type mice; <italic>Arg2<sup>-/-</sup></italic>, <italic>Arg2</italic> gene knockout mice.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-94794-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title><italic>Arg2</italic> and <italic>Arg1</italic> expression in male and female mice.</title><p><italic>Arg1</italic> mRNA levels of female (<bold>A</bold>) and male (<bold>B</bold>) young (3–4 months) and old (20–22 months) wild type (wt) heart tissues analyzed by qRT-PCR. <italic>Rps12</italic> served as the reference (n=6–7 animals per group); <italic>Arg2</italic> (<bold>C</bold>) and <italic>Arg1</italic> (<bold>D</bold>) expression extrapolated from high throughput sequencing database of male mice of 6, 18, and 27 months old (GSE201207, <xref ref-type="bibr" rid="bib75">Wolff et al., 2023</xref>). Data are presented as the fold change to the young-wt group. *p≤0.05 between the indicated groups. wt, wild-type mice; <italic>Arg2<sup>-/-</sup></italic>, <italic>Arg2</italic> gene knockout mice.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-94794-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Collagen gene expression in female mice.</title><p>(<bold>A</bold>) <italic>Col1a1</italic> and (<bold>B</bold>) <italic>Col3a1</italic> mRNA levels of young (3–4 months) and old (20–22 months) wt and <italic>Arg2<sup>-/-</sup></italic> female heart tissues analyzed by qRT-PCR. <italic>Rps12</italic> served as the reference (n=6–9 animals per group). Data are presented as the fold change to the young-wt group. *p≤0.05, **p≤0.01 between the indicated groups. wt, wild-type mice; <italic>Arg2<sup>-/-</sup></italic>, <italic>Arg2</italic> gene knockout mice.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-94794-fig1-figsupp2-v1.tif"/></fig></fig-group></sec><sec id="s2-2"><title><italic>Arg2</italic> ablation reduces cardiac aging phenotype</title><p>Next, we investigated the impact of <italic>Arg2</italic> ablation on cardiac phenotype. Masson’s staining reveals an enhanced peri-vascular and interstitial fibrosis in wt old mice, which is mitigated in age-matched <italic>Arg2<sup>-/-</sup></italic> animals (<xref ref-type="fig" rid="fig1">Figure 1B and C</xref>). The age-associated increase in cardiac fibrosis and its inhibition by <italic>Arg2<sup>-/-</sup></italic> are further confirmed by quantitative measurements of collagen content as assayed by determination of hydroxyproline levels in the heart tissues (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). The increased cardiac fibrosis in aging is, however, associated with decreased mRNA levels of <italic>collagen1α</italic> (<italic>Col3a1</italic>) and <italic>collagen3α</italic> (<italic>Col3al</italic>), the major isoforms of pre-collagen in the heart (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A and B</xref>), which is a well-known phenomenon in cardiac fibrotic remodeling (<xref ref-type="bibr" rid="bib6">Besse et al., 1994</xref>; <xref ref-type="bibr" rid="bib27">Horn and Trafford, 2016</xref>). The results demonstrate that age-associated cardiac fibrosis and prevention in <italic>Arg2<sup>-/-</sup></italic> mice are due to alterations of translational and/or post-translational regulations including collagen synthesis and/or degradation. Furthermore, an increased density of fibroblasts as characterized by positive staining of PDGF-Rα is observed in wt old mice, but not in age-matched <italic>Arg2<sup>-/-</sup></italic> animals (<xref ref-type="fig" rid="fig1">Figure 1E</xref> and <xref ref-type="fig" rid="fig1">Figure 1F</xref>). Interestingly, an age-associated increase in p16<sup>ink4</sup> positive senescent cells in wt mouse heart is prevented in the <italic>Arg2<sup>-/-</sup></italic> animals (<xref ref-type="fig" rid="fig1">Figure 1G and H</xref>).</p><p>Moreover, a significant increase in macrophage marker <italic>Adgre1</italic> (corresponding to F4-80 protein; <xref ref-type="fig" rid="fig2">Figure 2A</xref>) and elevated gene expression of numerous pro-inflammatory cytokines such as <italic>Mcp1</italic>, <italic>Il1b,</italic> and <italic>Tnfa</italic> are observed in aging heart of wt mice (<xref ref-type="fig" rid="fig2">Figure 2B–D</xref>). This age-associated increase in the inflammatory markers and cytokine gene expression (except <italic>Tnfa</italic>) is overall significantly reduced or prevented in <italic>Arg2<sup>-/-</sup></italic> mice (<xref ref-type="fig" rid="fig2">Figure 2A–D</xref>). In line with the gene expression of <italic>Adgre1</italic>, immunofluorescence staining reveals an age-associated increase in the numbers of F4-80<sup>+</sup> cells in the wt mouse heart, which is reduced in the age-matched <italic>Arg2<sup>-/-</sup></italic> animals (<xref ref-type="fig" rid="fig2">Figure 2E–G</xref>), demonstrating that <italic>Arg2</italic> gene ablation reduces macrophage accumulation in the aging heart. Interestingly, resident macrophages characterized by LYVE1<sup>+</sup>/F4-80<sup>+</sup> cells (<xref ref-type="fig" rid="fig2">Figure 2E and H</xref>; <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>) are predominant in the aging heart as compared to the infiltrated CCR2<sup>+</sup>/F4-80<sup>+</sup> cells (<xref ref-type="fig" rid="fig2">Figure 2F and I</xref>; <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>). The increase in both LYVE1<sup>+</sup>/F4-80<sup>+</sup> and CCR2<sup>+</sup>/F4-80<sup>+</sup> macrophages in aging heart is reduced in <italic>Arg2<sup>-/-</sup></italic> mice (<xref ref-type="fig" rid="fig2">Figure 2E, F, H and I</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Age-associated elevation in inflammatory cytokines and apoptosis in heart is prevented in female <italic>Arg2<sup>-/-</sup></italic> mice.</title><p>mRNA expression levels of (<bold>A</bold>) <italic>Adgre1</italic>, (<bold>B</bold>) <italic>Mcp-1</italic>, (<bold>C</bold>) <italic>Il1b,</italic> and (<bold>D</bold>) <italic>Tnfa</italic> in young and old wt and <italic>Arg2<sup>-/-</sup></italic> female mouse hearts were analyzed by qRT-PCR. <italic>Rps12</italic> served as the reference (n=6–12 mice per group); (<bold>E</bold>) Representative confocal images of young and old wt and <italic>Arg2<sup>-/-</sup></italic> heart tissue showing co-localization of LYVE1 (green) and F4-80 (red, mouse macrophage marker), (<bold>F</bold>) Representative co-localization images of CCR2 (green) and F4-80 (red) in wt and <italic>Arg2<sup>-/-</sup></italic> heart tissues. DAPI (blue) is used to stain nuclei. Scale bar = 50 µm. Graph showing the quantification of (<bold>G</bold>) F4-80<sup>+</sup> cells, (<bold>H</bold>) LYVE1<sup>+</sup>/F4-80<sup>+</sup> cells, and (<bold>I</bold>) CCR2<sup>+</sup>/F4-80<sup>+</sup> cells per mm<sup>2</sup> in heart tissue of wt and <italic>Arg2<sup>-/-</sup></italic> young and old mice (n=3 per each group). The values shown are mean ± SD. Data are expressed as fold change to the young wt group, except for panels <bold>G</bold> to <bold>I</bold>. *p≤0.05, **p≤0.01, ***p≤0.005, and ****p≤0.001 between the indicated groups. wt, wild-type mice; <italic>Arg2<sup>-/-</sup></italic>, <italic>Arg2<sup>-/-</sup></italic> gene knockout mice.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-94794-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Validation of CCR2 and LYVE1 antibodies.</title><p>(<bold>A</bold>) Confocal microscopy illustration of immunofluorescence double staining of NOS2 (green) and F4-80 (red; macrophage marker). Scale bar = 50 µm; The negative control was generated by omitting the two primary antibodies. The enlarged region of interests (ROIs) 1 and 2 show the existence of both LYVE1<sup>+</sup>/F4-80<sup>+</sup> and LYVE<sup>−</sup>/F4-80<sup>+</sup> signal excluding the cross-reactivity between secondary antibodies. (<bold>B</bold>) Confocal microscopy illustration of immunofluorescence double staining of CCR2 (green) and F4-80 (red; macrophage marker). Scale bar = 50 µm; The negative control was again generated by omitting the two primary antibodies. ROIs 1 and 2 show the existence of both CCR2<sup>+</sup>/F4-80<sup>+</sup> and CCR2<sup>−</sup>/F4-80<sup>+</sup> signal excluding the cross-reactivity between secondary antibodies.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-94794-fig2-figsupp1-v1.tif"/></fig></fig-group><p>We also observed an age-associated increase in total numbers of apoptotic cells as demonstrated by TUNEL staining in the heart of wt mice, which is reduced in age-matched <italic>Arg2<sup>-/-</sup></italic> animals (<xref ref-type="fig" rid="fig3">Figure 3A</xref> and <xref ref-type="fig" rid="fig3">Figure 3B</xref>). Further experiments with wheat germ agglutinin (WGA)-Alexa Fluor 488 (used to define cell borders; <xref ref-type="fig" rid="fig3">Figure 3C</xref>) show a higher percentage of apoptotic cardiomyocytes (CM) than non-cardiomyocytes (NCM) in wt mice (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). This increased percentage of cardiomyocyte apoptosis is also prevented in age-matched <italic>Arg2<sup>-/-</sup></italic> animals (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). The percentage of apoptotic non-cardiomyocytes in aged <italic>Arg2<sup>-/-</sup></italic> mice tended to be reduced as compared to wt mice, but it did not reach statistical significance (<xref ref-type="fig" rid="fig3">Figure 3D</xref>).</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Age-associated elevation in apoptotic cardiomyocytes is prevented in female <italic>Arg2<sup>-/-</sup></italic> mice.</title><p>(<bold>A</bold>) Representative confocal images and relative quantification of apoptotic cardiac cells in young and old wt and <italic>Arg2<sup>-/-</sup></italic> heart tissue. DAPI (blue) is used to stain nuclei. Scale bar = 50 µm; (<bold>B</bold>) graph showing the quantification of the TUNEL-positive cells in old wt and <italic>Arg2<sup>-/-</sup></italic> hearts; (<bold>C</bold>) Wheat germ agglutinin (WGA)-Alexa Fluor 488-conjugate was used to stain cell membrane, and separate cardiomyocytes and non-cardiomyocytes apoptotic cells. Cell distinction was based on cell size and shape. Scale bar = 10 µm; (<bold>D</bold>) Graphs showing the quantification of the TUNEL-positive cardiomyocytes (CM) and non-myocytes (NCM) in old wt and <italic>Arg2<sup>-/-</sup></italic> hearts. The values shown are mean ± SD. Data are expressed as fold change to the young wt group, except for panel <bold>D</bold>. **p≤0.01, ***p≤0.005 and ****p≤0.001 between the indicated groups. wt, wild-type mice; <italic>Arg2<sup>-/-</sup></italic>, <italic>Arg2</italic> gene knockout mice.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-94794-fig3-v1.tif"/></fig><p>In addition, heart from old wt mice reveals elevated levels of SNAIL (the master regulator of End-MT process) and vimentin (mesenchymal marker), which is prevented in <italic>Arg2<sup>-/-</sup></italic> mice (<xref ref-type="fig" rid="fig4">Figure 4A</xref> to <xref ref-type="fig" rid="fig4">Figure 4C</xref>). No changes in CD31 (endothelial marker) levels are observed among the four groups (<xref ref-type="fig" rid="fig4">Figure 4A and D</xref>). Immunofluorescence staining reveals that the age-related up-regulation of vimentin is mostly due to expansion of fibroblast population in left ventricle as shown in <xref ref-type="fig" rid="fig1">Figure 1E</xref> and <xref ref-type="fig" rid="fig1">Figure 1F</xref>. Confocal co-immunofluorescence staining shows that vimentin could be found in CD31<sup>+</sup> endothelial cells of blood vessels in the heart of old wt but rarely in age-matched <italic>Arg2<sup>-/-</sup></italic> mice (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). The results suggest at least a partial End-MT occurring in cardiac aging that is prevented by <italic>Arg2</italic> ablation. With aging, the heart weight to body weight ratio (HW/BW) increases to a similar extent between wt and <italic>Arg2<sup>-/-</sup></italic> mice (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>), suggesting no difference in age-related cardiac hypertrophy between wt and <italic>Arg2<sup>-/-</sup></italic> mice.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Age-related endothelial-to-mesenchymal transition (EndMT) in heart tissue.</title><p>(<bold>A</bold>) Immunoblotting analysis of CD31 (endothelial marker), vimentin (mesenchymal marker), and SNAIL (master regulator of EndMT) in the heart of wt and <italic>Arg2<sup>-/-</sup></italic> female young and old mice; tubulin and vinculin served as protein loading controls. Molecular weight (kDa) is indicated at the side of the blots. The plot graphs show the quantification of the SNAIL (<bold>B</bold>), vimentin (<bold>C</bold>), and CD31 (<bold>D</bold>) signals on immunoblots (n=6–10 mice in each group); (<bold>E</bold>) Representative confocal images showing co-localization of CD31 (green) and vimentin (red) in young and old wt and <italic>Arg2<sup>-/-</sup></italic> heart tissues. DAPI (blue) is used to stain nuclei. Scale bar = 20 µm. *p≤0.05 and **p≤0.01, between the indicated groups. wt, wild-type mice; <italic>Arg2<sup>-/-</sup></italic>, <italic>Arg2</italic> gene knockout mice.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-94794-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Age-related heart tissue hypertrophy.</title><p>Comparison between the heart weight to body weight ratio (HW/BW) of wt and <italic>Arg2<sup>-/-</sup></italic> young and old mice (n=5–9 per group). ****p≤0.001, between the indicated groups. wt, wild-type mice; <italic>Arg2<sup>-/-</sup></italic>, <italic>Arg2</italic> gene knockout mice.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-94794-fig4-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-3"><title>Cellular localization of ARG2 in aging heart</title><p>Next, the cellular localization of ARG2 in aging heart is investigated. Since <italic>Arg2</italic> mRNA levels are upregulated mostly in aged females, heart tissues from old female mice are used mainly for this purpose. To our surprise, confocal co-immunofluorescence staining does not show ARG2 in cardiomyocytes as evidenced by lack of ARG2 staining in Troponin T (TNNT)<sup>+</sup>-cells, a specific cardiomyocyte marker (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). ARG2 is only found in non-cardiomyocytes (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). In line with this notion, ARG2 is not detectable by immunoblotting in isolated primary cardiomyocytes from old wt mice at baseline or after exposure to hypoxia (1% O<sub>2</sub>, 24 hr, <xref ref-type="fig" rid="fig5">Figure 5B</xref>), a well-known strong stimulus for ARG2 upregulation in many cell types (<xref ref-type="bibr" rid="bib40">Liang et al., 2019</xref>; <xref ref-type="bibr" rid="bib41">Liang et al., 2021</xref>; <xref ref-type="bibr" rid="bib62">Ren et al., 2022</xref>; <xref ref-type="bibr" rid="bib86">Zhu et al., 2023</xref>). In contrast to cardiomyocytes, cardiac fibroblasts isolated from old wt mice show ARG2 protein which is up-regulated by hypoxia (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). The absence of <italic>Arg2</italic> mRNA in cardiomyocytes in contrast to fibroblasts isolated from wt old mouse hearts, is also confirmed with qRT-PCR (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). The absence of ARG2 in cardiomyocytes is also demonstrated in the heart of other species such as rats, in which no staining could be found in the cardiomyocytes (with or without infarction) but in non-cardiomyocytes that is cells between myocytes and endocardial cells (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). The specificity of the antibody against ARG2 was confirmed in the old wt and <italic>Arg2<sup>-/-</sup></italic> mouse kidneys in which ARG2 is constitutively expressed in the S3 proximal tubular cells (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>) as demonstrated by our previous study (<xref ref-type="bibr" rid="bib28">Huang et al., 2016</xref>). Again, ARG2 staining could be only found in cells between cardiomyocytes in the old wt mice but not in <italic>Arg2<sup>-/-</sup></italic> animals (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C</xref>). The absence of ARG2 in cardiomyocytes is also confirmed in human heart tissue biopsies (please see the results in <xref ref-type="fig" rid="fig5">Figure 5H</xref>). Moreover, ARG2 is detected in MAC-2<sup>+</sup> macrophages (<xref ref-type="fig" rid="fig5">Figure 5D</xref>), CD31<sup>+</sup> endothelial cells (<xref ref-type="fig" rid="fig5">Figure 5E</xref>), and PDGF-Rα<sup>+</sup>-fibroblasts (<xref ref-type="fig" rid="fig5">Figure 5F</xref>), but not in α-SMA<sup>+</sup> vascular smooth muscle cells (<xref ref-type="fig" rid="fig5">Figure 5G</xref>). These results demonstrate that ARG2 in aging mouse heart is mostly expressed in non-cardiomyocytes such as macrophages, endothelial cells, and fibroblasts. Similar to mouse heart, in human heart (obtained from a 66-year-old woman and a 76-year-old man with no significant cardiac pathology), ARG2 is also absent in cardiomyocytes as proved by lack of co-localization with TNNT<sup>+</sup>-cells (<xref ref-type="fig" rid="fig5">Figure 5H</xref>), and is expressed in CD31<sup>+</sup>-endothelial cells (<xref ref-type="fig" rid="fig5">Figure 5I</xref>), CD68<sup>+</sup>-macrophages (<xref ref-type="fig" rid="fig5">Figure 5J</xref>), and vimentin<sup>+</sup>- (<xref ref-type="fig" rid="fig5">Figure 5K</xref>) or α-SMA<sup>+</sup>- (<xref ref-type="fig" rid="fig5">Figure 5L</xref>) fibroblasts/myofibroblasts. In contrast to mouse heart, ARG2 could be found in very few vascular smooth muscle cells in human heart (<xref ref-type="fig" rid="fig5">Figure 5M</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Cellular localization of ARG2 in aging heart of female mice.</title><p>(<bold>A</bold>) Confocal microscopy illustration of immunofluorescence double staining of ARG2 (red) and TNNT (green; cardiomyocytes marker). Scale bar = 25 µm; (<bold>B</bold>) Bright-field microscopy images of isolated wt cardiomyocytes and primary cardiac fibroblasts. The immunoblot shows the level of ARG2 in both cardiomyocytes and fibroblasts upon exposure to hypoxia (1% O<sub>2</sub>) for 24 hr. <bold>C</bold> indicates freshly isolated cardiomyocytes used as control, <bold>N</bold> and <bold>H</bold> indicate normoxia and hypoxia conditions, and K indicates kidney tissue extract used as positive control. Tubulin served as protein loading control; (<bold>C</bold>) mRNA expression levels of <italic>Arg2</italic> in cardiomyocytes (card) and non-cardiomyocytes (non-c) cells isolated from old wt and <italic>Arg2 <sup>-/-</sup></italic> female mouse hearts. <italic>Gapdh</italic> served as the reference. (n=3–5 mice per group); (<bold>D</bold> to <bold>G</bold>) Representative confocal images of old wt mouse heart showing co-localization of (<bold>D</bold>) ARG2 (red) and MAC-2 (green, mouse macrophage marker), (<bold>E</bold>) ARG2 (red) and CD31 (green, endothelial marker), (<bold>F</bold>) ARG2 (red) and PDGF-Rα (green, fibroblasts marker), and (<bold>G</bold>) ARG2 and α-smooth muscle actin (α-SMA; green, smooth muscle cell/myofibroblasts marker); (<bold>H</bold> to <bold>M</bold>) Representative confocal images of human heart tissue showing co-localization of (<bold>H</bold>) ARG2 (green) and TNNT (red, cardiomyocytes marker), (<bold>I</bold>) ARG2 (red) and CD31 (green, endothelial marker), (<bold>J</bold>) ARG2 (red) and CD-68 (green, macrophage marker), (<bold>K</bold>) ARG2 (red) and vimentin (green, fibroblast marker), and (<bold>L–M</bold>) ARG2 (red) and α-smooth muscle actin (α-SMA; green), (<bold>L</bold>) myofibroblasts and (<bold>M</bold>) smooth muscle cell marker. DAPI (blue) stains cell nuclei. Scale bar = 20 µm. Each experiment was repeated with 3–5 animals.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-94794-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>ARG2 localization in mouse and rat tissues.</title><p>(<bold>A</bold>) Representative confocal images showing immunofluorescence staining of ARG2 (green) in old wt and <italic>Arg2<sup>-/-</sup></italic> kidney tissue. DAPI (blue) is used to stain nuclei. Brightfield light microscopy was combined with fluorescent signals to assess cell morphology. Scale bar = 20 µm; (<bold>B</bold>) Representative confocal images showing immunofluorescence staining of ARG2 (green) in heart tissue of control rat (Sham), rat under myocardial infarction followed by artery ligation (MI), and relative negative control (omission of primary Ab). DAPI (blue) is used to stain nuclei. The images show ARG2 localization in non-myocytes cells. (<bold>C</bold>) Representative confocal images showing ARG2 (green) in old wt mouse tissue with relative negative control (omission of primary Ab). DAPI (blue) is used to stain nuclei.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-94794-fig5-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-4"><title>Role of ARG2 in crosstalk between macrophages and cardiomyocytes through IL-1β</title><p>Given that age-associated cardiomyocyte apoptosis is prevented in <italic>Arg2<sup>-/-</sup></italic> mice despite absence of ARG2 in the cardiomyocytes, the non-cell-autonomous effects of ARG2 on cardiomyocytes are then investigated. As reported above, macrophage numbers and <italic>Il1b</italic> mRNA expression are increased in aging heart and reduced in <italic>Arg2<sup>-/-</sup></italic> mice (<xref ref-type="fig" rid="fig2">Figure 2A, C and G</xref>). Both immunoblotting and immunofluorescence staining confirm that IL-1β protein levels are higher in old wt heart tissues when compared to age-matched <italic>Arg2<sup>-/-</sup></italic> (<xref ref-type="fig" rid="fig6">Figure 6A–D</xref>). Furthermore, co-immunofluorescence staining reveals that IL-1β is localized in Mac2<sup>+</sup>- macrophages (<xref ref-type="fig" rid="fig6">Figure 6E</xref>). Taking into account that our previous studies demonstrated a relationship of ARG2 and IL-1β in vascular disease and obesity (<xref ref-type="bibr" rid="bib53">Ming et al., 2012</xref>) and in age-associated organ fibrosis such as renal and pulmonary fibrosis (<xref ref-type="bibr" rid="bib30">Huang et al., 2021</xref>; <xref ref-type="bibr" rid="bib86">Zhu et al., 2023</xref>), and IL-1β has been shown to play a causal role in patients with coronary atherosclerotic heart disease as shown by CANTOS trials (<xref ref-type="bibr" rid="bib63">Ridker et al., 2017</xref>), we therefore focused on the role of IL-1β in crosstalk between macrophages and cardiac cells such as cardiomyocytes, fibroblasts, and endothelial cells. Considering that the ablation of the <italic>Arg2</italic> gene specifically reduces the number of TUNEL-positive cardiomyocytes (<xref ref-type="fig" rid="fig3">Figure 3C and D</xref>), we hypothesized that ARG2 in macrophages may prime cardiomyocyte apoptosis. To test this hypothesis, splenic macrophages are isolated from young and old wt and age-matched <italic>Arg2<sup>-/-</sup></italic> mice, and conditioned medium from the cells is collected. Elevated ARG2 and IL-1β protein levels are observed in old wt macrophages as compared to the cells from young animals (<xref ref-type="fig" rid="fig7">Figure 7A–C</xref>). In line with this finding, IL-1β levels in conditioned medium from old wt mouse macrophages are higher as compared to the conditioned medium from young macrophages (<xref ref-type="fig" rid="fig7">Figure 7D</xref>). Interestingly, <italic>Arg2</italic> ablation substantially reduces IL-1β levels in the macrophages (<xref ref-type="fig" rid="fig7">Figure 7A, C and D</xref>). Importantly, cardiomyocytes isolated from adult (5 months) female wt mice as bioassay cells, when incubated with conditioned medium from old (but not from young) wt macrophages for 24 hr (<xref ref-type="fig" rid="fig7">Figure 7E</xref>), display more apoptosis as monitored by TUNEL assay (<xref ref-type="fig" rid="fig7">Figure 7F and G</xref>). This age-associated cardiac damaging effect of macrophages is not observed with <italic>Arg2<sup>-/-</sup></italic> macrophage conditioned medium (<xref ref-type="fig" rid="fig7">Figure 7F and G</xref>), suggesting a role of ARG2-expressing macrophages in mediating cardiomyocyte apoptosis in aging. To further examine whether IL-1β from macrophages is the paracrine mediator for cardiomyocyte apoptosis, the above-described experiment is performed in the presence of the IL-1 receptor antagonist IL-Ra. Indeed, cardiomyocyte apoptosis induced by the conditioned medium from old wt macrophages is abolished by IL-Ra (<xref ref-type="fig" rid="fig7">Figure 7F and G</xref>).</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>ARG2 ablation reduces Il-1β protein levels in aging heart.</title><p>(<bold>A</bold>) Immunoblotting analysis of Il-1β (active form) in the heart of old wt and <italic>Arg2 <sup>-/-</sup></italic> female mice; tubulin served as protein loading control. Molecular weight (kDa) is indicated at the side of the blots; (<bold>B</bold>) The plot graph shows quantification of the Il-1β signals on immunoblots (n=6–7 mice in each group); (<bold>C</bold>) Representative confocal images showing Il-1β localization in old wt and <italic>Arg2 <sup>-/-</sup></italic> heart tissues. DAPI (blue) is used to stain nuclei. Scale bar = 50 µm; (<bold>D</bold>) Relative Il-1β signal quantification of confocal images (n=9 per each group); (<bold>E</bold>) Representative confocal images showing co-localization of MAC-2 (green, mouse macrophage marker), and Il-1β (red) in wt heart tissues. This experiment was repeated with 3 animals. Scale bar = 10 µm. *p≤0.05 and ***p≤0.005, between the indicated groups. wt, wild-type mice; <italic>Arg2 <sup>-/-</sup></italic>, <italic>Arg2</italic> gene knockout mice.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-94794-fig6-v1.tif"/></fig><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>In vitro study of crosstalk between aging splenic macrophages and cardiomyocytes.</title><p>(<bold>A</bold>) Immunoblotting analysis of ARG2 and Il-1β (active form) in mouse splenic macrophages isolated from young and old wt and <italic>Arg2 <sup>-/-</sup></italic> female mice; tubulin served as protein loading control. Molecular weight (kDa) is indicated at the side of the blots. The plot graphs show the quantification of ARG2 (<bold>B</bold>) and IL-1β (<bold>C</bold>) protein signals on immunoblots (n=3 mice in each group); (<bold>D</bold>) IL-1β levels in the conditioned medium from young and old wt and <italic>Arg2 <sup>-/-</sup></italic> splenic macrophages were measured by ELISA; (<bold>E</bold>) Schematic representation of in vitro crosstalk study; (<bold>F</bold>) Representative confocal images of adult isolated mouse cardiomyocytes stimulated with conditioned media (CM) from young and old, wt and <italic>Arg2 <sup>-/-</sup></italic> splenic cells (24 hr incubation). Wheat Germ Agglutinin (WGA)-Alexa Fluor 488-conjugate was used to stain cell membrane, and TUNEL was performed to identify apoptotic cells. DAPI is used to stain nuclei. Interleukin receptor antagonist (ILRA; 50 ng/ml) is used to prevent IL-1β binding to its receptor; (<bold>G</bold>) Quantification of TUNEL-positive cardiomyocytes (% in respect to total number of cells). Scale bar = 20 µm. *p≤0.05, **p≤0.01, ***p≤0.005 and ****p≤0.001 between the indicated groups. MØ, splenic macrophage; Y, young; O, old; wt, wild-type mice; <italic>Arg2<sup>-/-</sup></italic>, <italic>Arg2</italic> gene knockout mice.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-94794-fig7-v1.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>In vitro crosstalk between LPS-activated RAW 264.7 macrophages and cardiomyocytes.</title><p>(<bold>A</bold>) Immunoblotting analysis of ARG2 and Il-1β (precursor) in RAW 264.7 mouse macrophages upon transduction with the rAd/U6-<italic>LacZ</italic>shRNA as the control or rAd/U6-<italic>Arg2</italic>shRNA to silence <italic>Arg2</italic>. RAW cells were polarized toward pro-inflammatory phenotype by incubation with lipopolysaccharide (LPS; 100 ng/ml) for 24 hr; tubulin served as protein loading control. Molecular weight (kDa) is indicated at the side of the blots. The plot graphs show the quantification of ARG2 (<bold>B</bold>) and Il-1β (<bold>C</bold>) protein signals on immunoblots (n=3); (<bold>D</bold>) Representative confocal images of adult isolated mouse cardiomyocytes stimulated with conditioned media (CM) from control RAW cells and RAW cells with <italic>Arg-ii</italic> silencing, with and without LPS (24 hr incubation). Wheat Germ Agglutinin (WGA)-Alexa Fluor 488-conjugate was used to stain cell membrane, and TUNEL was performed to identify apoptotic cells. DAPI is used to stain nuclei. Interleukin receptor antagonist (ILRA; 50 ng/ml) is used to prevent IL-1β binding to its receptor; (<bold>E</bold>) Quantification of TUNEL-positive cardiomyocytes (% in respect to total number of cells). Scale bar = 40 µm. **p≤0.01, ***p≤0.005 and ****p≤0.001 between the indicated groups.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-94794-fig7-figsupp1-v1.tif"/></fig><fig id="fig7s2" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 2.</label><caption><title>Effects of ARG2 and NOS2 in regulation of IL-1β production in macrophages.</title><p>(<bold>A</bold>) Immunoblotting analysis of ARG2 and NOS2 in human wt THP1 (THP1<sup>wt</sup>) and <italic>Arg2 <sup>-/-</sup></italic> THP1 (THP1<italic><sup>Arg2-/-</sup></italic>) cells stimulated with LPS (100 ng/ml, 24 hr). Tubulin served as a protein loading control. Mouse bone-marrow-derived macrophages (MØ) treated with LPS were used as positive control for NOS2 and ARG2 detection; Molecular weight (kDa) is indicated at the side of the blots; (<bold>B</bold>) qRT-PCR analyzing mRNA levels of <italic>il-1β</italic> in the cells. <italic>β-actin</italic> served as internal reference (n=6); (<bold>C</bold>), IL-1β levels in the conditioned medium from the THP1<sup>wt</sup> and THP1<italic><sup>Arg2 -/-</sup></italic> cells stimulated with LPS (100 ng/ml, 24 hr) measured by ELISA; (<bold>D</bold>) Immunoblotting analysis showing ARG2, NOS2, and IL-1β precursor protein levels in the wt and <italic>Nos2</italic> knockout (BMDM<italic><sup>Nos2-/-</sup></italic>) bone-marrow-derived macrophages (MØ) stimulated with LPS (100 ng/ml, 24 hr). GAPDH served as protein loading controls. Molecular weight (kDa) is indicated at the side of the blots (n=5 independent experiments). The plot graphs show the quantification of IL-1β (<bold>E</bold>), and ARG2 (<bold>F</bold>) protein levels on the immunoblots. *p≤0.05, **p≤0.01, ***p≤0.005, ****p≤0.001 between the indicated groups. (<bold>G</bold>) Schematic illustration of IL-1β production regulated by NOS2 and ARG2 in macrophages. The dotted line indicates inhibition. wt, wild-type; <italic>Arg2<sup>-/-</sup></italic>, <italic>Arg2</italic> gene knockout; Nos2<sup>−/−</sup>, NOS2 gene knockout; h ARG2, human ARG2; m ARG2, mouse ARG2.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-94794-fig7-figsupp2-v1.tif"/></fig></fig-group><p>Similar results are obtained with Raw264.7 cells, a widely used mouse macrophage model. Raw264.7 cells stimulated with lipopolysaccharide (LPS; 100 ng/ml) for 24 hr show a significant increase in both ARG2 and IL-1β, which is inhibited by silencing <italic>Arg2</italic> (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A to C</xref>), confirming the role of ARG2 in the production of IL-1β in macrophages (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A and C</xref>). In agreement with the results shown in <xref ref-type="fig" rid="fig7">Figure 7</xref>, conditioned medium from LPS-treated Raw264.7 cells significantly enhances cardiomyocyte apoptosis as assessed by TUNEL staining, which is reduced by either <italic>Arg2</italic> gene silencing or by IL-1 receptor blocker ILRa (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1D and E</xref>). It is of note that LPS alone does not induce cardiomyocyte apoptosis at the concentration tested (data not shown), confirming the role of ARG2-mediated IL-1β release from macrophages in cardiomyocyte apoptosis.</p><p>Next, we analyzed the relationship between ARG2 and NOS2 in regulation of IL-1β production in macrophages. In the human THP1 monocytes in which ARG2 but not NOS2 is induced by LPS (100 ng/ml for 24 hr; <xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2A</xref>), mRNA and protein levels of IL-1β are markedly reduced in <italic>Arg2</italic> knockout THP1 as compared to the wt cells (<xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2B and C</xref>), further confirming that ARG2 promotes IL-1β production as already shown in RAW264.7 macrophages (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A and C</xref>). Moreover, in the mouse bone-marrow-derived macrophages, LPS-induced IL-1β production is inhibited by <italic>Nos2</italic> (NOS2 gene) deficiency (<italic>Nos2</italic> knockout BMDM vs wt BMDM; <xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2D and E</xref>), while ARG2 levels are slightly enhanced in the <italic>Nos2</italic> knockout BMDM cells (<xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2D and F</xref>). All together, these results suggest that ARG2 and NOS2 are upregulated by LPS independently, and NOS2 slightly reduces ARG2 protein level. Both ARG2 and NOS2 are required for maximal IL-1β production upon LPS stimulation as illustrated in <xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2G</xref>.</p></sec><sec id="s2-5"><title>Role of ARG2 in crosstalk between macrophages and cardiac fibroblasts through IL-1β</title><p>Since cardiac fibrosis is accompanied by macrophage accumulation in our aging heart model, a crosstalk between macrophages and fibroblasts is then investigated. Cardiac fibroblasts isolated from adult (5 months) female wt mice as bioassay cells produce more hydroxyproline when they are incubated with conditioned medium from old as compared to young wt macrophages (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1A</xref>). This effect of old macrophages on fibroblasts is reduced with conditioned medium from <italic>Arg2<sup>-/-</sup></italic> macrophages (<xref ref-type="fig" rid="fig8">Figure 8A</xref>). In parallel, expression levels of genes involved in extracellular matrix remodeling such as <italic>Fn1</italic> (fibronectin), <italic>Col3a1, Tgfb1</italic> (<xref ref-type="fig" rid="fig8">Figure 8B</xref> to <xref ref-type="fig" rid="fig8">Figure 8D</xref>) as well as <italic>Mmp2</italic> and <italic>Mmp9</italic> (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1B and C</xref>) are reduced in fibroblasts stimulated with conditioned medium from <italic>Arg2<sup>-/-</sup></italic> macrophages as compared to the old wt macrophages, while expression of <italic>Col1a1</italic> is not altered under this condition (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1D</xref>). Importantly, the increase in hydroxyproline levels in cardiac fibroblasts incubated with conditioned medium from old wt macrophages is inhibited by ILRa (<xref ref-type="fig" rid="fig8">Figure 8E</xref>).</p><fig-group><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>Crosstalk between splenic macrophages and cardiac fibroblasts and cell-autonomous effect of ARG2 in cardiac fibroblasts.</title><p>(<bold>A</bold>) Collagen production measured as hydroxyproline content in mouse wt fibroblasts treated with conditioned media (CM) from old, wt, and <italic>Arg2 <sup>-/-</sup></italic> splenic cells (96 hr incubation) (n=3 mice in each group). The values shown are mean ± SD. mRNA expression levels of (<bold>B</bold>) <italic>Fib</italic>, (<bold>C</bold>) <italic>Col3a1,</italic> and (<bold>D</bold>) <italic>Tgfb1</italic> in wt fibroblasts treated with conditioned media (CM) from old wt and <italic>Arg2 <sup>-/-</sup></italic> splenic cells (96 hr incubation) were analyzed by qRT-PCR. <italic>Gapdh</italic> served as the reference. (n=4 mice per group); (<bold>E</bold>) Hydroxyproline content in fibroblasts treated with CM from old wt splenic cells (96 hr incubation). ILRa (50 ng/ml) is used to prevent IL-1β binding to its receptor (n=4 independent experiments). (<bold>F</bold>) Immunoblotting analysis of ARG2 and vimentin in human cardiac fibroblasts (HCFs) upon <italic>Arg2</italic> gene overexpression. GAPDH served as protein loading control; (<bold>G</bold>) qRT-PCR analysis of mRNA expression levels <italic>Arg2</italic> in HCF cells; (<bold>H</bold>) The plot graph shows the quantification of the vimentin signals on immunoblots shown in panel F. (n=3 independent experiments); (<bold>I</bold>) qRT-PCR analysis of mRNA expression levels of <italic>Col3a1</italic> in HCF cells. <italic>Gapdh</italic> served as the reference. (n=6 independent experiments); (<bold>J</bold>) Representative confocal images of human cardiac fibroblasts (HCF) upon transfection with rAd-CMV-Con/ <italic>Arg2</italic> for 48 hr. MitoSOX (Red) is used to stain mitochondrial ROS (mtROS). TEMPO (10 μmol/l) is used to prevent mtROS generation. DAPI (blue) stains cell nuclei. Scale bar = 50 µm. (<bold>K</bold>) Mitosox signal quantification (n=3 independent experiments); (<bold>L</bold>) qRT-PCR analysis of mRNA expression levels of <italic>Col3a1</italic> in HCF cells treated as indicated. <italic>Gapdh</italic> served as the reference. (n=5 independent experiments). (<bold>M</bold>) Immunoblotting analysis of ARG2 and HIF-1α in human cardiac fibroblasts (HCFs) upon 1% hypoxia incubation for 48 h. Tubulin served as a protein loading control; (<bold>N</bold>) Representative confocal images of HCFs under normoxia (21% O<sub>2</sub>) or hypoxia (1% O<sub>2</sub>) for 48 hr. MitoSOX (Red) is used to stain mitochondrial ROS (mtROS). TEMPO (10 μmol/l) is used to prevent mtROS generation. DAPI (blue) stains cell nuclei. Scale bar = 50 µm. (<bold>O</bold>) Representative confocal images of HCFs upon transfection with shRNA for <italic>Arg2</italic> gene silencing under normoxia or hypoxia. MitoSOX (Red) is used to stain mitochondrial ROS (mtROS). DAPI (blue) stains cell nuclei. Scale bar = 25 µm. (<bold>P</bold>) MitoSOX signal quantification of images shown in panel O (n=3 independent experiments). Data are expressed as fold change to respective control group. *p≤0.05, **p≤0.01, ***p≤0.005 and ****p≤0.001 between the indicated groups. MØ, splenic macrophage; Con, control.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-94794-fig8-v1.tif"/></fig><fig id="fig8s1" position="float" specific-use="child-fig"><label>Figure 8—figure supplement 1.</label><caption><title>Crosstalk between splenic macrophages and cardiac fibroblasts.</title><p>(<bold>A</bold>) Collagen production measured as hydroxyproline content in mouse wt fibroblasts treated with conditioned media (CM) from young and old wt splenic cells (96 hr of incubation) (n=3 mice in each group). mRNA expression levels of (<bold>B</bold>) <italic>Mmp2</italic>, (<bold>C</bold>) <italic>Mmp9,</italic> and (<bold>D</bold>) <italic>Col1a1</italic> in wt fibroblasts treated with conditioned media (CM) from old wt and <italic>Arg2 <sup>-/-</sup></italic> splenic cells (96 hr of incubation) were analyzed by qRT-PCR. <italic>Gapdh</italic> served as the reference. (n=4 mice per group). Data are expressed as fold change to respective control groups. *p≤0.05 between the indicated groups. MØ, splenic macrophage; CM, conditioned media; wt, wild-type mice; <italic>Arg2<sup>-/-</sup></italic>, <italic>Arg2</italic> gene knockout mice.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-94794-fig8-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-6"><title>Cell-autonomous effects of ARG2 in cardiac fibroblasts: role of mtROS</title><p>Since ARG2 is expressed in fibroblasts, a cell-autonomous effect of ARG2 in these cells is also investigated in cultured human cardiac fibroblasts (HCF). Overexpression of <italic>Arg2</italic> in the cells (<xref ref-type="fig" rid="fig8">Figure 8F and G</xref>) increases <italic>Vim</italic> (vimentin) and <italic>Col3a1</italic> expression levels (<xref ref-type="fig" rid="fig8">Figure 8H and I</xref>)<bold>,</bold> demonstrating a cell-autonomous effect of ARG2 in cardiac fibroblasts. Interestingly, upregulation of <italic>Col3a1</italic> expression by ARG2 is accompanied by increased mitochondrial ROS (mtROS) generation, and inhibition of mtROS by mito-TEMPO (10 μmol/l) prevents <italic>Col3a1</italic> upregulation (<xref ref-type="fig" rid="fig8">Figure 8J, K and L</xref>), suggesting a role of ARG2-induced mtROS in activation of fibroblasts. The effect of ARG2 in promoting mtROS is also confirmed under hypoxic conditions in which endogenous ARG2 is upregulated accompanied by elevated HIF-1α levels (<xref ref-type="fig" rid="fig8">Figure 8M and O</xref>). The enhanced mtROS generation under hypoxic conditions is inhibited either by mito-Tempo (<xref ref-type="fig" rid="fig8">Figure 8N</xref>), the specific inhibitor of mtROS, or by <italic>Arg2</italic> silencing (<xref ref-type="fig" rid="fig8">Figure 8O and P</xref>).</p></sec><sec id="s2-7"><title>Role of ARG2 in crosstalk between macrophages and endothelial cells through IL-1β</title><p>Results in <xref ref-type="fig" rid="fig4">Figure 4</xref> suggest EndMT in aging heart, which is regulated by ARG2. The role of ARG2-expressing macrophages in End-MT of endothelial cells is then investigated in cultured cells. Human endothelial cells exposed to macrophage-derived conditioned medium from old (not young) wt mice for 96 hr have no effect on VE-cadherin but enhance N-cadherin and vimentin (mesenchymal markers), and ARG2 protein levels (<xref ref-type="fig" rid="fig9">Figure 9A</xref> to <xref ref-type="fig" rid="fig9">Figure 9E</xref>), suggesting a partial End-MT induced by aged macrophages. Interestingly, these effects of macrophages are prevented in old <italic>Arg2<sup>-/-</sup></italic> mice (<xref ref-type="fig" rid="fig9">Figure 9A–E</xref>) or abolished in the presence of IL-1 receptor antagonist IL-Ra (<xref ref-type="fig" rid="fig9">Figure 9F–J</xref>). The results suggest a role of IL-1β from old wt macrophages in EndMT process.</p><fig id="fig9" position="float"><label>Figure 9.</label><caption><title>Aging wt macrophages induces EndMT in HUVEC.</title><p>(<bold>A</bold>) Immunoblotting analysis of VE-Cadherin (endothelial marker), N-Cadherin and vimentin (both mesenchymal markers), and ARG2 in HUVEC cells upon incubation with conditioned media (CM) from young and old wt and <italic>Arg2<sup>-/-</sup></italic> splenic cells (4 days incubation); GAPDH served as protein loading control. Molecular weight (kDa) is indicated at the side of the blots. The plot graphs show the quantification of Arg-II (<bold>B</bold>), N-Cadherin (<bold>C</bold>), Vimentin (<bold>D</bold>), and VE-Cadherin (<bold>E</bold>) protein levels (n=3 independent experiments); (<bold>F</bold>) Immunoblotting analysis of VE-Cadherin, N-Cadherin, Vimentin, and ARG2 in HUVEC cells upon incubation with CM from old wt splenic cells (4 days incubation); Interleukin receptor antagonist (IL-Ra; 50 ng/ml) is used to prevent IL-1β effect. GAPDH served as protein loading control. Molecular weight (kDa) is indicated at the side of the blots. The plot graphs show the quantification of Arg2 (<bold>G</bold>), N-Cadherin (<bold>H</bold>), Vimentin (<bold>I</bold>), and VE-Cadherin (<bold>J</bold>) protein signals on immunoblots (n=4 independent experiments); Data are expressed as fold change to respective control group. *p≤0.05, **p≤0.01 and ***p≤0.005 between the indicated groups. MØ, splenic macrophage; wt, wild-type mice; <italic>Arg2<sup>-/-</sup></italic>, <italic>Arg2</italic> gene knockout mice.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-94794-fig9-v1.tif"/></fig></sec><sec id="s2-8"><title><italic>Arg2</italic> gene ablation reduces ischemic damage in aging heart</title><p>To study the specific role of ARG2 in heart ischemia/reperfusion (I/R) injury during aging, ex vivo experiments with Langendorff-perfused heart from old wt and <italic>Arg2<sup>-/-</sup></italic> mice were performed followed by cardiac functional analysis. The experimental protocol of global ischemia/reperfusion is shown in <xref ref-type="fig" rid="fig10">Figure 10A</xref>. Under normoxic baseline conditions, the cardiac functions, i.e., dP/dt<sub>max</sub>. (maximal rate of contraction), dP/dt<sub>min</sub>. (maximal rate of relaxation) and left ventricular developed pressure (LVDP) are comparable between wt and <italic>Arg2<sup>-/-</sup></italic> old mice (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). <italic>Arg2</italic> ablation improves cardiac function following I/R injury, i.e., the inotropic contractile function as measured by LVDP and dP/dt<sub>max</sub>, lusitropic dP/dt<sub>min</sub> (<xref ref-type="fig" rid="fig10">Figure 10B</xref>). The post I/R recovery is significantly improved in <italic>Arg2<sup>-/-</sup></italic> mice when compared to age-matched wt animals (<xref ref-type="fig" rid="fig10">Figure 10B</xref>). In addition to functional recovery, infarct size after I/R injury was analyzed by triphenyl tetrazolium chloride (TTC) staining in old mice. Under the ischemic/reperfusion condition (20 min ischemia and 30 min reperfusion), no myocardial infarct was detected (<xref ref-type="fig" rid="fig10s1">Figure 10—figure supplement 1</xref>), while longer ischemia and reperfusion time (30 min and 45 min, respectively) is required to induce myocardial infarct, that is 10.5 ± 2.9% in wt old mice, which is significantly reduced in the age-matched <italic>Arg2<sup>-/-</sup></italic> mice (3.2 ± 0.9%, <xref ref-type="fig" rid="fig10">Figure 10C and D</xref>). It is to note that following ischemia/reperfusion injury, male mice display cardiac dysfunction, that is reduced left ventricular developed pressure (LVDP), as well as the inotropic and lusitropic states (expressed as dP/dt max and dP/dt min, respectively; <xref ref-type="fig" rid="fig10s2">Figure 10—figure supplement 2</xref>). As previously reported (<xref ref-type="bibr" rid="bib58">Murphy and Steenbergen, 2007</xref>), we also found that old male mice are more prone to I/R injury than age-matched female animals. Specifically, 15 min of ischemic time is enough to significantly affect the left ventricle contractile function in the male mice (<xref ref-type="fig" rid="fig10s2">Figure 10—figure supplement 2</xref>). As opposed to age-matched old female mice, which are relatively resistant to I/R injury, at least 20 min of ischemia are necessary to induce a significant impairment of the contractile function (<xref ref-type="fig" rid="fig10">Figure 10</xref>). Similar to females, the post-I/R recovery of cardiac function is also significantly improved in the male <italic>Arg2<sup>-/-</sup></italic> mice as compared to age-matched wt animals. In addition to functional recovery, triphenyl tetrazolium chloride (TTC) staining (myocardial infarction) upon I/R injury in males is significantly reduced in the age-matched male <italic>Arg2<sup>-/-</sup></italic> animals (<xref ref-type="fig" rid="fig10s2">Figure 10—figure supplement 2C and D</xref>). All together, these results reveal a role for ARG2 in heart function impairment during aging in both genders with a higher vulnerability in males (<xref ref-type="fig" rid="fig10s2">Figure 10—figure supplement 2</xref>).</p><fig-group><fig id="fig10" position="float"><label>Figure 10.</label><caption><title>ARG2 ablation improves heart function recovery from global ischemia/reperfusion injury (I/R-I).</title><p>(<bold>A</bold>) Protocol applied for ex vivo Langendorff-heart functional assessment of old wt and age-matched <italic>Arg2<sup>-/-</sup></italic> female mice. After baseline recordings, 20 min global ischemia is followed by 30 min of reperfusion; (<bold>B</bold>) Ex vivo Langendorff-heart assessment of old female wt (black line) and <italic>Arg2<sup>-/-</sup></italic> (red line) hearts. The graphs show the functional recovery of the left ventricular developed pressure (LVDP), left ventricular end diastolic pressure (LVED), and maximal rate of contraction (dP/dt<sub>max</sub>) and relaxation (dP/dt<sub>min</sub>). The data are expressed as % of recovery in respect to baseline values and represent the mean ± SD of data from 5 mice per group; (<bold>C</bold>) Representative sections of wt and <italic>Arg2<sup>-/-</sup></italic> female hearts stained with 2,3,5-TTC. The healthy/normal tissue appears deep red. The arrows indicate the white infarct tissue showing the absence of living cells. (<bold>D</bold>) Relative quantification of infarcted areas. *p≤0.05 and **p≤0.01 between the indicated groups. wt, wild-type mice; <italic>Arg2<sup>-/-</sup></italic>, <italic>Arg2</italic> gene knockout mice.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-94794-fig10-v1.tif"/></fig><fig id="fig10s1" position="float" specific-use="child-fig"><label>Figure 10—figure supplement 1.</label><caption><title>Short ischemia/reperfusion induces negligible myocardial infarct in female mice.</title><p>(<bold>A</bold>) Representative sections of wt and <italic>Arg2<sup>-/-</sup></italic> hearts stained with 2,3,5-TTC and (<bold>B</bold>) relative quantification of infarcted areas. 20 minutes global ischemia is followed by 30 minutes reperfusion. wt, wild-type mice; <italic>Arg2<sup>-/-</sup></italic>, <italic>Arg2</italic> gene knockout mice.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-94794-fig10-figsupp1-v1.tif"/></fig><fig id="fig10s2" position="float" specific-use="child-fig"><label>Figure 10—figure supplement 2.</label><caption><title><italic>Arg2</italic> ablation improves heart function recovery from global ischemia/reperfusion injury (I/R-I) in male mice.</title><p>(<bold>A</bold>) Protocol applied for ex vivo Langendorff-heart functional assessment of old wt and age-matched <italic>Arg2<sup>-/-</sup></italic> male mice. After baseline recordings, 15 min global ischemia is followed by 30 min of reperfusion; (<bold>B</bold>) Ex vivo Langendorff-heart assessment of old male wt (black line) and <italic>Arg2<sup>-/-</sup></italic> (red line) hearts. The graphs show the functional recovery of the left ventricular developed pressure (LVDP), left ventricular end diastolic pressure (LVED), and maximal rate of contraction (dP/dtmax) and relaxation (dP/dtmin). The data are expressed as % of recovery in respect to baseline values and represent the mean ± SD of data from 5 mice per group; (<bold>C</bold>) Representative sections of wt and <italic>Arg2<sup>-/-</sup></italic> male hearts stained with 2,3,5-TTC and (<bold>D</bold>) quantification of infarcted areas. *p≤0.05 between the indicated groups. wt, wild-type mice; <italic>Arg2<sup>-/-</sup></italic>, <italic>Arg2</italic> gene knockout mice.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-94794-fig10-figsupp2-v1.tif"/></fig></fig-group></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p> Previous studies have reported the presence of both ARG1 and ARG2 isoenzymes in the cardiac tissues of various animal models including feline, pig, rats, rabbit, and mice (<xref ref-type="bibr" rid="bib22">Gonon et al., 2012</xref>; <xref ref-type="bibr" rid="bib25">Heusch et al., 2010</xref>; <xref ref-type="bibr" rid="bib34">Jung et al., 2006</xref>; <xref ref-type="bibr" rid="bib35">Jung et al., 2010</xref>; <xref ref-type="bibr" rid="bib67">Steppan et al., 2006</xref>). These isoenzymes have been implicated in cardiac ischemic injury and cardiac aging (<xref ref-type="bibr" rid="bib35">Jung et al., 2010</xref>; <xref ref-type="bibr" rid="bib77">Xiong et al., 2017a</xref>). It has been widely assumed that ARG1 and ARG2 are expressed in cardiomyocytes, where they play a role in cardiac injury via a cell-autonomous effect on the cardiomyocytes. However, the cellular localization of arginase isoforms has not been convincingly demonstrated due to the following two reasons: species-specific expression of arginase isoforms and lack of including negative controls with gene knockout samples.</p><p>Our current study systematically investigated the expression and cellular localization of the mitochondrial ARG2 in the heart of a natural aging mouse model and in human biopsies. We found an age-associated increase in <italic>Arg2</italic> but not <italic>Arg1</italic> in the heart of male and female mice. Data extracted from a high-throughput sequencing database of male mice (no data on females are available, unfortunately) confirms our findings showing the age-dependent enhancement of <italic>Arg2</italic> but not <italic>Arg1</italic> expression in the heart (GSE201207; <xref ref-type="bibr" rid="bib75">Wolff et al., 2023</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C and D</xref>). Surprisingly, we found that neither <italic>Arg2</italic> gene expression nor its protein levels were detectable in cardiomyocytes from either young or old mice. Despite increased <italic>Arg2</italic> mRNA (but not <italic>Arg1</italic> mRNA) expression in the aging heart, mitochondrial ARG2 was absent from cardiomyocytes. This observation aligns with previous findings in vascular endothelial cells from mice and humans, where ARG2 (not ARG1) is the predominant isoenzyme (<xref ref-type="bibr" rid="bib51">Ming et al., 2004</xref>). It is to note that a previous study reported that ARG2 is exclusively expressed in isolated cardiomyocytes from rats (<xref ref-type="bibr" rid="bib67">Steppan et al., 2006</xref>). However, we could not confirm this finding. The reason for this discrepancy is not clear. However, we made a great effort to confirm the cellular localization of ARG2 in the heart from different species including mice, rats, and humans. Importantly, negative controls, that is <italic>Arg2<sup>-/-</sup></italic> samples, are always included in our present study to avoid any possible background signals. Our experiments confirm that ARG2 could be found only in non-cardiomyocytes but not in cardiomyocytes from different species. The experiments with freshly isolated primary cells also confirm that even under hypoxia, a well-known strong stimulus for ARG2 protein levels in different cell types (<xref ref-type="bibr" rid="bib40">Liang et al., 2019</xref>; <xref ref-type="bibr" rid="bib86">Zhu et al., 2023</xref>), no ARG2 protein expression could be detected in the cardiomyocytes but elevated in fibroblasts from old female mice. Furthermore, RT-qPCR could not detect <italic>Arg2</italic> mRNA in cardiomyocytes but in non-cardiomyocytes. All together, these results demonstrate that ARG2 is not expressed or at negligible levels in cardiomyocytes but expressed in non-cardiomyocytes. Further experiments identified that ARG2 is expressed in macrophages, fibroblasts, and endothelial cells in aged mouse heart and human cardiac biopsies. These results suggest that ARG2 exerts non-cell-autonomous effects on aging cardiomyocytes.</p><p> It is well known that the aging heart is associated with accumulation of senescent cells, increased cardiomyocyte apoptosis, chronic inflammation, oxidative stress, and cardiac fibrosis (<xref ref-type="bibr" rid="bib71">Vakka et al., 2023</xref>). In the current study, we observe that <italic>Arg2<sup>-/-</sup></italic> mice are protected from cardiac aging phenotype and reveal a decrease in apoptotic cells, particularly cardiomyocytes but also non-cardiomyocytes. Since cardiomyocytes do not express ARG2 in aging and ARG2 could not even be induced in these cells under hypoxic condition, a non-cell-autonomous effect of ARG2 on cardiomyocyte apoptosis must be involved, meaning that the increased cardiomyocyte apoptosis in aging must be due to paracrine effects of other cell types such as macrophages in which ARG2 levels are elevated in aging. It is evident that crosstalk between cardiomyocytes and non-cardiomyocytes is critical in cardiac functional changes and remodeling (<xref ref-type="bibr" rid="bib31">Hulsmans et al., 2016</xref>). Substantial evidence demonstrates that immune cells, particularly monocytes and/or macrophages, are important contributors to cardiac remodeling in aging and disease conditions (<xref ref-type="bibr" rid="bib31">Hulsmans et al., 2016</xref>; <xref ref-type="bibr" rid="bib33">Jimenez and Lavine, 2022</xref>; <xref ref-type="bibr" rid="bib73">Wang et al., 2020</xref>). Under acute and chronic ischemic heart disease conditions, blood monocytes can be mobilized from bone marrow and spleen and recruited into the injury site of the heart where they play an important role in cardiac remodeling (<xref ref-type="bibr" rid="bib26">Honold and Nahrendorf, 2018</xref>; <xref ref-type="bibr" rid="bib69">Swirski et al., 2009</xref>). An increased accumulation of myeloid cells, including in aging hearts, has been reported and contributes to cardiac inflammaging (<xref ref-type="bibr" rid="bib17">Esfahani et al., 2021</xref>). Besides infiltrated macrophages, tissue resident macrophages also contribute to cardiac inflammation and remodeling in heart disease (<xref ref-type="bibr" rid="bib68">Suku et al., 2022</xref>; <xref ref-type="bibr" rid="bib74">Weinberger et al., 2024</xref>). Interestingly, we demonstrate that total numbers of macrophages in the heart are significantly increased in aging heart, which is due to both enhanced accumulation of resident tissue macrophages and infiltrated macrophages, and both macrophage populations are reduced in <italic>Arg2<sup>-/-</sup></italic> mice. The enhanced infiltrated macrophages must be due to sustained cardiac injury occurring with aging in the heart accompanied by repairing process, which is manifested by resident macrophage proliferation and fibroblast activation (<xref ref-type="bibr" rid="bib74">Weinberger et al., 2024</xref>). Our previous study demonstrated that ARG2 plays a role in macrophage infiltration in different organ/tissues in high-fat diet and high-cholesterol diet-induced atherosclerosis and obesity mouse models (<xref ref-type="bibr" rid="bib53">Ming et al., 2012</xref>). It remains to be investigated whether ARG2 regulates resident macrophage proliferation in the aging heart and what the underlying mechanisms. Whether infiltrated macrophages can be switched to resident ones and regulated by ARG2 is also an interesting question to be investigated.</p><p>As shown above, an increased macrophage accumulation in aging heart associates with elevated expression of numerous inflammatory cytokines in macrophages. This age-associated cardiac inflammation is inhibited in <italic>Arg2<sup>-/-</sup></italic> animals. Among these inflammatory cytokines, an increase in IL-1β levels in cardiac tissue and macrophages or monocytes/macrophages derived from spleen of old mice is demonstrated accompanied by elevated ARG2 levels as compared to young animals. Importantly, we showed that ARG2 in the aged macrophages enhances IL-1β expression which mediates cardiomyocyte apoptosis. In support of this notion, cardiomyocyte apoptosis caused by aged macrophages is inhibited in <italic>Arg2<sup>-/-</sup></italic> mice and prevented by IL-1β receptor antagonist. These results further confirm our previous findings demonstrating a pro-inflammatory role of ARG2 in macrophages in vascular atherosclerosis and high-fat-diet-induced type 2 diabetes mouse models (<xref ref-type="bibr" rid="bib53">Ming et al., 2012</xref>). This conclusion is also further supported by the findings with a mouse macrophage cell line RAW264.7. The question of what the underlying mechanisms are that upregulate ARG2 levels in macrophages in aging remains to be investigated. Moreover, we also found increased apoptosis of other cell types in aging hearts, which is also prevented in <italic>Arg2<sup>-/-</sup></italic> mice. What are these cells, how is this cell apoptosis triggered, and what is the impact on age-associated cardiac vulnerability to stressors that requires further investigation. Moreover, research has provided evidence that cellular senescence, including , endothelial cells, fibroblasts, and immune cells, all contributes to the cardiac aging and age-associated cardiac dysfunction (<xref ref-type="bibr" rid="bib46">Luan et al., 2024</xref>). Future research shall investigate which cell types are protected from <italic>arg-ii</italic> deficiency from senescence and what the underlying mechanisms are.</p><p> One of the interesting questions is the relationship between ARG2 and NOS2 in regulation of IL-1β production in macrophages. Both NOS2 and ARG2 (not ARG1) are highly induced in macrophages in response to several pro-inflammatory stimuli such as LPS, TNFα, and IFN-γ, etc. (<xref ref-type="bibr" rid="bib7">Bogdan, 2015</xref>; <xref ref-type="bibr" rid="bib53">Ming et al., 2012</xref>) and considered as pro-inflammatory M1-macrophage markers (<xref ref-type="bibr" rid="bib49">Martinez and Gordon, 2014</xref>; <xref ref-type="bibr" rid="bib53">Ming et al., 2012</xref>). Since arginase and NOS2 share the same metabolic substrate L-arginine, an increase in arginase levels is proposed to decrease intracellular L-arginine bioavailability for NOS2, and in turn, to reduce pro-inflammatory responses of macrophages (<xref ref-type="bibr" rid="bib12">Chang et al., 1998</xref>). Hence, arginase including the two isoforms ARG1 and ARG2 is regarded as anti-inflammatory (<xref ref-type="bibr" rid="bib80">Yang and Ming, 2014</xref>). ARG1 is indeed associated with M2-anti-inflammatory macrophages (<xref ref-type="bibr" rid="bib80">Yang and Ming, 2014</xref>), while ARG2 (but not ARG1) along with NOS2 is enhanced in pro-inflammatory macrophages upon LPS stimulation as shown in the previous study (<xref ref-type="bibr" rid="bib53">Ming et al., 2012</xref>) and also confirmed in our present study. Importantly, knockout or knockdown of the <italic>Arg2</italic> gene reduces IL-1β production as shown in our present study and decreases pro-inflammatory cytokine levels in vitro and in vivo in various chronic inflammatory disease models and inflammaging (<xref ref-type="bibr" rid="bib4">Atawia et al., 2019</xref>; <xref ref-type="bibr" rid="bib53">Ming et al., 2012</xref>; <xref ref-type="bibr" rid="bib83">You et al., 2013</xref>). These results demonstrate that ARG2, in contrast to ARG1, exerts pro-inflammatory functions in macrophages. Despite controversies published in the literature (<xref ref-type="bibr" rid="bib7">Bogdan, 2015</xref>), NOS2 is generally considered to exert pro-inflammatory effects in macrophages (<xref ref-type="bibr" rid="bib18">Eslami et al., 2017</xref>; <xref ref-type="bibr" rid="bib81">Yao et al., 2022</xref>). This is confirmed by our present study showing that LPS-stimulated IL-1β production in murine macrophages is inhibited when the NOS2 gene <italic>Nos2</italic> is ablated. Since ARG2 promotes IL-1β production and ARG2 levels are increased under <italic>Nos2</italic>-deficiency condition, one would expect an increased IL-1β production in <italic>Nos2</italic> knockout (<italic>Nos2<sup>-/-</sup></italic>) macrophages. This is, however, not the case. A strong inhibition of IL-1β production in <italic>Nos2<sup>-/-</sup></italic> macrophages is observed. These results implicate that NOS2 promotes IL-1β production independently of ARG2, and the inhibiting effect of IL-1β by <italic>Nos2</italic> deficiency is dominant and able to counteract ARG2’s stimulating effect on IL-1β production. On the other hand, the question of whether ARG2 promotes IL-1β production through NOS2 could also be excluded due to the following reasons. First, in the human THP1 cells in which ARG2 but not NOS2 is induced by LPS, ablation of the <italic>Arg2</italic> gene reduces IL-1β mRNA and protein levels; second, both ARG1 and ARG2 are believed to inhibit endothelial NOS-mediated NO synthesis, <italic>Arg2</italic> deficiency would increase L-arginine bioavailability for NOS activity (<xref ref-type="bibr" rid="bib16">Durante et al., 2007</xref>). Since NOS2 induction by LPS is promoting IL-1β production as demonstrated in our current study, an increase in IL-1β production by <italic>Arg2</italic> deficiency would be expected under this condition. We observe, however, a decreased IL-1β production in <italic>Arg2<sup>-/-</sup></italic> cells. Hence, our results demonstrate that ARG2 promotes IL-1β production in macrophages independently of NOS2 (This concept is illustrated in the <xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2G</xref>). Future study shall further confirm the NOS2-independent stimulating effect on IL-1β production by ARG2 in the <italic>Nos2<sup>-/-</sup></italic> mouse model. It remains to be investigated what the exact molecular mechanisms of IL-1β production promoted by ARG2 and NOS2 in macrophages are, respectively. Since IL-1β is produced and released via activation of inflammasome (<xref ref-type="bibr" rid="bib2">Agostini et al., 2004</xref>; <xref ref-type="bibr" rid="bib13">Cullen et al., 2015</xref>), whether ARG2 and NOS2 promote macrophage pro-inflammatory responses and IL-1β release through inflammasome activation remains to be studied.</p><p>Previous studies suggest that ARG2 exerts both L-arginine metabolizing-dependent and -independent (pleiotropic) effects depending on cell types. For example, in vascular smooth muscle cells in which no NOS exists, even inactive mutant of ARG2 is capable of inducing cell senescence (<xref ref-type="bibr" rid="bib76">Xiong et al., 2013</xref>), while in endothelial cells, eNOS-uncoupling, that is decreased NO and increased superoxide anion production, is dependent on the L-arginine metabolizing activity of ARG2 (<xref ref-type="bibr" rid="bib82">Yepuri et al., 2012</xref>). It is understandable that endothelial dysfunction caused by enhanced ARG2 levels would reduce coronary perfusion and in turn decrease cardiac contractile function as reported in the literature (<xref ref-type="bibr" rid="bib36">Khan et al., 2012</xref>; <xref ref-type="bibr" rid="bib47">Luo et al., 2014</xref>). Whether ARG2 promotes inflammatory responses in macrophages through the pleiotropic effects remains to be investigated.</p><p> It is of note that a study reported that ARG2 is required for IL-10-mediated inhibition of IL-1β in mouse BMDM upon LPS stimulation (<xref ref-type="bibr" rid="bib15">Dowling et al., 2021</xref>), which suggests an anti-inflammatory function of ARG2. The results of our study, however, demonstrate a pro-inflammatory effect of ARG2 in macrophages. Our findings are supported by the study from another group, which shows decreased pro-inflammatory cytokine production including IL-6 and IL-1β in <italic>Arg2<sup>-/-</sup></italic> BMDM most likely through suppression of NFκB pathway, since <italic>Arg2<sup>-/-</sup></italic> BMDM reveals decreased activation of NFκB and IL-1β levels upon LPS stimulation (<xref ref-type="bibr" rid="bib70">Uchida et al., 2023</xref>). Most importantly, our previous study also showed that reintroducing the <italic>Arg2</italic> gene back to the <italic>Arg2<sup>-/-</sup></italic> macrophages markedly enhances LPS-stimulated pro-inflammatory cytokine production (<xref ref-type="bibr" rid="bib53">Ming et al., 2012</xref>), providing further evidence for a pro-inflammatory role of <italic>Arg2</italic> under LPS stimulation. In support of this conclusion, chronic inflammatory diseases such as atherosclerosis and type 2 diabetes (<xref ref-type="bibr" rid="bib53">Ming et al., 2012</xref>), inflammaging in lung (<xref ref-type="bibr" rid="bib86">Zhu et al., 2023</xref>), kidney (<xref ref-type="bibr" rid="bib30">Huang et al., 2021</xref>), and pancreas (<xref ref-type="bibr" rid="bib78">Xiong et al., 2017b</xref>) of aged animals or acute organ injury such as acute ischemic/reperfusion or cisplatin-induced renal injury are reduced in the <italic>Arg2<sup>-/-</sup></italic> mice (<xref ref-type="bibr" rid="bib70">Uchida et al., 2023</xref>). The discrepant findings between these studies and those with IL-10 may implicate dichotomous functions of ARG2 in macrophages, depending on the experimental context or conditions. Nevertheless, our results strongly implicate a pro-inflammatory role of ARG2 in macrophages in the inflammaging in aging heart.</p><p> One of the important features of cardiac aging is fibrosis, which is due to chronic inflammation processes (<xref ref-type="bibr" rid="bib45">Lu et al., 2017</xref>). There is convincing evidence demonstrating that chronic inflammation facilitates development of myocardial fibrosis in heart failure which is associated with aging (<xref ref-type="bibr" rid="bib42">Lillo et al., 2023</xref>). A crosstalk between macrophages and fibroblasts has been demonstrated to be important for cardiac fibrosis in diseased conditions (<xref ref-type="bibr" rid="bib23">Hartupee and Mann, 2016</xref>). Studies show that monocyte-derived macrophages from bone marrow and spleen are recruited in advanced age, contributing to cardiac fibrosis and myocardial dysfunction (<xref ref-type="bibr" rid="bib32">Hulsmans et al., 2018</xref>). In our present study using an in vitro cellular model, we show a pivotal role of Arg-II-expressing macrophages in activation of cardiac fibroblasts in aging heart. First, ARG2 protein is present in the cardiac macrophages and enhanced in monocyte-derived macrophages in aging mice; second, conditioned medium from aged <italic>Arg2<sup>-/-</sup></italic> macrophages exhibits decreased potential of stimulating cardiac fibroblasts to produce components that are essentially involved in fibrosis such as hydroxyproline, <italic>Fn1, Col3a1,</italic> and <italic>Tgfb1</italic>. Interestingly, the enhanced hydroxyproline levels stimulated by old wt mouse macrophage-derived conditioned medium are inhibited by the IL-1β receptor blocker, demonstrating a paracrine effect of IL-1β release from aged macrophages on cardiac fibroblast activation. Moreover, the age-associated cardiac fibrosis and increase in fibroblast number in the heart is prevented in <italic>Arg2<sup>-/-</sup></italic> mice, demonstrating a crosstalk between macrophage and fibroblasts in cardiac aging.</p><p>The fact that cardiac fibroblasts in aging hearts express elevated ARG2 indicates a contribution of a cell-autonomous effect of ARG2 in this cell type to cardiac fibrosis in aging. This concept is confirmed by the experiments showing that overexpression of <italic>Arg2</italic> in cardiac fibroblasts enhances vimentin levels associated with increased expression of <italic>Col3a1</italic> and mitochondrial ROS generation. Importantly, the inhibition of mitochondrial ROS by TEMPO abolished the effect of <italic>Arg2</italic> overexpression in the fibroblasts, demonstrating that ARG2 exerts its cell-autonomous stimulating effects in fibroblasts through mitochondrial ROS. The role of ARG2 in mitochondrial ROS generation is further confirmed by the results showing that silencing <italic>Arg2</italic> abolished miROS generation in fibroblasts when ARG2 is upregulated under hypoxic conditions. These findings are supported by the studies showing that ROS favors cardiac fibroblast proliferation and activation to produce collagen (<xref ref-type="bibr" rid="bib3">Alili et al., 2014</xref>; <xref ref-type="bibr" rid="bib59">Ohtsu et al., 2005</xref>). With these results, we demonstrate that cardiac fibroblasts are activated in aging by a paracrine effect of macrophages, that is mediated by ARG2/IL-1β and also by a cell-autonomous effect of ARG2 through mtROS.</p><p>Endothelial cells play a key role in regulation of blood flow to organs through eNOS pathway, one of the most important regulatory mechanisms in cardiovascular system (<xref ref-type="bibr" rid="bib20">Godo and Shimokawa, 2017</xref>). Previous studies demonstrated a causal role of ARG2 in promotion of vascular endothelial aging through eNOS uncoupling (<xref ref-type="bibr" rid="bib82">Yepuri et al., 2012</xref>). In line with this, our current study showed that ARG2 is expressed in the coronary vascular endothelium of old mice and also in human heart. Emerging evidence also suggests that endothelial cells have a significant capacity for plasticity and can change their phenotype, including endothelial-to-mesenchymal transition (EndMT), a process that endothelial cells undergo extensive alterations, including changes in gene and protein expression, loss of the endothelial phenotype, and switch to mesenchymal phenotype such as increased cell migration, proliferation, and increased collagen production, contributing to cardiovascular disease and fibrosis (<xref ref-type="bibr" rid="bib57">Murdoch et al., 2014</xref>; <xref ref-type="bibr" rid="bib84">Zeisberg et al., 2007</xref>; <xref ref-type="bibr" rid="bib85">Zhang et al., 2021</xref>). Although EndMT in cardiac fibrotic models, particularly in pro-atherosclerotic mouse models, is at least partially evidenced, it is less known in cardiovascular aging (<xref ref-type="bibr" rid="bib19">Evrard et al., 2016</xref>; <xref ref-type="bibr" rid="bib37">Kidder et al., 2023</xref>; <xref ref-type="bibr" rid="bib79">Xu and Kovacic, 2023</xref>). When compared to young animals, aged wt heart tissues show enhanced levels of SNAIL, the master regulator of End-MT process. Moreover, immunofluorescence reveals that CD31<sup>+</sup> endothelial cells also co-express vimentin (mesenchymal marker). No changes in endothelial marker expression such as CD31 and vascular-endothelial cadherin (data not shown) are appreciated, suggesting that partial End-MT occurs during aging. Ablation of ARG2 blunts the age-related elevation of both vimentin and SNAIL, thereby reducing the number of CD31<sup>+</sup>/vimentin<sup>+</sup> endothelial cells. This data hints that lower cardiac tissue fibrosis in <italic>Arg2<sup>-/-</sup></italic> is at least partially contributed to by dampened End-MT process. Indeed, the conditioned medium from old wt macrophages can enhance mesenchymal markers N-cadherin and vimentin, as well as ARG2 protein levels in endothelial cells without changes in endothelial markers such as VE-cadherin, confirming a partial End-MT induced by aged macrophages. Interestingly, this effect of macrophages is prevented when <italic>Arg2</italic> was ablated. Furthermore, the paracrine effects of the old macrophages on EndMT are prevented by IL-1 receptor antagonist ILRa, demonstrating a role of IL1β from old wt macrophages expressing ARG2 in EndMT process. Moreover, ARG2 is expressed and upregulated in endothelial cells with aging (<xref ref-type="bibr" rid="bib82">Yepuri et al., 2012</xref>). Overexpression of <italic>Arg2</italic> in the endothelial cells did not affect the End-MT markers (data not shown), suggesting that ARG2 alone is not sufficient to induce a cell-autonomous effect in End-MT. Finally, we demonstrate that <italic>Arg2<sup>-/-</sup></italic> mice in aging exhibit improved cardiac function and are more resistant to ischemic/reperfusion stress and reveal a better recovery and less myocardial infarct area as compared to the old wt animals. This protection against age-related cardiac dysfunction and vulnerability to ischemic stress in <italic>Arg2<sup>-/-</sup></italic> animals could be explained by the above-described cardiac aging phenotype such as increase in apoptosis of cardiac cells, decrease in macrophage-mediated inflammation, endothelial dysfunction and EndMT, and fibroblast activation.</p><p>Previous studies provided sex-related differences in ARG2 levels at both mRNA (<xref ref-type="bibr" rid="bib77">Xiong et al., 2017a</xref>) and protein levels in various organs (<xref ref-type="bibr" rid="bib30">Huang et al., 2021</xref>; <xref ref-type="bibr" rid="bib78">Xiong et al., 2017b</xref>). We further confirmed the observation that in female mice, there is a greater age-associated upregulation of <italic>Arg2</italic> levels in the heart, which is specifically found in non-cardiomyocytes but not in cardiomyocytes. A possible explanation for this sex-specific phenomenon may lie in differences in hormonal patterns between male and female animals throughout the aging process. Indeed, sex hormones, including estrogen and testosterone, have been shown to regulate <italic>arg-ii</italic> expression in various tissues. Estrogen seems to downregulate ARG2 (<xref ref-type="bibr" rid="bib24">Hayashi et al., 2006</xref>). The age-related greater increase in <italic>Arg2</italic> in the female mice might be due to loss or lack of estrogen in old female animals, which requires further investigation. However, testosterone has been reported to upregulate <italic>Arg2</italic> expression (<xref ref-type="bibr" rid="bib38">Levillain et al., 2005</xref>). This observation, however, does not seem to support the hypothesis that increased <italic>Arg2</italic> expression in aged male mouse heart is related to sex hormones. Nevertheless, how age enhances ARG2 in a sex-specific manner remains a topic of further investigation. Of note, previous studies showed that sex-related differences in pathological phenotypes in the aging kidney, pancreas, and lung are associated with higher levels of ARG2 in the females (<xref ref-type="bibr" rid="bib30">Huang et al., 2021</xref>; <xref ref-type="bibr" rid="bib78">Xiong et al., 2017b</xref>; <xref ref-type="bibr" rid="bib86">Zhu et al., 2023</xref>). The fact that aged females have higher ARG2 but are more resistant to I/R injury seems contradictory to the detrimental effect of Arg-II in I/R injury. It is presumable that cardiac vulnerability to injuries stressors depends on multiple factors/mechanisms in aging. Other factors/mechanisms associated with sex may prevail and determine the higher sensitivity of male heart to I/R injury, which requires further investigation. Nevertheless, the results of our study show that ARG2 plays a role in cardiac I/R injury also in males.</p><p>In conclusion, our study demonstrates that age-related upregulation of ARG2 in macrophages, fibroblasts, and endothelial cells contributes to the cardiac aging phenotype. This includes manifestations, such as cardiac inflammatory response, partial EndMT, fibroblast activation, resulting in cardiomyocyte apoptosis, cardiac fibrosis, and ultimately, myocardial dysfunction. Moreover, it enhances the vulnerability of aging heart to ischemic/reperfusion injury, primarily through a non-cell-autonomous paracrine release of IL-1β from macrophages acting on cardiomyocytes and endothelial cells. This effect is in addition to a cell-autonomous effect of ARG2 in cardiac fibroblasts (<xref ref-type="fig" rid="fig11">Figure 11</xref>). Future research shall develop the macrophage-specific <italic>Arg2<sup>-/-</sup></italic> mouse model to confirm this conclusion with aging animals. Since ARG2 is also expressed in fibroblasts and endothelial cells and exerts cell-autonomous and paracrine functions, aging mouse models with conditional <italic>Arg2</italic> knockout in the specific cell types would be the next step to elucidate cell-specific function of ARG2 in cardiac aging. In this context, another interesting aspect is the crosstalk between macrophages and vascular SMC in the aging heart. In our present study, we could not detect ARG2 in vascular SMC of mouse heart but in that of human heart. This could be due to the difference in species-specific ARG2 expression in the heart or related to the disease conditions in human heart which is harvested from patients with cardiovascular diseases. Indeed, in the <italic>Apoe<sup>-/-</sup></italic> mouse atherosclerosis model, aortic SMCs do express Arg-II (<xref ref-type="bibr" rid="bib76">Xiong et al., 2013</xref>). It is interesting to note that rodents hardly develop atherosclerosis as compared to humans. Whether this could be partly contributed to the different expression of ARG2 in vascular SMC between rodents and humans requires further investigation. In our present study, the aspect of the crosstalk between macrophages and vascular SMC is not studied. Since the crosstalk between macrophages and vascular SMC has been implicated in the context of atherogenesis as reviewed (<xref ref-type="bibr" rid="bib21">Gong et al., 2025</xref>), further work shall investigate whether ARG2-expressing macrophages could interact with vascular SMC in the coronary arteries in the heart and contribute to the development of coronary artery disease and/or vascular remodeling and the underlying mechanisms. Nevertheless, our study strongly suggests that targeting ARG2 has a wide spectrum of direct and indirect effects on multiple cell types in aging heart including macrophages, fibroblasts, endothelial cells, and cardiomyocytes, resulting in improved cardiac resistance to ischemia/reperfusion injury, which is due to inhibition of inflammation, fibrosis, and cell apoptosis. Thus, ARG2 shall represent a promising therapeutic target in the treatment of age-related cardiac dysfunction and protect the heart under diseased conditions.</p><fig id="fig11" position="float"><label>Figure 11.</label><caption><title>Schematic illustration of the role of Arg-II and underlying mechanisms in cardiac aging.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-94794-fig11-v1.tif"/></fig></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Arg2<sup>-/-</sup> mouse and sample preparation</title><p>Wild type (wt) and <italic>Arg2</italic> knockout (<italic>Arg2<sup>-/-</sup></italic>) mice were kindly provided by Dr. William O’Brien (<xref ref-type="bibr" rid="bib65">Shi et al., 2001</xref>) and back crossed to C57BL/6  J for more than 10 generations. Genotypes of mice were confirmed by polymerase chain reaction (PCR) as previously described (<xref ref-type="bibr" rid="bib53">Ming et al., 2012</xref>). Offspring of wt and <italic>Arg2<sup>-/-</sup></italic> mice were generated by interbreeding from hetero/hetero cross. Mice were housed at 23°C with a 12-hr-light-dark cycle. Animals were fed a normal chow diet and had free access to water and food. The animals were selected and included in the study according to age, gender, and genotype. Only healthy animals, based on scoring of activity, posture, general appearance (coat, skin), locomotion, eyes/nose, body weight loss, were used. In this study, confounders such as the animal/cage location were controlled. All experimenters were aware of the group allocation at the different stages of the experiments. Male and female mice at the age of 3–4 months (young) or 20–22 months (old) were euthanized under deep anesthesia (i.p. injection of a mixture of ketamine/xylazine 50 mg/kg and 5 mg/kg, respectively) and death was confirmed by absence of all the reflexes and by exsanguination. The heart was then isolated and either snap frozen in liquid nitrogen and kept at −80°C until use or fixed with 4% paraformaldehyde (pH 7.0) and then embedded in paraffin for immunofluorescence staining experiments. Experimental work with animals was approved by the Ethical Committee of the Veterinary Office of Fribourg Switzerland (2020–01-FR) and performed in compliance with guidelines on animal experimentation at our institution and in accordance with the updated ARRIVE guidelines (<xref ref-type="bibr" rid="bib60">Percie du Sert et al., 2020</xref>). Experiments with human heart biopsies were approved by the Ethics Committee of Northwestern and Central Switzerland (Project-ID 2021–01445). Rat heart tissues were obtained from a previous study (<xref ref-type="bibr" rid="bib8">Borrego et al., 2022</xref>) approved by the Ethical Committee of the Veterinary Office of Fribourg Switzerland (2019–21-FR).</p></sec><sec id="s4-2"><title>Langendorff-perfused mouse heart preparation</title><p>Ex vivo functional assessments were performed by using an isolated heart system (Langendorff apparatus – EMKA technologies, France). Briefly, after euthanasia as above described, the hearts of wt and <italic>Arg2<sup>-/-</sup></italic> male and female mice (20–22 months old) were excised, cannulated, and retrogradely perfused on the Langendorff system. 150 µl of heparin (2000 units/ml) was injected 15 min before the heart removal to prevent blood coagulation. Hearts trimmed of extracardiac tissue were weighed immediately after surgical removal, prior to cannulation, and heart weight to body weight ratio (HW/BW) was calculated as hypertrophy index. The aorta was cannulated on a shortened and blunted 21-gauge needle and perfusion initiated at a constant pressure of 80 mmHg. The hearts were perfused with a modified Krebs–Henseleit solution composed of (mmol/L): 118 NaCl, 4.7 KCl, 1.2 MgSO<sub>4</sub>, 1.2 KH<sub>2</sub>PO<sub>4</sub>, 25 NaHCO<sub>3</sub>, 11 Glucose, 2 CaCl<sub>2</sub>. The fluid was bubbled with a mix of 95% O<sub>2</sub> and 5% CO<sub>2</sub> at 37°C to give a pH of 7.4 and was filtered through an in-line 0.45 μm Sterivex-HV filter before delivery to the heart. A fluid-filled balloon was introduced into the left ventricle through an incision in the left atrial appendage. The ventricular balloon was connected via fluid-filled tubing to a pressure transducer for continuous assessment of ventricular function. The balloon was inflated to yield a left ventricular end-diastolic pressure between 5–15 mmHg. Hearts were immersed in warmed perfusate in a jacketed bath maintained at 37 °C, and perfusate delivered to the coronary circulation was maintained at the same temperature. After 20 min stabilization, hearts were subjected to 15 min (males), 20 min, and 30 min (females) of no-flow ischemia followed by 30–45 min of reperfusion. Recovery of contraction and relaxation rates (dt/dp<sub>min</sub>) as well as the recovery of the left ventricle developed pressure (LV-DP) and left ventricular end diastolic pressure (LV-EDP) were measured to investigate tolerance to ischemia/reperfusion (I/R)-injury. In addition to functional recovery, triphenyl tetrazolium chloride (TTC) staining was also performed to investigate a potential reduction in infarct size upon I/R injury in <italic>Arg2<sup>-/-</sup></italic> animals. TTC is a colorless water-soluble dye that is reduced by the mitochondrial enzyme succinate dehydrogenase of living cells into a water-insoluble, light-sensitive compound (formazan) that turns healthy/normal tissue deep red. In contrast, damaged/dead tissue remains white, showing the absence of living cells and thereby indicating the infarct region (<xref ref-type="bibr" rid="bib5">Bederson et al., 1986</xref>). After completing the I/R protocol, the heart was carefully removed from the experimental set-up. After a freeze-thaw cycle (–20 °C for 1 hr), the heart was cross-sectioned from the apex to the atrioventricular groove into four 2.5-mm-thick slices. The slices were first incubated in TTC (20 min at 37 °C) and then fixed in 10% formalin for 30 min. A cover glass was then placed over the tissues and images were acquired (<xref ref-type="bibr" rid="bib61">Redfors et al., 2012</xref>). ImageJ software was used to analyze the images and assess the infarcted area.</p></sec><sec id="s4-3"><title>Real-time quantitative RT-PCR</title><p>mRNA expression level of genes from mouse and human origin was measured by two-step quantitative Real Time-PCR as described previously (<xref ref-type="bibr" rid="bib53">Ming et al., 2012</xref>). Ribosomal Protein S12 (<italic>Rps12</italic>) and glyceraldehyde-3-phosphate dehydrogenase (<italic>Gapdh</italic>) were used as reference genes. Total RNA from mouse tissue, splenic macrophages, and human cardiac fibroblasts was extracted with Trizol Reagent (TR-118, Molecular Research Center) following the manufacturer’s protocol. Real-time PCR reaction was performed with the GOTaq qPCR Master Mix (A6001, Promega) and CFX96 Real-Time PCR Detection System (Bio-Rad). The mRNA expression level of all genes was normalized to the reference gene <italic>Rps12</italic> or <italic>Gapdh</italic>. All the qRT-PCR primer sequences are shown in <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>.</p></sec><sec id="s4-4"><title>Confocal immunofluorescence microscope</title><p>Immunofluorescence staining was performed with heart tissues. Briefly, mouse hearts or human cardiac biopsies were fixed with 4% paraformaldehyde (pH 7.0) and embedded in paraffin. After deparaffinization in xylene (2 times of 10 min), the sections were treated in ethanol (twice in 100% ethanol for 3 min and twice in 95% ethanol and once in 80%, 75%, 50% ethanol for 1 min sequentially) followed by antigen retrieval (EDTA buffer, pH 8.0) for ARG2, TNNT, CD31, p16, MAC-2, IL-1β, Vimentin (VIM), CD-68, PDGF-Rα and α-smooth muscle actin (αSMA) in a pressure cooker. For co-immunofluorescence staining of ARG2/TNNT, ARG2/CD31, ARG2/VIM, Arg2/CD-68, ARG2/MAC-2, ARG2/PDGF-Rα, ARG2/αSMA, IL-1β/MAC-2, F4-80/CCR2, F4-80/LYVE1 (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref> shows the validation of CCR2 and LYVE1 antibodies) and CD31/VIM, primary antibodies of different species were used. Transverse sections (5 μm) were blocked with mouse Ig blocking reagent (M.O.M, Vector laboratories) for 2 hr and then with PBS containing 1% BSA and 10% goat serum for 1 hr. For CD31 and PDGF-Rα (both polyclonal Goat IgGs), a blocking reagent containing 10% BSA was used. The sections were then incubated overnight at 4°C in a dark/humidified chamber with target primary antibodies and subsequently incubated for 2 hr with the following secondary antibodies: Alexa Fluor 488–conjugated goat anti-rabbit IgG (H + L) and Alexa Fluor 568-conjugated goat anti-mouse IgG (H + L); Alexa Fluor 488–conjugated goat anti-mouse IgG (H + L) and Alexa Fluor 594-conjugated goat anti-rabbit IgG (H + L); Alexa Fluor 488–conjugated donkey anti-goat IgG (H + L) and Alexa Fluor 594-conjugated goat anti-rabbit IgG (H + L). All sections were finally counterstained with 300 nmol/l DAPI for 5  min. Immunofluorescence signals were visualized under Leica TCS SP5 confocal laser microscope. The antibodies used are shown in <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>.</p></sec><sec id="s4-5"><title>Isolation and cultivation of ventricular cardiomyocytes</title><p>Ventricular myocytes were isolated from 5-month-old female mice according to an established protocol (<xref ref-type="bibr" rid="bib43">Louch et al., 2011</xref>). Briefly, the hearts were excised, cannulated, and retrogradely perfused on a Langendorff system as described above. 150 µl of heparin (2000 units/ml) was injected 15 min before the heart removal to prevent blood coagulation. To isolate the cardiomyocytes, hearts were perfused at 37°C for 20 min with a Ca<sup>2+</sup>-free solution composed of (in mmol/ l): 130 NaCl, 5 KCl, 0.5 NaH<sub>2</sub>PO<sub>4</sub>, 10 HEPES, 10 Glucose, 10 2.3 butanedione monoxime (BDM), 10 Taurine, 1 MgCl<sub>2</sub> (pH 7.4, adjusted with NaOH). Cells were enzymatically dissociated using a cocktail of collagenase type II (210 U/ml, Worthington), collagenase type IV (260 U/ml, Worthington), and protease type XIV (0.21 U/ml; Sigma-Aldrich). After isolation, cardiomyocytes were separated by gravity settling and Ca<sup>2+</sup> was restored to a final concentration of 1 mmol/l. The cardiomyocytes was finally plated onto laminin-coated coverslips (5 μg/ml, Thermo Scientific) and cultured in the M-199 medium supplemented with bovine serum albumin (BSA; 0.1% - A1470, Sigma-Aldrich), BDM (10 mmol/l), insulin, transferrin, selenium (ITS; I3146 - Sigma-Aldrich), CD lipid (11905–031 - Sigma-Aldrich) and penicillin / streptomycin mix (1 %).</p></sec><sec id="s4-6"><title>Cell culture, adenoviral transduction, and Nos2<sup>-/-</sup> and Arg2<sup>-/-</sup> macrophages</title><p>Human cardiac fibroblasts (HCF) from adult human heart tissue were purchased from Innoprot (P10452) and cultured in the proprietary fibroblast culture medium (P60108-2, Innoprot) composed as follows: 500 ml of fibroblast basal medium, 25 ml of FBS, 5 ml of fibroblast growth supplement-2, and 5 ml of penicillin/streptomycin in the Poly-L-Lysine (PLL) coated flasks and dishes. The cells were maintained at 37°C in a humidified incubator (5% CO<sub>2</sub> and 95% atmosphere air). To overexpress <italic>Arg2</italic>, the cells were seeded on 6 cm dishes for 24 hr and transduced with rAd-CMV-Con/ <italic>Arg2</italic> for 48 hr as described previously (<xref ref-type="bibr" rid="bib53">Ming et al., 2012</xref>).</p><p>Human umbilical vein endothelial cells (HUVEC) were cultured in RPMI-1640 (with 25 mmol/l HEPES and stable glutamine; Thermo Fisher Scientific) containing 5% fetal calf serum (FCS; Gibco) and 1% streptomycin and penicillin in gelatin (1%) coated dishes.</p><p>Raw 264.7 cells (mouse macrophage cell line) were cultured in Dulbecco modified Eagle medium/F12 (DMEM/F12; Thermo Fisher Scientific) containing 10% fetal bovine serum (FBS; Gibco) and 1% streptomycin and penicillin. To silence <italic>Arg2</italic>, the cells were seeded on 6 cm dishes for 24 hr and transduced first with the rAd at titers of 100 Multiplicity of Infection (MOI) and cultured in the complete medium for 2 days and then in serum-free medium for another 24 hr before experiments. The rAd expressing shRNA targeting <italic>Arg2</italic> driven by the U6 promoter (rAd/U6-<italic>arg-ii</italic>-shRNA) and control rAd expressing shRNA targeting <italic>Lacz</italic> (rAd/U6-<italic>lacz</italic>-shRNA) were generated as described previously (<xref ref-type="bibr" rid="bib52">Ming et al., 2009</xref>).</p><p>Wt and <italic>Nos2</italic> gene-deficient bone-marrow-derived macrophage cell lines (MØ<sup>wt</sup> and MØ<italic><sup>Nos2-/-</sup></italic>) were purchased from Kerafast (ENH166-FP and ENH176-FP) and cultured in Dulbecco modified Eagle medium (DMEM; Thermo Fisher Scientific) containing 10% fetal bovine serum (FBS; Gibco) and 1% streptomycin and penicillin. The cells were treated with LPS (100 ng/ml) for 24 hr before harvest. Gene deficiency of <italic>Nos2</italic> was verified by immunoblotting analysis.</p><p>Knockout of the <italic>Arg2</italic> gene in human THP-1 cells was generated by CRISPR-UTM-mediated genome engineering with gRNA targeting exon 1 (Guangzhou Ubigene Biosciences Co., Ltd.). The control THP1 cell line was generated with scramble gRNA and Cas9. Gene deficiency of <italic>Arg2</italic> was verified by immunoblotting analysis.</p><p>All cell lines used in this study (RAW 264.7, THP-1 wt and <italic>Arg2</italic> knockout, and BMDMs wt and <italic>Nos2</italic> knockout) were routinely tested and confirmed to be negative for mycoplasma contamination throughout the experimental period.</p><p>Short tandem repeat (STR) profiling was performed through Microsynth for all cell lines. STR profiles for THP-1 and RAW 264.7 demonstrated excellent concordance (≥98.6%) with reference cell lines in the Cellosaurus database, confirming their identity and excluding contamination. The full STR datasets are provided as supplementary data (<xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>, <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>, <xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref> for RAW 264.7, THP-1 wt, and THP-1 <italic>Arg2</italic> knockout, respectively).</p><p>For the BMDMs (wt and <italic>Nos2</italic> knockout), STR analysis confirmed murine origin, absence of human DNA contamination, and a 100% match between wt and knockout cells, consistent with a shared genetic background. However, no external STR reference profile is currently available for these cells, as confirmed by both the supplier (Kerafast) and the Cellosaurus database. Therefore, direct validation against a reference cannot be carried out at this time. STR profiles are provided as supplementary data (<xref ref-type="supplementary-material" rid="supp7">Supplementary file 7</xref> and <xref ref-type="supplementary-material" rid="supp8">Supplementary file 8</xref> for BMDMs wt and BMDMs <italic>Nos2</italic> knockout, respectively).</p></sec><sec id="s4-7"><title>TUNEL Staining</title><p>Mouse hearts were isolated and fixed with 4% paraformaldehyde (pH 7.0), embedded in paraffin and sliced at 5 μm of thickness. After deparaffinization (xylene, 2 times for 10  min) and rehydration (sequential washing in 100%, 95%, 80%, 75%, and 50% ethanol), TUNEL staining was performed using a commercial kit (in situ Cell Death Detection Kit, TMR red – Roche, Switzerland). Briefly, 50 μl of TUNEL mixture, containing TdT and dUTP in reaction buffer, were added onto the sections and incubated in a humidified chamber for 60 min at 37°C in darkness. Positive controls were generated by incubating samples at room temperature (RT) for 10 min with DNase in PBS (1 mg/ml) to induce strand breaks. Negative controls were generated by incubation with TUNEL mixture lacking TdT. DAPI counterstaining was finally performed (300 nmol/l for 5 min).</p><p>TUNEL staining was also performed on isolated ventricular cardiomyocytes. After tissue digestion, the cardiomyocytes were plated onto murine laminin-coated coverslips to promote cell adhesion. One hour after plating, several PBS washing steps were performed to remove damaged and partially adherent cells, ensuring that only well-shaped, viable, and strongly adherent cells remained as bioassay cells. These ‘healthy’ cells were then selected for the experiments. After washing, cardiomyocytes were incubated for 24 hr with either splenic macrophage conditioned media (CM; see below) or with RAW cells CM, and the following protocol was applied: cells are fixed using 4% paraformaldehyde for 1 hr at RT, and then permeabilized via Triton X (0.1 %). As for tissues, 50 μl of TUNEL mixture, containing TdT and dUTP in reaction buffer, was added onto each slide and then incubated at 37°C for 60 min in darkness. DAPI counterstaining was then performed.</p><p>Upon plating onto murine laminin-coated coverslips, the cardiomyocytes were first incubated for 24 hr with either splenic macrophage conditioned media (CM; see below) or with RAW cells CM, and the following protocol was applied: cells are fixed using 4% paraformaldehyde for 1 hr at RT, and then permeabilized via Triton X (0.1 %). As for tissues, 50 μl of TUNEL mixture, containing TdT and dUTP in reaction buffer, were added onto each slide and then incubated at 37°C for 60 min in darkness. DAPI counterstaining was then performed.</p><p>For experiments aiming to define cell borders, TUNEL protocol was followed by a staining with Wheat Germ Agglutinin (WGA)-Alexa Fluor 488 (10 μg/ml for 30 min). For heart tissue, five representative images of each section are taken using a Leica TCS SP5 confocal system, and WGA staining was performed to differentiate cardiomyocytes and non-cardiomyocytes according to cell size and presence or absence of striations (characteristics of cardiomyocytes). Data was reported as number of TUNEL-positive nuclei over the total number of nuclei in the images.</p></sec><sec id="s4-8"><title>Masson’s trichrome staining</title><p>To analyze cardiac fibrosis, heart sections (5  µm) were subjected to Masson’s trichrome (ab150686, Abcam) staining according to the manufacturer’s instructions (<xref ref-type="bibr" rid="bib14">de Guzman et al., 2023</xref>).</p></sec><sec id="s4-9"><title>Hydroxyproline colorimetric assay</title><p>Collagen content was analyzed by determination of hydroxyproline levels in left ventricles or in cell homogenates using the Hydroxyproline Assay kit (MAK008, Sigma) according to the manufacturer’s instructions.</p></sec><sec id="s4-10"><title>Isolation of splenic macrophages</title><p>Splenic cells were isolated as previously described (<xref ref-type="bibr" rid="bib72">Wang et al., 2013</xref>). Briefly, young and old wt and <italic>Arg2<sup>-/-</sup></italic> female mice were euthanized as described and spleens were dissected from abdominal cavity and filtered through a 70 μm nylon strainer. Red blood cell lysis buffer was used to remove red blood cells. The cell suspension obtained was plated onto gelatin-coated dishes at a density of 2 × 10<sup>6</sup> cells/ml. After 3 days, cells were washed to ensure macrophage enrichment. Following washing, the macrophages were cultured for a further 4 days in RPMI culture media with 20% of L929 cell line conditioned medium (source of the macrophage growth factor M-CSF) to allow cell maturation. Medium was changed every two days.</p></sec><sec id="s4-11"><title>Crosstalk between macrophages and heart cells</title><p>For crosstalk experiments of splenic macrophages from wt and <italic>Arg2<sup>-/-</sup></italic> mice with cardiac cells, conditioned medium from the isolated splenic macrophages was collected and transferred to cardiomyocytes, fibroblasts, and endothelial cells in 1:1 dilution with the specific cell culture medium for the indicated time. To study the effects of IL-1β in the conditioned medium of splenic macrophages (CM-SM), cardiac cells, fibroblasts, or endothelial cells were pre-treated with IL-1 receptor antagonist IL-1RA (50 ng/ml) for 2 hr followed by the specific experimental protocols for analysis of cardiac apoptosis, fibroblast activation, and EndMT transition, respectively.</p><p>For the experiments with mouse macrophage cell line Raw 264.7, the cells were seeded on six-well plates with a density of 2 × 10<sup>5</sup> cells per well. Upon transduction with rAd expressing <italic>Arg2<sup>shRNA</sup></italic> (see above) and overnight serum starvation, the mouse macrophages were polarized toward a pro-inflammatory secretion profile by stimulation with lipopolysaccharide (LPS; 100 ng/ml) for 24 hr. The conditioned medium (CM) from non-treated control and LPS-activated RAW cells (referred to as CM-RAW) was then filtered and transferred onto cardiomyocytes for 24 hr to investigate cell apoptosis. To study the effects of IL-1β in CM-RAW on cardiac cells apoptosis, myocytes were pre-treated with IL-1 receptor antagonist IL-1RA (280-RA, R&amp;D systems) for 2 hr.</p></sec><sec id="s4-12"><title>Hypoxia experiments with murine cardiac fibroblasts and cardiomyocytes</title><p>Cardiac cells were isolated from wt mice according to an established protocol (<xref ref-type="bibr" rid="bib43">Louch et al., 2011</xref>). Briefly, after euthanasia of mice, hearts were excised, cannulated, and retrogradely perfused on a Langendorff system. Cells were enzymatically dissociated using a cocktail of collagenase type II, collagenase type IV, and protease type XIV. After isolation, cardiomyocytes were separated from the pull of cardiac cells by gravity settling and plated onto laminin-coated coverslips. After 2 hr, the cardiomyocytes were washed to remove non-adhering cells and incubated for 24 hr at 1% oxygen level in a Coy In Vitro Hypoxic Cabinet System (The Coy Laboratory Products, Grass Lake, MI USA). The rest of cardiac cells were plated on 12-well plates and cultured in DMEM (10% FBS) for 3 days, allowing cardiac fibroblasts to adhere. The fibroblasts were passaged once and subjected to hypoxia as for cardiomyocytes.</p></sec><sec id="s4-13"><title>Hypoxia experiments with human cardiac fibroblasts and mitochondrial superoxide detection (MitoSOX staining)</title><p>Human cardiac fibroblasts (HCF) from adult human heart tissue were incubated for 48 hr at 1% oxygen level in a Coy In Vitro Hypoxic Cabinet System (The Coy Laboratory Products, Grass Lake, MI USA). To silence <italic>Arg2</italic>, HCFs were seeded on 6 cm dishes for 24 hr and transduced first with the rAd at titers of 100 Multiplicity of Infection (MOI) and cultured in the complete medium for 2 days and then in serum-free medium for another 24 hr before experiments. The rAd expressing shRNA targeting <italic>Arg2</italic> driven by the U6 promoter (rAd/U6- <italic>Arg2</italic>-shRNA) and control rAd expressing shRNA targeting <italic>Lacz</italic> (rAd/U6-<italic>Lacz</italic>-shRNA) were generated as described previously (<xref ref-type="bibr" rid="bib52">Ming et al., 2009</xref>). Mitochondrial superoxide generation was monitored by MitoSOX. Briefly, the cells were incubated with MitoSOX at the concentration of 1 μmol/l for 30 min. After washing, the cells were then fixed with 3.7% paraformaldehyde followed by counterstaining with DAPI and then subjected to imaging through 40×objectives with Leica TCS SP5 confocal laser microscope. To ensure the mitochondria as a source of the ROS, cells were treated with Mito TEMPO (10 μmol/l, 1 hr) followed by MitoSOX staining.</p></sec><sec id="s4-14"><title>ELISA for IL-1β detection in conditioned media</title><p>IL-1β concentrations in the conditioned medium from murine splenic cells were measured by ELISA kits (mouse IL-1β, 432604, BioLegend, San Diego, USA) according to the manufacturer’s instructions. IL-1β concentrations in the conditioned medium from THP1 human cells were measured by ELISA kits (human IL-1β, 437004, BioLegend, San Diego, USA) according to the manufacturer’s instructions.</p></sec><sec id="s4-15"><title>Immunoblotting</title><p>Heart tissue or cell lysate preparation, SDS-PAGE and immunoblotting, antibody incubation, and signal detection were performed as described previously (<xref ref-type="bibr" rid="bib53">Ming et al., 2012</xref>). To prepare heart homogenates, frozen cardiac tissues were crushed into the fine powder using a mortar and pestle in liquid nitrogen on ice. A portion of the fine powder was then homogenized (XENOX-Motorhandstück MHX homogenizer) on ice in 150  µl of ice-cold lysis buffer with the following composition: 10 mmol/l Tris-HCl (pH 7.4), 0.4% Triton X-100, 10 μg/ml leupeptin, and 0.1 mmol/l phenylmethylsulfonyl fluoride (PMSF), protease inhibitor cocktail (B14002, Bio-Tool) and phosphatase inhibitor cocktail (B15002; Bio-Tool). Homogenates were centrifuged (Sorvall Legend Micro 17 R) at 13,000 ×<italic> g</italic> for 15  min at 4°C. Protein concentrations of supernatants were determined by Lowry method (500–0116, Bio-Rad). An equal amount of protein from each sample was heated at 75°C for 15  min in loading buffer and separated by SDS-PAGE electrophoresis. Proteins in the SDS-PAGE gel were then transferred to PVDF membranes which are blocked with PBS-Tween-20 supplemented with 5% skimmed milk. The membranes were then incubated with the corresponding primary antibody overnight at 4°C with gentle agitation. After washing with blocking buffer, the membranes were then incubated with the corresponding anti-mouse or anti-rabbit secondary antibody. Signals were visualized using the Odyssey Infrared Imaging System (LI-COR Biosciences), or the FUSION FX Imaging system (Witec AG) for chemiluminescence, and quantified by Image Studio Lite (5.2, LI-COR Biosciences). The antibodies used in this study are listed in the <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>.</p></sec><sec id="s4-16"><title>Statistical analysis</title><p>Data was presented as mean  ± SD. Data distribution was determined by Kolmogorov-Smirnov test and statistical analysis was performed by using GraphPad Prism software. Student’s T test or analysis of variance (ANOVA) with post hoc test was used to test significance. Differences in mean values were considered statistically significant at a two-tailed p-value≤0.05.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Validation, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis, Validation, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Data curation, Formal analysis, Validation, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Conceptualization, Resources, Data curation, Supervision, Funding acquisition, Validation, Investigation, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Investigation, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Experimental work with animals was approved by the Ethical Committee of the Veterinary Office of Fribourg Switzerland (2020-01-FR, and 2019-21-FR) and performed in compliance with guidelines on animal experimentation at our institution. The study was conducted according to the principles expressed in the Declaration of Helsinki.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Baseline comparison between <italic>wt</italic> and <italic>Arg2<sup>-/-</sup></italic> mice under Langendorff recordings.</title></caption><media xlink:href="elife-94794-supp1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>List of RT-PCR primer sequences.</title></caption><media xlink:href="elife-94794-supp2-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>List of antibodies used in the study with specific dilutions for immunoblotting and immunofluorescence staining.</title></caption><media xlink:href="elife-94794-supp3-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp4"><label>Supplementary file 4.</label><caption><title>Short tandem repeat (STR) profiling of RAW 264.7, which shows 98.6% concordance with reference cell lines in the Cellosaurus database, confirming the cell line identity.</title></caption><media xlink:href="elife-94794-supp4-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material><supplementary-material id="supp5"><label>Supplementary file 5.</label><caption><title>Short tandem repeat (STR) profiling of THP1 wt, which shows 100% concordance with reference cell lines in the Cellosaurus database, confirming the cell line identity.</title></caption><media xlink:href="elife-94794-supp5-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material><supplementary-material id="supp6"><label>Supplementary file 6.</label><caption><title>Short tandem repeat (STR) profiling of THP1 <italic>Arg2</italic> knockout, which shows 100% concordance with reference cell lines in the Cellosaurus database, confirming the cell line identity.</title></caption><media xlink:href="elife-94794-supp6-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material><supplementary-material id="supp7"><label>Supplementary file 7.</label><caption><title>Short tandem repeat (STR) profiling of wt bone-marrow-derived macrophage cell line.</title></caption><media xlink:href="elife-94794-supp7-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material><supplementary-material id="supp8"><label>Supplementary file 8.</label><caption><title>Short tandem repeat (STR) profiling of <italic>Nos2</italic> knockout bone-marrow-derived macrophage cell line.</title></caption><media xlink:href="elife-94794-supp8-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-94794-mdarchecklist1-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All datasets generated and analyzed during this study (including western blot images) have been deposited in the Dryad Digital Repository and are publicly available at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5061/dryad.hx3ffbgrt">https://doi.org/10.5061/dryad.hx3ffbgrt</ext-link>. Further details regarding the dataset content, structure, and data organization are fully described within the Dryad entry.</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Potenza</surname><given-names>DM</given-names></name><name><surname>Cheng</surname><given-names>X</given-names></name><name><surname>Ajalbert</surname><given-names>G</given-names></name><name><surname>Brenna</surname><given-names>A</given-names></name><name><surname>Giraud</surname><given-names>M</given-names></name><name><surname>Frobert</surname><given-names>A</given-names></name><name><surname>Cook</surname><given-names>S</given-names></name><name><surname>Mertz</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Ming</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2025">2025</year><data-title>Cell-autonomous and non-cell-autonomous effects of Arginase 2 on cardiac aging</data-title><source>Dryad Digital Repository</source><pub-id pub-id-type="doi">10.5061/dryad.hx3ffbgrt</pub-id></element-citation></p><p>The following previously published dataset was used:</p><p><element-citation publication-type="data" specific-use="references" id="dataset2"><person-group person-group-type="author"><name><surname>Wolff</surname><given-names>C</given-names></name><name><surname>Gutierrez-Monreal</surname><given-names>M</given-names></name><name><surname>Meng</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Douma</surname><given-names>L</given-names></name><name><surname>Costello</surname><given-names>H</given-names></name><name><surname>Douglas</surname><given-names>C</given-names></name><name><surname>Ebrahimi</surname><given-names>E</given-names></name><name><surname>Alava</surname><given-names>B</given-names></name><name><surname>Morris</surname><given-names>A</given-names></name><name><surname>Endale</surname><given-names>M</given-names></name><name><surname>Crislip</surname><given-names>G</given-names></name><name><surname>Cheng</surname><given-names>K</given-names></name><name><surname>Schroder</surname><given-names>E</given-names></name><name><surname>Delisle</surname><given-names>B</given-names></name><name><surname>Bryant</surname><given-names>A</given-names></name><name><surname>Gumz</surname><given-names>M</given-names></name><name><surname>Huo</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>A</given-names></name><name><surname>Esser</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>Defining the age-dependent and tissue-specific circadian transcriptome in male mice</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE201207">GSE201207</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdellatif</surname><given-names>M</given-names></name><name><surname>Rainer</surname><given-names>PP</given-names></name><name><surname>Sedej</surname><given-names>S</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Hallmarks of cardiovascular ageing</article-title><source>Nature Reviews. Cardiology</source><volume>20</volume><fpage>754</fpage><lpage>777</lpage><pub-id pub-id-type="doi">10.1038/s41569-023-00881-3</pub-id><pub-id pub-id-type="pmid">37193857</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agostini</surname><given-names>L</given-names></name><name><surname>Martinon</surname><given-names>F</given-names></name><name><surname>Burns</surname><given-names>K</given-names></name><name><surname>McDermott</surname><given-names>MF</given-names></name><name><surname>Hawkins</surname><given-names>PN</given-names></name><name><surname>Tschopp</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder</article-title><source>Immunity</source><volume>20</volume><fpage>319</fpage><lpage>325</lpage><pub-id pub-id-type="doi">10.1016/s1074-7613(04)00046-9</pub-id><pub-id pub-id-type="pmid">15030775</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alili</surname><given-names>L</given-names></name><name><surname>Sack</surname><given-names>M</given-names></name><name><surname>Puschmann</surname><given-names>K</given-names></name><name><surname>Brenneisen</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Fibroblast-to-myofibroblast switch is mediated by NAD(P)H oxidase generated reactive oxygen species</article-title><source>Bioscience Reports</source><volume>34</volume><elocation-id>e00089</elocation-id><pub-id pub-id-type="doi">10.1042/BSR20130091</pub-id><pub-id pub-id-type="pmid">27919042</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atawia</surname><given-names>RT</given-names></name><name><surname>Toque</surname><given-names>HA</given-names></name><name><surname>Meghil</surname><given-names>MM</given-names></name><name><surname>Benson</surname><given-names>TW</given-names></name><name><surname>Yiew</surname><given-names>NKH</given-names></name><name><surname>Cutler</surname><given-names>CW</given-names></name><name><surname>Weintraub</surname><given-names>NL</given-names></name><name><surname>Caldwell</surname><given-names>RB</given-names></name><name><surname>Caldwell</surname><given-names>RW</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Role of arginase 2 in systemic metabolic activity and adipose tissue fatty acid metabolism in diet-induced obese mice</article-title><source>International Journal of Molecular Sciences</source><volume>20</volume><elocation-id>1462</elocation-id><pub-id pub-id-type="doi">10.3390/ijms20061462</pub-id><pub-id pub-id-type="pmid">30909461</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bederson</surname><given-names>JB</given-names></name><name><surname>Pitts</surname><given-names>LH</given-names></name><name><surname>Germano</surname><given-names>SM</given-names></name><name><surname>Nishimura</surname><given-names>MC</given-names></name><name><surname>Davis</surname><given-names>RL</given-names></name><name><surname>Bartkowski</surname><given-names>HM</given-names></name></person-group><year iso-8601-date="1986">1986</year><article-title>Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats</article-title><source>Stroke</source><volume>17</volume><fpage>1304</fpage><lpage>1308</lpage><pub-id pub-id-type="doi">10.1161/01.str.17.6.1304</pub-id><pub-id pub-id-type="pmid">2433817</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Besse</surname><given-names>S</given-names></name><name><surname>Robert</surname><given-names>V</given-names></name><name><surname>Assayag</surname><given-names>P</given-names></name><name><surname>Delcayre</surname><given-names>C</given-names></name><name><surname>Swynghedauw</surname><given-names>B</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Nonsynchronous changes in myocardial collagen mRNA and protein during aging: effect of DOCA-salt hypertension</article-title><source>The American Journal of Physiology</source><volume>267</volume><fpage>H2237</fpage><lpage>H2244</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.1994.267.6.H2237</pub-id><pub-id pub-id-type="pmid">7810723</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bogdan</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Nitric oxide synthase in innate and adaptive immunity: an update</article-title><source>Trends in Immunology</source><volume>36</volume><fpage>161</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1016/j.it.2015.01.003</pub-id><pub-id pub-id-type="pmid">25687683</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borrego</surname><given-names>I</given-names></name><name><surname>Frobert</surname><given-names>A</given-names></name><name><surname>Ajalbert</surname><given-names>G</given-names></name><name><surname>Valentin</surname><given-names>J</given-names></name><name><surname>Kaltenrieder</surname><given-names>C</given-names></name><name><surname>Fellay</surname><given-names>B</given-names></name><name><surname>Stumpe</surname><given-names>M</given-names></name><name><surname>Cook</surname><given-names>S</given-names></name><name><surname>Dengjel</surname><given-names>J</given-names></name><name><surname>Giraud</surname><given-names>MN</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Fibrin, bone marrow cells and macrophages interactively modulate cardiomyoblast fate</article-title><source>Biomedicines</source><volume>10</volume><elocation-id>527</elocation-id><pub-id pub-id-type="doi">10.3390/biomedicines10030527</pub-id><pub-id pub-id-type="pmid">35327330</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bujak</surname><given-names>M</given-names></name><name><surname>Kweon</surname><given-names>HJ</given-names></name><name><surname>Chatila</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Taffet</surname><given-names>G</given-names></name><name><surname>Frangogiannis</surname><given-names>NG</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Aging-related defects are associated with adverse cardiac remodeling in a mouse model of reperfused myocardial infarction</article-title><source>Journal of the American College of Cardiology</source><volume>51</volume><fpage>1384</fpage><lpage>1392</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2008.01.011</pub-id><pub-id pub-id-type="pmid">18387441</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caldwell</surname><given-names>RB</given-names></name><name><surname>Toque</surname><given-names>HA</given-names></name><name><surname>Narayanan</surname><given-names>SP</given-names></name><name><surname>Caldwell</surname><given-names>RW</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Arginase: an old enzyme with new tricks</article-title><source>Trends in Pharmacological Sciences</source><volume>36</volume><fpage>395</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2015.03.006</pub-id><pub-id pub-id-type="pmid">25930708</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cevenini</surname><given-names>E</given-names></name><name><surname>Monti</surname><given-names>D</given-names></name><name><surname>Franceschi</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Inflamm-ageing</article-title><source>Current Opinion in Clinical Nutrition and Metabolic Care</source><volume>16</volume><fpage>14</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1097/MCO.0b013e32835ada13</pub-id><pub-id pub-id-type="pmid">23132168</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>CI</given-names></name><name><surname>Liao</surname><given-names>JC</given-names></name><name><surname>Kuo</surname><given-names>L</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Arginase modulates nitric oxide production in activated macrophages</article-title><source>American Journal of Physiology-Heart and Circulatory Physiology</source><volume>274</volume><fpage>H342</fpage><lpage>H348</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.1998.274.1.H342</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cullen</surname><given-names>SP</given-names></name><name><surname>Kearney</surname><given-names>CJ</given-names></name><name><surname>Clancy</surname><given-names>DM</given-names></name><name><surname>Martin</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Diverse activators of the NLRP3 inflammasome promote IL-1β secretion by triggering necrosis</article-title><source>Cell Reports</source><volume>11</volume><fpage>1535</fpage><lpage>1548</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2015.05.003</pub-id><pub-id pub-id-type="pmid">26027935</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Guzman</surname><given-names>RC</given-names></name><name><surname>Meer</surname><given-names>AS</given-names></name><name><surname>Mathews</surname><given-names>AA</given-names></name><name><surname>Israel</surname><given-names>AR</given-names></name><name><surname>Moses</surname><given-names>MT</given-names></name><name><surname>Sams</surname><given-names>CM</given-names></name><name><surname>Deegan</surname><given-names>DB</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Reduced fibrous capsule elastic fibers from biologic ECM-enveloped CIEDs in minipigs, supported with a novel compression mechanics model</article-title><source>Bio-Medical Materials and Engineering</source><volume>34</volume><fpage>289</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.3233/BME-221488</pub-id><pub-id pub-id-type="pmid">36617774</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dowling</surname><given-names>JK</given-names></name><name><surname>Afzal</surname><given-names>R</given-names></name><name><surname>Gearing</surname><given-names>LJ</given-names></name><name><surname>Cervantes-Silva</surname><given-names>MP</given-names></name><name><surname>Annett</surname><given-names>S</given-names></name><name><surname>Davis</surname><given-names>GM</given-names></name><name><surname>De Santi</surname><given-names>C</given-names></name><name><surname>Assmann</surname><given-names>N</given-names></name><name><surname>Dettmer</surname><given-names>K</given-names></name><name><surname>Gough</surname><given-names>DJ</given-names></name><name><surname>Bantug</surname><given-names>GR</given-names></name><name><surname>Hamid</surname><given-names>FI</given-names></name><name><surname>Nally</surname><given-names>FK</given-names></name><name><surname>Duffy</surname><given-names>CP</given-names></name><name><surname>Gorman</surname><given-names>AL</given-names></name><name><surname>Liddicoat</surname><given-names>AM</given-names></name><name><surname>Lavelle</surname><given-names>EC</given-names></name><name><surname>Hess</surname><given-names>C</given-names></name><name><surname>Oefner</surname><given-names>PJ</given-names></name><name><surname>Finlay</surname><given-names>DK</given-names></name><name><surname>Davey</surname><given-names>GP</given-names></name><name><surname>Robson</surname><given-names>T</given-names></name><name><surname>Curtis</surname><given-names>AM</given-names></name><name><surname>Hertzog</surname><given-names>PJ</given-names></name><name><surname>Williams</surname><given-names>BRG</given-names></name><name><surname>McCoy</surname><given-names>CE</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Mitochondrial arginase-2 is essential for IL-10 metabolic reprogramming of inflammatory macrophages</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>1460</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-21617-2</pub-id><pub-id pub-id-type="pmid">33674584</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durante</surname><given-names>W</given-names></name><name><surname>Johnson</surname><given-names>FK</given-names></name><name><surname>Johnson</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Arginase: a critical regulator of nitric oxide synthesis and vascular function</article-title><source>Clinical and Experimental Pharmacology &amp; Physiology</source><volume>34</volume><fpage>906</fpage><lpage>911</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1681.2007.04638.x</pub-id><pub-id pub-id-type="pmid">17645639</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esfahani</surname><given-names>NS</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Kumar</surname><given-names>N</given-names></name><name><surname>Ganesan</surname><given-names>LP</given-names></name><name><surname>Lafuse</surname><given-names>WP</given-names></name><name><surname>Rajaram</surname><given-names>MVS</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Aging influences the cardiac macrophage phenotype and function during steady state and during inflammation</article-title><source>Aging Cell</source><volume>20</volume><elocation-id>e13438</elocation-id><pub-id pub-id-type="doi">10.1111/acel.13438</pub-id><pub-id pub-id-type="pmid">34342127</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eslami</surname><given-names>SM</given-names></name><name><surname>Ghasemi</surname><given-names>M</given-names></name><name><surname>Bahremand</surname><given-names>T</given-names></name><name><surname>Momeny</surname><given-names>M</given-names></name><name><surname>Gholami</surname><given-names>M</given-names></name><name><surname>Sharifzadeh</surname><given-names>M</given-names></name><name><surname>Dehpour</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Involvement of nitrergic system in anticonvulsant effect of zolpidem in lithium-pilocarpine induced status epilepticus: Evaluation of iNOS and COX-2 genes expression</article-title><source>European Journal of Pharmacology</source><volume>815</volume><fpage>454</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2017.10.002</pub-id><pub-id pub-id-type="pmid">28987270</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evrard</surname><given-names>SM</given-names></name><name><surname>Lecce</surname><given-names>L</given-names></name><name><surname>Michelis</surname><given-names>KC</given-names></name><name><surname>Nomura-Kitabayashi</surname><given-names>A</given-names></name><name><surname>Pandey</surname><given-names>G</given-names></name><name><surname>Purushothaman</surname><given-names>K-R</given-names></name><name><surname>d’Escamard</surname><given-names>V</given-names></name><name><surname>Li</surname><given-names>JR</given-names></name><name><surname>Hadri</surname><given-names>L</given-names></name><name><surname>Fujitani</surname><given-names>K</given-names></name><name><surname>Moreno</surname><given-names>PR</given-names></name><name><surname>Benard</surname><given-names>L</given-names></name><name><surname>Rimmele</surname><given-names>P</given-names></name><name><surname>Cohain</surname><given-names>A</given-names></name><name><surname>Mecham</surname><given-names>B</given-names></name><name><surname>Randolph</surname><given-names>GJ</given-names></name><name><surname>Nabel</surname><given-names>EG</given-names></name><name><surname>Hajjar</surname><given-names>R</given-names></name><name><surname>Fuster</surname><given-names>V</given-names></name><name><surname>Boehm</surname><given-names>M</given-names></name><name><surname>Kovacic</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Endothelial to mesenchymal transition is common in atherosclerotic lesions and is associated with plaque instability</article-title><source>Nature Communications</source><volume>7</volume><elocation-id>11853</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms11853</pub-id><pub-id pub-id-type="pmid">27340017</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Godo</surname><given-names>S</given-names></name><name><surname>Shimokawa</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Endothelial Functions</article-title><source>Arteriosclerosis, Thrombosis, and Vascular Biology</source><volume>37</volume><fpage>e108</fpage><lpage>e114</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.117.309813</pub-id><pub-id pub-id-type="pmid">28835487</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Yan</surname><given-names>K</given-names></name><name><surname>Shi</surname><given-names>Z</given-names></name><name><surname>Leng</surname><given-names>J</given-names></name><name><surname>Bao</surname><given-names>Y</given-names></name><name><surname>Ning</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>The crosstalk between endothelial cells, smooth muscle cells, and macrophages in atherosclerosis</article-title><source>International Journal of Molecular Sciences</source><volume>26</volume><elocation-id>1457</elocation-id><pub-id pub-id-type="doi">10.3390/ijms26041457</pub-id><pub-id pub-id-type="pmid">40003923</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonon</surname><given-names>AT</given-names></name><name><surname>Jung</surname><given-names>C</given-names></name><name><surname>Katz</surname><given-names>A</given-names></name><name><surname>Westerblad</surname><given-names>H</given-names></name><name><surname>Shemyakin</surname><given-names>A</given-names></name><name><surname>Sjöquist</surname><given-names>P-O</given-names></name><name><surname>Lundberg</surname><given-names>JO</given-names></name><name><surname>Pernow</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Local arginase inhibition during early reperfusion mediates cardioprotection via increased nitric oxide production</article-title><source>PLOS ONE</source><volume>7</volume><elocation-id>e42038</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0042038</pub-id><pub-id pub-id-type="pmid">22860052</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartupee</surname><given-names>J</given-names></name><name><surname>Mann</surname><given-names>DL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Role of inflammatory cells in fibroblast activation</article-title><source>Journal of Molecular and Cellular Cardiology</source><volume>93</volume><fpage>143</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1016/j.yjmcc.2015.11.016</pub-id><pub-id pub-id-type="pmid">26593723</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayashi</surname><given-names>T</given-names></name><name><surname>Esaki</surname><given-names>T</given-names></name><name><surname>Sumi</surname><given-names>D</given-names></name><name><surname>Mukherjee</surname><given-names>T</given-names></name><name><surname>Iguchi</surname><given-names>A</given-names></name><name><surname>Chaudhuri</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Modulating role of estradiol on arginase II expression in hyperlipidemic rabbits as an atheroprotective mechanism</article-title><source>PNAS</source><volume>103</volume><fpage>10485</fpage><lpage>10490</lpage><pub-id pub-id-type="doi">10.1073/pnas.0603918103</pub-id><pub-id pub-id-type="pmid">16801563</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heusch</surname><given-names>P</given-names></name><name><surname>Aker</surname><given-names>S</given-names></name><name><surname>Boengler</surname><given-names>K</given-names></name><name><surname>Deindl</surname><given-names>E</given-names></name><name><surname>van de Sand</surname><given-names>A</given-names></name><name><surname>Klein</surname><given-names>K</given-names></name><name><surname>Rassaf</surname><given-names>T</given-names></name><name><surname>Konietzka</surname><given-names>I</given-names></name><name><surname>Sewell</surname><given-names>A</given-names></name><name><surname>Menazza</surname><given-names>S</given-names></name><name><surname>Canton</surname><given-names>M</given-names></name><name><surname>Heusch</surname><given-names>G</given-names></name><name><surname>Di Lisa</surname><given-names>F</given-names></name><name><surname>Schulz</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Increased inducible nitric oxide synthase and arginase II expression in heart failure: no net nitrite/nitrate production and protein S-nitrosylation</article-title><source>American Journal of Physiology. Heart and Circulatory Physiology</source><volume>299</volume><fpage>H446</fpage><lpage>H453</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.01034.2009</pub-id><pub-id pub-id-type="pmid">20511413</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honold</surname><given-names>L</given-names></name><name><surname>Nahrendorf</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Resident and monocyte-derived macrophages in cardiovascular disease</article-title><source>Circulation Research</source><volume>122</volume><fpage>113</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.117.311071</pub-id><pub-id pub-id-type="pmid">29301844</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horn</surname><given-names>MA</given-names></name><name><surname>Trafford</surname><given-names>AW</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Aging and the cardiac collagen matrix: Novel mediators of fibrotic remodelling</article-title><source>Journal of Molecular and Cellular Cardiology</source><volume>93</volume><fpage>175</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1016/j.yjmcc.2015.11.005</pub-id><pub-id pub-id-type="pmid">26578393</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Rajapakse</surname><given-names>A</given-names></name><name><surname>Xiong</surname><given-names>Y</given-names></name><name><surname>Montani</surname><given-names>JP</given-names></name><name><surname>Verrey</surname><given-names>F</given-names></name><name><surname>Ming</surname><given-names>XF</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Genetic targeting of Arginase-II in mouse prevents renal oxidative stress and inflammation in diet-induced obesity</article-title><source>Frontiers in Physiology</source><volume>7</volume><elocation-id>560</elocation-id><pub-id pub-id-type="doi">10.3389/fphys.2016.00560</pub-id><pub-id pub-id-type="pmid">27920727</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>XW</given-names></name><name><surname>Pan</surname><given-names>MD</given-names></name><name><surname>Du</surname><given-names>PH</given-names></name><name><surname>Wang</surname><given-names>LX</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Arginase-2 protects myocardial ischemia-reperfusion injury via NF-κB/TNF-α pathway</article-title><source>European Review for Medical and Pharmacological Sciences</source><volume>22</volume><fpage>6529</fpage><lpage>6537</lpage><pub-id pub-id-type="doi">10.26355/eurrev_201810_16067</pub-id><pub-id pub-id-type="pmid">30338823</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Liang</surname><given-names>X</given-names></name><name><surname>Ladeiras</surname><given-names>D</given-names></name><name><surname>Fellay</surname><given-names>B</given-names></name><name><surname>Ming</surname><given-names>XF</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Role of tubular epithelial arginase-II in renal inflammaging</article-title><source>NPJ Aging and Mechanisms of Disease</source><volume>7</volume><elocation-id>5</elocation-id><pub-id pub-id-type="doi">10.1038/s41514-021-00057-8</pub-id><pub-id pub-id-type="pmid">33654066</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hulsmans</surname><given-names>M</given-names></name><name><surname>Sam</surname><given-names>F</given-names></name><name><surname>Nahrendorf</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Monocyte and macrophage contributions to cardiac remodeling</article-title><source>Journal of Molecular and Cellular Cardiology</source><volume>93</volume><fpage>149</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1016/j.yjmcc.2015.11.015</pub-id><pub-id pub-id-type="pmid">26593722</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hulsmans</surname><given-names>M</given-names></name><name><surname>Sager</surname><given-names>HB</given-names></name><name><surname>Roh</surname><given-names>JD</given-names></name><name><surname>Valero-Muñoz</surname><given-names>M</given-names></name><name><surname>Houstis</surname><given-names>NE</given-names></name><name><surname>Iwamoto</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Wilson</surname><given-names>RM</given-names></name><name><surname>Wojtkiewicz</surname><given-names>G</given-names></name><name><surname>Tricot</surname><given-names>B</given-names></name><name><surname>Osborne</surname><given-names>MT</given-names></name><name><surname>Hung</surname><given-names>J</given-names></name><name><surname>Vinegoni</surname><given-names>C</given-names></name><name><surname>Naxerova</surname><given-names>K</given-names></name><name><surname>Sosnovik</surname><given-names>DE</given-names></name><name><surname>Zile</surname><given-names>MR</given-names></name><name><surname>Bradshaw</surname><given-names>AD</given-names></name><name><surname>Liao</surname><given-names>R</given-names></name><name><surname>Tawakol</surname><given-names>A</given-names></name><name><surname>Weissleder</surname><given-names>R</given-names></name><name><surname>Rosenzweig</surname><given-names>A</given-names></name><name><surname>Swirski</surname><given-names>FK</given-names></name><name><surname>Sam</surname><given-names>F</given-names></name><name><surname>Nahrendorf</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Cardiac macrophages promote diastolic dysfunction</article-title><source>The Journal of Experimental Medicine</source><volume>215</volume><fpage>423</fpage><lpage>440</lpage><pub-id pub-id-type="doi">10.1084/jem.20171274</pub-id><pub-id pub-id-type="pmid">29339450</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jimenez</surname><given-names>J</given-names></name><name><surname>Lavine</surname><given-names>KJ</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The dynamic role of cardiac macrophages in aging and disease</article-title><source>Current Cardiology Reports</source><volume>24</volume><fpage>925</fpage><lpage>933</lpage><pub-id pub-id-type="doi">10.1007/s11886-022-01714-4</pub-id><pub-id pub-id-type="pmid">35595950</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>AS</given-names></name><name><surname>Kubo</surname><given-names>H</given-names></name><name><surname>Wilson</surname><given-names>R</given-names></name><name><surname>Houser</surname><given-names>SR</given-names></name><name><surname>Margulies</surname><given-names>KB</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Modulation of contractility by myocyte-derived arginase in normal and hypertrophied feline myocardium</article-title><source>American Journal of Physiology. Heart and Circulatory Physiology</source><volume>290</volume><fpage>H1756</fpage><lpage>H1762</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.01104.2005</pub-id><pub-id pub-id-type="pmid">16327014</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>C</given-names></name><name><surname>Gonon</surname><given-names>AT</given-names></name><name><surname>Sjöquist</surname><given-names>P-O</given-names></name><name><surname>Lundberg</surname><given-names>JO</given-names></name><name><surname>Pernow</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Arginase inhibition mediates cardioprotection during ischaemia-reperfusion</article-title><source>Cardiovascular Research</source><volume>85</volume><fpage>147</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvp303</pub-id><pub-id pub-id-type="pmid">19726439</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>M</given-names></name><name><surname>Steppan</surname><given-names>J</given-names></name><name><surname>Schuleri</surname><given-names>KH</given-names></name><name><surname>Ryoo</surname><given-names>S</given-names></name><name><surname>Tuday</surname><given-names>E</given-names></name><name><surname>Bugaj</surname><given-names>L</given-names></name><name><surname>Santhanam</surname><given-names>L</given-names></name><name><surname>Berkowitz</surname><given-names>T</given-names></name><name><surname>Nyhan</surname><given-names>D</given-names></name><name><surname>Shoukas</surname><given-names>AA</given-names></name><name><surname>Berkowitz</surname><given-names>DE</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Upregulation of arginase-II contributes to decreased age-related myocardial contractile reserve</article-title><source>European Journal of Applied Physiology</source><volume>112</volume><fpage>2933</fpage><lpage>2941</lpage><pub-id pub-id-type="doi">10.1007/s00421-011-2257-9</pub-id><pub-id pub-id-type="pmid">22160208</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kidder</surname><given-names>E</given-names></name><name><surname>Pea</surname><given-names>M</given-names></name><name><surname>Cheng</surname><given-names>S</given-names></name><name><surname>Koppada</surname><given-names>SP</given-names></name><name><surname>Visvanathan</surname><given-names>S</given-names></name><name><surname>Henderson</surname><given-names>Q</given-names></name><name><surname>Thuzar</surname><given-names>M</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Alfaidi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>The interleukin-1 receptor type-1 in disturbed flow-induced endothelial mesenchymal activation</article-title><source>Frontiers in Cardiovascular Medicine</source><volume>10</volume><elocation-id>1190460</elocation-id><pub-id pub-id-type="doi">10.3389/fcvm.2023.1190460</pub-id><pub-id pub-id-type="pmid">37539090</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levillain</surname><given-names>O</given-names></name><name><surname>Diaz</surname><given-names>J-J</given-names></name><name><surname>Blanchard</surname><given-names>O</given-names></name><name><surname>Déchaud</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Testosterone down-regulates ornithine aminotransferase gene and up-regulates arginase II and ornithine decarboxylase genes for polyamines synthesis in the murine kidney</article-title><source>Endocrinology</source><volume>146</volume><fpage>950</fpage><lpage>959</lpage><pub-id pub-id-type="doi">10.1210/en.2004-1199</pub-id><pub-id pub-id-type="pmid">15539552</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Ren</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Lv</surname><given-names>Z</given-names></name><name><surname>Qian</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Xiong</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Arginase: shedding light on the mechanisms and opportunities in cardiovascular diseases</article-title><source>Cell Death Discovery</source><volume>8</volume><elocation-id>413</elocation-id><pub-id pub-id-type="doi">10.1038/s41420-022-01200-4</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>X</given-names></name><name><surname>Arullampalam</surname><given-names>P</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Ming</surname><given-names>XF</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Hypoxia enhances endothelial intercellular adhesion molecule 1 protein level through upregulation of arginase type II and mitochondrial oxidative stress</article-title><source>Frontiers in Physiology</source><volume>10</volume><elocation-id>1003</elocation-id><pub-id pub-id-type="doi">10.3389/fphys.2019.01003</pub-id><pub-id pub-id-type="pmid">31474872</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>X</given-names></name><name><surname>Potenza</surname><given-names>DM</given-names></name><name><surname>Brenna</surname><given-names>A</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Ren</surname><given-names>Z</given-names></name><name><surname>Cheng</surname><given-names>X</given-names></name><name><surname>Ming</surname><given-names>XF</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Hypoxia induces renal epithelial injury and activates fibrotic signaling through up-regulation of Arginase-II</article-title><source>Frontiers in Physiology</source><volume>12</volume><elocation-id>773719</elocation-id><pub-id pub-id-type="doi">10.3389/fphys.2021.773719</pub-id><pub-id pub-id-type="pmid">34867480</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lillo</surname><given-names>R</given-names></name><name><surname>Graziani</surname><given-names>F</given-names></name><name><surname>Franceschi</surname><given-names>F</given-names></name><name><surname>Iannaccone</surname><given-names>G</given-names></name><name><surname>Massetti</surname><given-names>M</given-names></name><name><surname>Olivotto</surname><given-names>I</given-names></name><name><surname>Crea</surname><given-names>F</given-names></name><name><surname>Liuzzo</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Inflammation across the spectrum of hypertrophic cardiac phenotypes</article-title><source>Heart Failure Reviews</source><volume>28</volume><fpage>1065</fpage><lpage>1075</lpage><pub-id pub-id-type="doi">10.1007/s10741-023-10307-4</pub-id><pub-id pub-id-type="pmid">37115472</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Louch</surname><given-names>WE</given-names></name><name><surname>Sheehan</surname><given-names>KA</given-names></name><name><surname>Wolska</surname><given-names>BM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Methods in cardiomyocyte isolation, culture, and gene transfer</article-title><source>Journal of Molecular and Cellular Cardiology</source><volume>51</volume><fpage>288</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1016/j.yjmcc.2011.06.012</pub-id><pub-id pub-id-type="pmid">21723873</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>MJ</given-names></name><name><surname>Chen</surname><given-names>YS</given-names></name><name><surname>Huang</surname><given-names>HS</given-names></name><name><surname>Ma</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Erythropoietin alleviates post-ischemic injury of rat hearts by attenuating nitrosative stress</article-title><source>Life Sciences</source><volume>90</volume><fpage>776</fpage><lpage>784</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2012.04.012</pub-id><pub-id pub-id-type="pmid">22521289</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Hua</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>K</given-names></name><name><surname>Magaye</surname><given-names>R</given-names></name><name><surname>Cornell</surname><given-names>J</given-names></name><name><surname>Kelly</surname><given-names>DJ</given-names></name><name><surname>Reid</surname><given-names>C</given-names></name><name><surname>Liew</surname><given-names>D</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>A</given-names></name><name><surname>Xiao</surname><given-names>W</given-names></name><name><surname>Fu</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>BH</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Cardiac fibrosis in the ageing heart: Contributors and mechanisms</article-title><source>Clinical and Experimental Pharmacology &amp; Physiology</source><volume>44 Suppl 1</volume><fpage>55</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1111/1440-1681.12753</pub-id><pub-id pub-id-type="pmid">28316086</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luan</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Jiao</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Pei</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Ren</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Cardiac cell senescence: molecular mechanisms, key proteins and therapeutic targets</article-title><source>Cell Death Discovery</source><volume>10</volume><elocation-id>017925</elocation-id><pub-id pub-id-type="doi">10.1038/s41420-023-01792-5</pub-id><pub-id pub-id-type="pmid">38355681</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>S</given-names></name><name><surname>Lei</surname><given-names>H</given-names></name><name><surname>Qin</surname><given-names>H</given-names></name><name><surname>Xia</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Molecular mechanisms of endothelial NO synthase uncoupling</article-title><source>Current Pharmaceutical Design</source><volume>20</volume><fpage>3548</fpage><lpage>3553</lpage><pub-id pub-id-type="doi">10.2174/13816128113196660746</pub-id><pub-id pub-id-type="pmid">24180388</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mariani</surname><given-names>J</given-names></name><name><surname>Ou</surname><given-names>R</given-names></name><name><surname>Bailey</surname><given-names>M</given-names></name><name><surname>Rowland</surname><given-names>M</given-names></name><name><surname>Nagley</surname><given-names>P</given-names></name><name><surname>Rosenfeldt</surname><given-names>F</given-names></name><name><surname>Pepe</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Tolerance to ischemia and hypoxia is reduced in aged human myocardium</article-title><source>The Journal of Thoracic and Cardiovascular Surgery</source><volume>120</volume><fpage>660</fpage><lpage>667</lpage><pub-id pub-id-type="doi">10.1067/mtc.2000.106528</pub-id><pub-id pub-id-type="pmid">11003745</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>FO</given-names></name><name><surname>Gordon</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The M1 and M2 paradigm of macrophage activation: time for reassessment</article-title><source>F1000prime Reports</source><volume>6</volume><elocation-id>13</elocation-id><pub-id pub-id-type="doi">10.12703/P6-13</pub-id><pub-id pub-id-type="pmid">24669294</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meschiari</surname><given-names>CA</given-names></name><name><surname>Ero</surname><given-names>OK</given-names></name><name><surname>Pan</surname><given-names>H</given-names></name><name><surname>Finkel</surname><given-names>T</given-names></name><name><surname>Lindsey</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The impact of aging on cardiac extracellular matrix</article-title><source>GeroScience</source><volume>39</volume><fpage>7</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1007/s11357-017-9959-9</pub-id><pub-id pub-id-type="pmid">28299638</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ming</surname><given-names>XF</given-names></name><name><surname>Barandier</surname><given-names>C</given-names></name><name><surname>Viswambharan</surname><given-names>H</given-names></name><name><surname>Kwak</surname><given-names>BR</given-names></name><name><surname>Mach</surname><given-names>F</given-names></name><name><surname>Mazzolai</surname><given-names>L</given-names></name><name><surname>Hayoz</surname><given-names>D</given-names></name><name><surname>Ruffieux</surname><given-names>J</given-names></name><name><surname>Rusconi</surname><given-names>S</given-names></name><name><surname>Montani</surname><given-names>JP</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Thrombin stimulates human endothelial arginase enzymatic activity via RhoA/ROCK pathway: implications for atherosclerotic endothelial dysfunction</article-title><source>Circulation</source><volume>110</volume><fpage>3708</fpage><lpage>3714</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.0000142867.26182.32</pub-id><pub-id pub-id-type="pmid">15569838</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ming</surname><given-names>XF</given-names></name><name><surname>Rajapakse</surname><given-names>AG</given-names></name><name><surname>Carvas</surname><given-names>JM</given-names></name><name><surname>Ruffieux</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Inhibition of S6K1 accounts partially for the anti-inflammatory effects of the arginase inhibitor L-norvaline</article-title><source>BMC Cardiovascular Disorders</source><volume>9</volume><elocation-id>12</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2261-9-12</pub-id><pub-id pub-id-type="pmid">19284655</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ming</surname><given-names>XF</given-names></name><name><surname>Rajapakse</surname><given-names>AG</given-names></name><name><surname>Yepuri</surname><given-names>G</given-names></name><name><surname>Xiong</surname><given-names>Y</given-names></name><name><surname>Carvas</surname><given-names>JM</given-names></name><name><surname>Ruffieux</surname><given-names>J</given-names></name><name><surname>Scerri</surname><given-names>I</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Popp</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Sartori</surname><given-names>C</given-names></name><name><surname>Scherrer</surname><given-names>U</given-names></name><name><surname>Kwak</surname><given-names>BR</given-names></name><name><surname>Montani</surname><given-names>JP</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Arginase II promotes macrophage inflammatory responses through mitochondrial reactive oxygen species, contributing to insulin resistance and atherogenesis</article-title><source>Journal of the American Heart Association</source><volume>1</volume><elocation-id>e000992</elocation-id><pub-id pub-id-type="doi">10.1161/JAHA.112.000992</pub-id><pub-id pub-id-type="pmid">23130157</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ming</surname><given-names>XF</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Functions and mechanisms of arginase in age-associated cardiovascular diseases</article-title><source>Current Translational Geriatrics and Experimental Gerontology Reports</source><volume>2</volume><fpage>268</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1007/s13670-013-0060-7</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moretto</surname><given-names>J</given-names></name><name><surname>Girard</surname><given-names>C</given-names></name><name><surname>Demougeot</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The role of arginase in aging: A systematic review</article-title><source>Experimental Gerontology</source><volume>116</volume><fpage>54</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1016/j.exger.2018.12.011</pub-id><pub-id pub-id-type="pmid">30578842</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moturi</surname><given-names>S</given-names></name><name><surname>Ghosh-Choudhary</surname><given-names>SK</given-names></name><name><surname>Finkel</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Cardiovascular disease and the biology of aging</article-title><source>Journal of Molecular and Cellular Cardiology</source><volume>167</volume><fpage>109</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1016/j.yjmcc.2022.04.005</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murdoch</surname><given-names>CE</given-names></name><name><surname>Chaubey</surname><given-names>S</given-names></name><name><surname>Zeng</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>B</given-names></name><name><surname>Ivetic</surname><given-names>A</given-names></name><name><surname>Walker</surname><given-names>SJ</given-names></name><name><surname>Vanhoutte</surname><given-names>D</given-names></name><name><surname>Heymans</surname><given-names>S</given-names></name><name><surname>Grieve</surname><given-names>DJ</given-names></name><name><surname>Cave</surname><given-names>AC</given-names></name><name><surname>Brewer</surname><given-names>AC</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Shah</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Endothelial NADPH oxidase-2 promotes interstitial cardiac fibrosis and diastolic dysfunction through proinflammatory effects and endothelial-mesenchymal transition</article-title><source>Journal of the American College of Cardiology</source><volume>63</volume><fpage>2734</fpage><lpage>2741</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2014.02.572</pub-id><pub-id pub-id-type="pmid">24681145</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>E</given-names></name><name><surname>Steenbergen</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Gender-based differences in mechanisms of protection in myocardial ischemia–reperfusion injury</article-title><source>Cardiovascular Research</source><volume>75</volume><fpage>478</fpage><lpage>486</lpage><pub-id pub-id-type="doi">10.1016/j.cardiores.2007.03.025</pub-id><pub-id pub-id-type="pmid">17466956</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohtsu</surname><given-names>H</given-names></name><name><surname>Frank</surname><given-names>GD</given-names></name><name><surname>Utsunomiya</surname><given-names>H</given-names></name><name><surname>Eguchi</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Redox-dependent protein kinase regulation by angiotensin II: mechanistic insights and its pathophysiology</article-title><source>Antioxidants &amp; Redox Signaling</source><volume>7</volume><fpage>1315</fpage><lpage>1326</lpage><pub-id pub-id-type="doi">10.1089/ars.2005.7.1315</pub-id><pub-id pub-id-type="pmid">16115037</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Percie du Sert</surname><given-names>N</given-names></name><name><surname>Ahluwalia</surname><given-names>A</given-names></name><name><surname>Alam</surname><given-names>S</given-names></name><name><surname>Avey</surname><given-names>MT</given-names></name><name><surname>Baker</surname><given-names>M</given-names></name><name><surname>Browne</surname><given-names>WJ</given-names></name><name><surname>Clark</surname><given-names>A</given-names></name><name><surname>Cuthill</surname><given-names>IC</given-names></name><name><surname>Dirnagl</surname><given-names>U</given-names></name><name><surname>Emerson</surname><given-names>M</given-names></name><name><surname>Garner</surname><given-names>P</given-names></name><name><surname>Holgate</surname><given-names>ST</given-names></name><name><surname>Howells</surname><given-names>DW</given-names></name><name><surname>Hurst</surname><given-names>V</given-names></name><name><surname>Karp</surname><given-names>NA</given-names></name><name><surname>Lazic</surname><given-names>SE</given-names></name><name><surname>Lidster</surname><given-names>K</given-names></name><name><surname>MacCallum</surname><given-names>CJ</given-names></name><name><surname>Macleod</surname><given-names>M</given-names></name><name><surname>Pearl</surname><given-names>EJ</given-names></name><name><surname>Petersen</surname><given-names>OH</given-names></name><name><surname>Rawle</surname><given-names>F</given-names></name><name><surname>Reynolds</surname><given-names>P</given-names></name><name><surname>Rooney</surname><given-names>K</given-names></name><name><surname>Sena</surname><given-names>ES</given-names></name><name><surname>Silberberg</surname><given-names>SD</given-names></name><name><surname>Steckler</surname><given-names>T</given-names></name><name><surname>Würbel</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Reporting animal research: Explanation and elaboration for the ARRIVE guidelines 2.0</article-title><source>PLOS Biology</source><volume>18</volume><elocation-id>e3000411</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.3000411</pub-id><pub-id pub-id-type="pmid">32663221</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Redfors</surname><given-names>B</given-names></name><name><surname>Shao</surname><given-names>Y</given-names></name><name><surname>Omerovic</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Myocardial infarct size and area at risk assessment in mice</article-title><source>Experimental and Clinical Cardiology</source><volume>17</volume><fpage>268</fpage><lpage>272</lpage><pub-id pub-id-type="pmid">23592952</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>Z</given-names></name><name><surname>Potenza</surname><given-names>DM</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Ajalbert</surname><given-names>G</given-names></name><name><surname>Hoogewijs</surname><given-names>D</given-names></name><name><surname>Ming</surname><given-names>XF</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Role of Arginase-II in podocyte injury under hypoxic conditions</article-title><source>Biomolecules</source><volume>12</volume><elocation-id>1213</elocation-id><pub-id pub-id-type="doi">10.3390/biom12091213</pub-id><pub-id pub-id-type="pmid">36139052</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ridker</surname><given-names>PM</given-names></name><name><surname>Everett</surname><given-names>BM</given-names></name><name><surname>Thuren</surname><given-names>T</given-names></name><name><surname>MacFadyen</surname><given-names>JG</given-names></name><name><surname>Chang</surname><given-names>WH</given-names></name><name><surname>Ballantyne</surname><given-names>C</given-names></name><name><surname>Fonseca</surname><given-names>F</given-names></name><name><surname>Nicolau</surname><given-names>J</given-names></name><name><surname>Koenig</surname><given-names>W</given-names></name><name><surname>Anker</surname><given-names>SD</given-names></name><name><surname>Kastelein</surname><given-names>JJP</given-names></name><name><surname>Cornel</surname><given-names>JH</given-names></name><name><surname>Pais</surname><given-names>P</given-names></name><name><surname>Pella</surname><given-names>D</given-names></name><name><surname>Genest</surname><given-names>J</given-names></name><name><surname>Cifkova</surname><given-names>R</given-names></name><name><surname>Lorenzatti</surname><given-names>A</given-names></name><name><surname>Forster</surname><given-names>T</given-names></name><name><surname>Kobalava</surname><given-names>Z</given-names></name><name><surname>Vida-Simiti</surname><given-names>L</given-names></name><name><surname>Flather</surname><given-names>M</given-names></name><name><surname>Shimokawa</surname><given-names>H</given-names></name><name><surname>Ogawa</surname><given-names>H</given-names></name><name><surname>Dellborg</surname><given-names>M</given-names></name><name><surname>Rossi</surname><given-names>PRF</given-names></name><name><surname>Troquay</surname><given-names>RPT</given-names></name><name><surname>Libby</surname><given-names>P</given-names></name><name><surname>Glynn</surname><given-names>RJ</given-names></name><collab>CANTOS Trial Group</collab></person-group><year iso-8601-date="2017">2017</year><article-title>Antiinflammatory therapy with canakinumab for atherosclerotic disease</article-title><source>The New England Journal of Medicine</source><volume>377</volume><fpage>1119</fpage><lpage>1131</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1707914</pub-id><pub-id pub-id-type="pmid">28845751</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruiz-Meana</surname><given-names>M</given-names></name><name><surname>Bou-Teen</surname><given-names>D</given-names></name><name><surname>Ferdinandy</surname><given-names>P</given-names></name><name><surname>Gyongyosi</surname><given-names>M</given-names></name><name><surname>Pesce</surname><given-names>M</given-names></name><name><surname>Perrino</surname><given-names>C</given-names></name><name><surname>Schulz</surname><given-names>R</given-names></name><name><surname>Sluijter</surname><given-names>JPG</given-names></name><name><surname>Tocchetti</surname><given-names>CG</given-names></name><name><surname>Thum</surname><given-names>T</given-names></name><name><surname>Madonna</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Cardiomyocyte ageing and cardioprotection: consensus document from the ESC working groups cell biology of the heart and myocardial function</article-title><source>Cardiovascular Research</source><volume>116</volume><fpage>1835</fpage><lpage>1849</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvaa132</pub-id><pub-id pub-id-type="pmid">32384145</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>O</given-names></name><name><surname>Morris</surname><given-names>SM</given-names><suffix>Jr</suffix></name><name><surname>Zoghbi</surname><given-names>H</given-names></name><name><surname>Porter</surname><given-names>CW</given-names></name><name><surname>O’Brien</surname><given-names>WE</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Generation of a mouse model for Arginase II deficiency by targeted disruption of the arginase II gene</article-title><source>Molecular and Cellular Biology</source><volume>21</volume><fpage>811</fpage><lpage>813</lpage><pub-id pub-id-type="doi">10.1128/MCB.21.3.811-813.2001</pub-id><pub-id pub-id-type="pmid">11154268</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sin</surname><given-names>YY</given-names></name><name><surname>Baron</surname><given-names>G</given-names></name><name><surname>Schulze</surname><given-names>A</given-names></name><name><surname>Funk</surname><given-names>CD</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Arginase-1 deficiency</article-title><source>Journal of Molecular Medicine</source><volume>93</volume><fpage>1287</fpage><lpage>1296</lpage><pub-id pub-id-type="doi">10.1007/s00109-015-1354-3</pub-id><pub-id pub-id-type="pmid">26467175</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steppan</surname><given-names>J</given-names></name><name><surname>Ryoo</surname><given-names>S</given-names></name><name><surname>Schuleri</surname><given-names>KH</given-names></name><name><surname>Gregg</surname><given-names>C</given-names></name><name><surname>Hasan</surname><given-names>RK</given-names></name><name><surname>White</surname><given-names>AR</given-names></name><name><surname>Bugaj</surname><given-names>LJ</given-names></name><name><surname>Khan</surname><given-names>M</given-names></name><name><surname>Santhanam</surname><given-names>L</given-names></name><name><surname>Nyhan</surname><given-names>D</given-names></name><name><surname>Shoukas</surname><given-names>AA</given-names></name><name><surname>Hare</surname><given-names>JM</given-names></name><name><surname>Berkowitz</surname><given-names>DE</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Arginase modulates myocardial contractility by a nitric oxide synthase 1-dependent mechanism</article-title><source>PNAS</source><volume>103</volume><fpage>4759</fpage><lpage>4764</lpage><pub-id pub-id-type="doi">10.1073/pnas.0506589103</pub-id><pub-id pub-id-type="pmid">16537391</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suku</surname><given-names>M</given-names></name><name><surname>Forrester</surname><given-names>L</given-names></name><name><surname>Biggs</surname><given-names>M</given-names></name><name><surname>Monaghan</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Resident macrophages and their potential in cardiac tissue engineering</article-title><source>Tissue Engineering Part B</source><volume>28</volume><fpage>579</fpage><lpage>591</lpage><pub-id pub-id-type="doi">10.1089/ten.teb.2021.0036</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swirski</surname><given-names>FK</given-names></name><name><surname>Nahrendorf</surname><given-names>M</given-names></name><name><surname>Etzrodt</surname><given-names>M</given-names></name><name><surname>Wildgruber</surname><given-names>M</given-names></name><name><surname>Cortez-Retamozo</surname><given-names>V</given-names></name><name><surname>Panizzi</surname><given-names>P</given-names></name><name><surname>Figueiredo</surname><given-names>JL</given-names></name><name><surname>Kohler</surname><given-names>RH</given-names></name><name><surname>Chudnovskiy</surname><given-names>A</given-names></name><name><surname>Waterman</surname><given-names>P</given-names></name><name><surname>Aikawa</surname><given-names>E</given-names></name><name><surname>Mempel</surname><given-names>TR</given-names></name><name><surname>Libby</surname><given-names>P</given-names></name><name><surname>Weissleder</surname><given-names>R</given-names></name><name><surname>Pittet</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Identification of splenic reservoir monocytes and their deployment to inflammatory sites</article-title><source>Science</source><volume>325</volume><fpage>612</fpage><lpage>616</lpage><pub-id pub-id-type="doi">10.1126/science.1175202</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uchida</surname><given-names>Y</given-names></name><name><surname>Torisu</surname><given-names>K</given-names></name><name><surname>Aihara</surname><given-names>S</given-names></name><name><surname>Imazu</surname><given-names>N</given-names></name><name><surname>Ooboshi</surname><given-names>H</given-names></name><name><surname>Kitazono</surname><given-names>T</given-names></name><name><surname>Nakano</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Arginase 2 promotes cisplatin-induced acute kidney injury by the inflammatory response of macrophages</article-title><source>Laboratory Investigation; a Journal of Technical Methods and Pathology</source><volume>103</volume><elocation-id>100227</elocation-id><pub-id pub-id-type="doi">10.1016/j.labinv.2023.100227</pub-id><pub-id pub-id-type="pmid">37541621</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vakka</surname><given-names>A</given-names></name><name><surname>Warren</surname><given-names>JS</given-names></name><name><surname>Drosatos</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Cardiovascular aging: from cellular and molecular changes to therapeutic interventions</article-title><source>The Journal of Cardiovascular Aging</source><volume>3</volume><elocation-id>23</elocation-id><pub-id pub-id-type="doi">10.20517/jca.2023.09</pub-id><pub-id pub-id-type="pmid">37274126</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Cao</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>G</given-names></name><name><surname>Tan</surname><given-names>TK</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Harris</surname><given-names>DC</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Characterization of murine macrophages from bone marrow, spleen and peritoneum</article-title><source>BMC Immunology</source><volume>14</volume><elocation-id>6</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2172-14-6</pub-id><pub-id pub-id-type="pmid">23384230</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Sano</surname><given-names>S</given-names></name><name><surname>Yura</surname><given-names>Y</given-names></name><name><surname>Ke</surname><given-names>Z</given-names></name><name><surname>Sano</surname><given-names>M</given-names></name><name><surname>Oshima</surname><given-names>K</given-names></name><name><surname>Ogawa</surname><given-names>H</given-names></name><name><surname>Horitani</surname><given-names>K</given-names></name><name><surname>Min</surname><given-names>KD</given-names></name><name><surname>Miura-Yura</surname><given-names>E</given-names></name><name><surname>Kour</surname><given-names>A</given-names></name><name><surname>Evans</surname><given-names>MA</given-names></name><name><surname>Zuriaga</surname><given-names>MA</given-names></name><name><surname>Hirschi</surname><given-names>KK</given-names></name><name><surname>Fuster</surname><given-names>JJ</given-names></name><name><surname>Pietras</surname><given-names>EM</given-names></name><name><surname>Walsh</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Tet2-mediated clonal hematopoiesis in nonconditioned mice accelerates age-associated cardiac dysfunction</article-title><source>JCI Insight</source><volume>5</volume><elocation-id>e135204</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.135204</pub-id><pub-id pub-id-type="pmid">32154790</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinberger</surname><given-names>T</given-names></name><name><surname>Denise</surname><given-names>M</given-names></name><name><surname>Joppich</surname><given-names>M</given-names></name><name><surname>Fischer</surname><given-names>M</given-names></name><name><surname>Garcia Rodriguez</surname><given-names>C</given-names></name><name><surname>Kumaraswami</surname><given-names>K</given-names></name><name><surname>Wimmler</surname><given-names>V</given-names></name><name><surname>Ablinger</surname><given-names>S</given-names></name><name><surname>Räuber</surname><given-names>S</given-names></name><name><surname>Fang</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>WH</given-names></name><name><surname>Winterhalter</surname><given-names>J</given-names></name><name><surname>Lichti</surname><given-names>J</given-names></name><name><surname>Thomas</surname><given-names>L</given-names></name><name><surname>Esfandyari</surname><given-names>D</given-names></name><name><surname>Percin</surname><given-names>G</given-names></name><name><surname>Matin</surname><given-names>S</given-names></name><name><surname>Hidalgo</surname><given-names>A</given-names></name><name><surname>Waskow</surname><given-names>C</given-names></name><name><surname>Engelhardt</surname><given-names>S</given-names></name><name><surname>Todica</surname><given-names>A</given-names></name><name><surname>Zimmer</surname><given-names>R</given-names></name><name><surname>Pridans</surname><given-names>C</given-names></name><name><surname>Gomez Perdiguero</surname><given-names>E</given-names></name><name><surname>Schulz</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Resident and recruited macrophages differentially contribute to cardiac healing after myocardial ischemia</article-title><source>eLife</source><volume>12</volume><elocation-id>89377</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.89377</pub-id><pub-id pub-id-type="pmid">38775664</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolff</surname><given-names>CA</given-names></name><name><surname>Gutierrez-Monreal</surname><given-names>MA</given-names></name><name><surname>Meng</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Douma</surname><given-names>LG</given-names></name><name><surname>Costello</surname><given-names>HM</given-names></name><name><surname>Douglas</surname><given-names>CM</given-names></name><name><surname>Ebrahimi</surname><given-names>E</given-names></name><name><surname>Pham</surname><given-names>A</given-names></name><name><surname>Oliveira</surname><given-names>AC</given-names></name><name><surname>Fu</surname><given-names>C</given-names></name><name><surname>Nguyen</surname><given-names>A</given-names></name><name><surname>Alava</surname><given-names>BR</given-names></name><name><surname>Hesketh</surname><given-names>SJ</given-names></name><name><surname>Morris</surname><given-names>AR</given-names></name><name><surname>Endale</surname><given-names>MM</given-names></name><name><surname>Crislip</surname><given-names>GR</given-names></name><name><surname>Cheng</surname><given-names>K-Y</given-names></name><name><surname>Schroder</surname><given-names>EA</given-names></name><name><surname>Delisle</surname><given-names>BP</given-names></name><name><surname>Bryant</surname><given-names>AJ</given-names></name><name><surname>Gumz</surname><given-names>ML</given-names></name><name><surname>Huo</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>AC</given-names></name><name><surname>Esser</surname><given-names>KA</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Defining the age-dependent and tissue-specific circadian transcriptome in male mice</article-title><source>Cell Reports</source><volume>42</volume><elocation-id>111982</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2022.111982</pub-id><pub-id pub-id-type="pmid">36640301</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Montani</surname><given-names>JP</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Ming</surname><given-names>XF</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Arginase-II induces vascular smooth muscle cell senescence and apoptosis through p66Shc and p53 independently of its l-arginine ureahydrolase activity: implications for atherosclerotic plaque vulnerability</article-title><source>Journal of the American Heart Association</source><volume>2</volume><elocation-id>e000096</elocation-id><pub-id pub-id-type="doi">10.1161/JAHA.113.000096</pub-id><pub-id pub-id-type="pmid">23832324</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>Y</given-names></name><name><surname>Yepuri</surname><given-names>G</given-names></name><name><surname>Montani</surname><given-names>JP</given-names></name><name><surname>Ming</surname><given-names>XF</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2017">2017a</year><article-title>Arginase-II deficiency extends lifespan in mice</article-title><source>Frontiers in Physiology</source><volume>8</volume><elocation-id>682</elocation-id><pub-id pub-id-type="doi">10.3389/fphys.2017.00682</pub-id><pub-id pub-id-type="pmid">28943853</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>Y</given-names></name><name><surname>Yepuri</surname><given-names>G</given-names></name><name><surname>Necetin</surname><given-names>S</given-names></name><name><surname>Montani</surname><given-names>JP</given-names></name><name><surname>Ming</surname><given-names>XF</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2017">2017b</year><article-title>Arginase-II promotes tumor necrosis factor-α release from pancreatic acinar cells causing β-Cell apoptosis in aging</article-title><source>Diabetes</source><volume>66</volume><fpage>1636</fpage><lpage>1649</lpage><pub-id pub-id-type="doi">10.2337/db16-1190</pub-id><pub-id pub-id-type="pmid">28356309</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Kovacic</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Endothelial to mesenchymal transition in health and disease</article-title><source>Annual Review of Physiology</source><volume>85</volume><fpage>245</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1146/annurev-physiol-032222-080806</pub-id><pub-id pub-id-type="pmid">36266259</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Ming</surname><given-names>XF</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Functions of arginase isoforms in macrophage inflammatory responses: impact on cardiovascular diseases and metabolic disorders</article-title><source>Frontiers in Immunology</source><volume>5</volume><elocation-id>533</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2014.00533</pub-id><pub-id pub-id-type="pmid">25386179</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>X</given-names></name><name><surname>Jin</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>chen</surname><given-names>Y</given-names></name><name><surname>Duan</surname><given-names>Z</given-names></name><name><surname>Bi</surname><given-names>Y</given-names></name><name><surname>Yan</surname><given-names>F</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Dong</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Cheng</surname><given-names>S</given-names></name><name><surname>Tang</surname><given-names>H</given-names></name><name><surname>Hong</surname><given-names>F</given-names></name><name><surname>Si</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Inducible nitric oxide synthase regulates macrophage polarization via the MAPK signals in concanavalin A‐induced hepatitis</article-title><source>Immunity, Inflammation and Disease</source><volume>10</volume><elocation-id>643</elocation-id><pub-id pub-id-type="doi">10.1002/iid3.643</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yepuri</surname><given-names>G</given-names></name><name><surname>Velagapudi</surname><given-names>S</given-names></name><name><surname>Xiong</surname><given-names>YY</given-names></name><name><surname>Rajapakse</surname><given-names>AG</given-names></name><name><surname>Montani</surname><given-names>JP</given-names></name><name><surname>Ming</surname><given-names>XF</given-names></name><name><surname>Yang</surname><given-names>ZH</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Positive crosstalk between arginase‐II and S6K1 in vascular endothelial inflammation and aging</article-title><source>Aging Cell</source><volume>11</volume><fpage>1005</fpage><lpage>1016</lpage><pub-id pub-id-type="doi">10.1111/acel.12001</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>You</surname><given-names>H</given-names></name><name><surname>Gao</surname><given-names>T</given-names></name><name><surname>Cooper</surname><given-names>TK</given-names></name><name><surname>Morris</surname><given-names>SM</given-names></name><name><surname>Awad</surname><given-names>AS</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Arginase inhibition mediates renal tissue protection in diabetic nephropathy by a nitric oxide synthase 3-dependent mechanism</article-title><source>Kidney International</source><volume>84</volume><fpage>1189</fpage><lpage>1197</lpage><pub-id pub-id-type="doi">10.1038/ki.2013.215</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeisberg</surname><given-names>EM</given-names></name><name><surname>Tarnavski</surname><given-names>O</given-names></name><name><surname>Zeisberg</surname><given-names>M</given-names></name><name><surname>Dorfman</surname><given-names>AL</given-names></name><name><surname>McMullen</surname><given-names>JR</given-names></name><name><surname>Gustafsson</surname><given-names>E</given-names></name><name><surname>Chandraker</surname><given-names>A</given-names></name><name><surname>Yuan</surname><given-names>X</given-names></name><name><surname>Pu</surname><given-names>WT</given-names></name><name><surname>Roberts</surname><given-names>AB</given-names></name><name><surname>Neilson</surname><given-names>EG</given-names></name><name><surname>Sayegh</surname><given-names>MH</given-names></name><name><surname>Izumo</surname><given-names>S</given-names></name><name><surname>Kalluri</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Endothelial-to-mesenchymal transition contributes to cardiac fibrosis</article-title><source>Nature Medicine</source><volume>13</volume><fpage>952</fpage><lpage>961</lpage><pub-id pub-id-type="doi">10.1038/nm1613</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Deng</surname><given-names>B</given-names></name><name><surname>Wei</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Liang</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Xian</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Knockout RAGE alleviates cardiac fibrosis through repressing endothelial-to-mesenchymal transition (EndMT) mediated by autophagy</article-title><source>Cell Death &amp; Disease</source><volume>12</volume><elocation-id>037504</elocation-id><pub-id pub-id-type="doi">10.1038/s41419-021-03750-4</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>C</given-names></name><name><surname>Potenza</surname><given-names>DM</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Ajalbert</surname><given-names>G</given-names></name><name><surname>Mertz</surname><given-names>KD</given-names></name><name><surname>von Gunten</surname><given-names>S</given-names></name><name><surname>Ming</surname><given-names>X-F</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Role of pulmonary epithelial arginase-II in activation of fibroblasts and lung inflammaging</article-title><source>Aging Cell</source><volume>22</volume><elocation-id>e13790</elocation-id><pub-id pub-id-type="doi">10.1111/acel.13790</pub-id><pub-id pub-id-type="pmid">36794355</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.94794.3.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Radisic</surname><given-names>Milica</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>University of Toronto</institution><country>Canada</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Convincing</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Fundamental</kwd></kwd-group></front-stub><body><p>This study provides <bold>fundamental</bold> information on how Arg-II participates in cardiac aging. The phenotypic data provide <bold>convincing</bold> evidence of non-cell-autonomous contributions to aging-related pathologies. Overall, the study highlights the importance of intercellular signaling in maintaining cardiac health during aging.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.94794.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>The manuscript by Duilio M. Potenza et al. explores the role of Arginase II in cardiac aging, majorly using whole-body arg-ii knock-out mice. In this work, the authors have found that Arg-II exerts non-cell-autonomous effects on aging cardiomyocytes, fibroblasts, and endothelial cells mediated by IL-1b from aging macrophages. The authors have used arg II KO mice and an in vitro culture system to study the role of Arg II. Authors have also reported the cell-autonomous effect of Arg-II through mitochondrial ROS in fibroblasts that contribute to cardiac aging. These findings are sufficiently novel in cardiac aging and provide interesting insights. While the phenotypic data seem strong, the mechanistic details are unclear. How Arg II regulates the IL-1b and modulates cardiac aging is still being determined.</p><p>Strengths:</p><p>This study provides interesting information on the role of Arg II in cardiac aging.</p><p>The phenotypic data in the Arg II KO mice is convincing, and the authors have assessed most of the aging-related changes.</p><p>The data is supported by an in vitro cell culture system.</p><p>Weaknesses:</p><p>The manuscript needs more mechanistic details on how Arg II regulates IL-1b and modulates cardiac aging.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.94794.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>This study investigates the role of arginase-II (Arg-II) in cardiac aging. The authors challenge previous assumptions by demonstrating that Arg-II is not expressed in aged cardiomyocytes, but is upregulated in non-myocyte cells, specifically macrophages, fibroblasts, and endothelial cells. Using Arg-II knockout mice, they show protection against age-associated cardiac inflammation, fibrosis, apoptosis, endothelial-to-mesenchymal transition (EndMT), and ischemic injury. Mechanistically, Arg-II promotes IL-1β release from macrophages and increases mitochondrial ROS in fibroblasts, contributing to cardiac aging through both cell-autonomous and non-cell-autonomous mechanisms.</p><p>The study is well-structured and combines genetic models, molecular assays, and histological analyses to support its conclusions. Including both human and mouse samples strengthens the translational relevance of the findings. The authors have addressed most of the reviewers' comments and have made efforts to improve the manuscript by adding experimental data, explanations, and further discussion.</p><p>The data convincingly support their conclusions. This work provides valuable insights into the mechanisms of cardiac aging, aligns with growing evidence of non-cell-autonomous contributions to aging-related pathologies, and highlights the importance of intercellular signaling in maintaining cardiac health during aging.</p><p>Although the use of cell-specific knockout mouse models would enhance the depth and translational potential of the findings, it is understandable that such an approach would be beyond the scope of a single study. This work lays the groundwork for future investigations into conditional Arg-II knockouts in specific cell types to elucidate the cell-specific roles of Arg-II in cardiac aging.</p><p>Overall, this is a solid and impactful study with strong experimental support</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.94794.3.sa3</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Potenza</surname><given-names>Duilio M</given-names></name><role specific-use="author">Author</role><aff><institution>University of Freiburg</institution><addr-line><named-content content-type="city">Freiburg</named-content></addr-line><country>Switzerland</country></aff></contrib><contrib contrib-type="author"><name><surname>Cheng</surname><given-names>Xin</given-names></name><role specific-use="author">Author</role><aff><institution>University of Freiburg</institution><addr-line><named-content content-type="city">Freiburg</named-content></addr-line><country>Switzerland</country></aff></contrib><contrib contrib-type="author"><name><surname>Ajalbert</surname><given-names>Guillaume</given-names></name><role specific-use="author">Author</role><aff><institution>University of Fribourg</institution><addr-line><named-content content-type="city">Fribourg</named-content></addr-line><country>Switzerland</country></aff></contrib><contrib contrib-type="author"><name><surname>Brenna</surname><given-names>Andrea</given-names></name><role specific-use="author">Author</role><aff><institution>University of Fribourg</institution><addr-line><named-content content-type="city">Fribourg</named-content></addr-line><country>Switzerland</country></aff></contrib><contrib contrib-type="author"><name><surname>Giraud</surname><given-names>Marie-Noelle</given-names></name><role specific-use="author">Author</role><aff><institution>university of Fribourg</institution><addr-line><named-content content-type="city">Fribourg</named-content></addr-line><country>Switzerland</country></aff></contrib><contrib contrib-type="author"><name><surname>Frobert</surname><given-names>Aurelien</given-names></name><role specific-use="author">Author</role><aff><institution>University of Fribourg</institution><addr-line><named-content content-type="city">Fribourg</named-content></addr-line><country>Switzerland</country></aff></contrib><contrib contrib-type="author"><name><surname>Cook</surname><given-names>Stephane</given-names></name><role specific-use="author">Author</role><aff><institution>University of Freiburg</institution><addr-line><named-content content-type="city">Freiburg</named-content></addr-line><country>Switzerland</country></aff></contrib><contrib contrib-type="author"><name><surname>Mertz</surname><given-names>Kirsten D</given-names></name><role specific-use="author">Author</role><aff><institution>Cantonal Hospital Baselland</institution><addr-line><named-content content-type="city">Liestal</named-content></addr-line><country>Switzerland</country></aff></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Zhihong</given-names></name><role specific-use="author">Author</role><aff><institution>University of Freiburg</institution><addr-line><named-content content-type="city">Freiburg</named-content></addr-line><country>Switzerland</country></aff></contrib><contrib contrib-type="author"><name><surname>Ming</surname><given-names>Xiu-Fen</given-names></name><role specific-use="author">Author</role><aff><institution>University of Freiburg</institution><addr-line><named-content content-type="city">Freiburg</named-content></addr-line><country>Switzerland</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews</p><disp-quote content-type="editor-comment"><p><bold>Public Reviews:</bold></p><p><bold>Reviewer #1 (Public Review):</bold></p><p>Summary:</p><p>The manuscript by Duilio M. Potenza et al. explores the role of Arginase II in cardiac aging, majorly using whole-body arg-ii knock-out mice. In this work, the authors have found that Arg-II exerts non-cell-autonomous effects on aging cardiomyocytes, fibroblasts, and endothelial cells mediated by IL-1b from aging macrophages. The authors have used arg II KO mice and an in vitro culture system to study the role of Arg II. The authors have also reported the cell-autonomous effect of Arg-II through mitochondrial ROS in fibroblasts that contribute to cardiac aging. These findings are sufficiently novel in cardiac aging and provide interesting insights. While the phenotypic data seems strong, the mechanistic details are unclear. How Arg II regulates the IL-1b and modulates cardiac aging is still being determined. The authors still need to determine whether Arg II in fibroblasts and endothelial contributes to cardiac fibrosis and cell death. This study also lacks a comprehensive understanding of the pathways modulated by Arg II to regulate cardiac aging.</p></disp-quote><p>We sincerely appreciate the valuable feedback provided by the reviewer. It's gratifying to hear that our work provided novel information on the role of arginase-II in cardiac aging which is a complex process involving various cell types and mechanisms. We have devoted considerable effort by performing new experiments to address the reviewer's comments and to delineate more detailed mechanisms of Arg-II in cardiac aging. Please, see below our specific answers to each point of the reviewers.</p><disp-quote content-type="editor-comment"><p>Strengths:</p><p>This study provides interesting information on the role of Arg II in cardiac aging.</p><p>The phenotypic data in the arg II KO mice is convincing, and the authors have assessed most of the aging-related changes.</p><p>The data is supported by an in vitro cell culture system.</p></disp-quote><p>We appreciate this reviewer’s positive assessment on the strength of our study.</p><disp-quote content-type="editor-comment"><p>Weaknesses:</p><p>The manuscript needs more mechanistic details on how Arg II regulates IL-1b and modulates cardiac aging.</p></disp-quote><p>We made great effort and have performed new experiments in human monocyte cell line (THP1) in which iNOS is not expressed and not inducible by LPS and <italic>arg-ii</italic> gene was knocked out by CRISPR technology. Moreover, murine bone-marrow derived macrophages in which <italic>inos</italic> gene was ablated, is also use for this purpose. We found that in the human THP1 monocytes in which Arg-II but not iNOS is induced by LPS (100 ng/mL for 24 hours) (Suppl. Fig. 6A), mRNA and protein levels of IL-1b precursor are markedly reduced in <italic>arg-ii</italic> knockout THP1<italic>arg-ii-/-</italic> as compared to the THP1<italic>wt</italic> cells (Suppl. Fig. 6B and 6C), further confirming that Arg-II promotes IL-1b production as also shown in RAW264.7 macrophages (Suppl. Fig. 5A and 5C). Moreover, in the mouse bone-marrow-derived macrophages, LPS-induced IL-1b production is inhibited by <italic>inos</italic> deficiency (BMDM<italic>inos-/-</italic> vs BMDM<italic>wt</italic>) (Suppl. Fig. 6D and 6E), while Arg-II levels are slightly enhanced in the BMDM<italic>inos-/-</italic> cells (Suppl. Fig. 6D and 6F). All together, these results suggest that iNOS slightly reduces Arg-II expression. Arg-II and iNOS can be upregulated by LPS independently. Both Arg-II and iNOS are required for IL-1b production upon LPS stimulation as illustrated in Suppl. Fig. 6G. For detailed results and discussion, please see answers to the comments point 2 or point 6 raised by this reviewer.</p><disp-quote content-type="editor-comment"><p>The authors used whole-body KO mice, and the role of macrophages in cardiac aging is not studied in this model. A macrophage-specific arg II Ko would be a better model.</p></disp-quote><p>We fully agree with this comment of the reviewer. Unfortunately, this macrophage specific <italic>arg-ii</italic> knockout animal model is not available, yet. Future research shall develop the macrophage-specific <italic>arg-ii-/-</italic> mouse model to confirm this conclusion with aging animals. Since Arg-II is also expressed in fibroblasts and endothelial cells and exerts cell-autonomous and paracrine functions, aging mouse models with conditional <italic>arg-ii</italic> knockout in the specific cell types would be the next step to elucidate cell-specific function of Arg-II in cardiac aging. We have pointed out this aspect for future research on page 19, lines 2 to 6.</p><disp-quote content-type="editor-comment"><p>Experiments need to validate the deficiency of Arg II in cardiomyocytes.</p></disp-quote><p>As pointed out by this reviewer in the comment point 10, Arg-II was previously reported to be expressed in isolated cardiomyocytes from in rats (PMID: 16537391). Unfortunately, negative controls. i.e., <italic>arg-ii-/-</italic> samples were not included in the study to avoid any possible background signals. We made great effort to investigate whether Arg-II is present in the cardiomyocytes from different species including mice, rats and humans and have included old <italic>arg-ii-/-</italic> mouse samples as a negative control. This allows to validate the antibody specificity and background noises beyond any reasonable doubt. The new experiments in Suppl. Fig. 4 confirms the specificity of the antibody against Arg-II in old mouse kidney which is known to express Arg-II in the S3 proximal tubular cells (Huang J, et al. 2021). To exclude the possible species-specific different expression of Arg-II in the cardiomyocytes, aged mouse and rat heart tissues were used for cellular localization of Arg-II by confocal immunofluorescence staining. As shown in Suppl. Fig. 4B and 4C, both species show Arg-II expression only in non-cardiomyocytes (cells between striated cardiomyocytes) (red arrows) but not in striated cardiomyocytes. Even in the rat myocardial infarction tissues, Arg-II was not found in cardiomyocytes but in endocardium cells (Suppl. Fig. 4B). In isolated cardiomyocytes exposed to hypoxia, a well know strong stimulus for Arg-II protein levels, no Arg-II signals could be detected, while in fibroblasts from the same animals, an elevated Arg-II levels under hypoxia is demonstrated (Fig. 5B). Furthermore, even RT-qPCR could not detect <italic>arg-ii</italic> mRNA in cardiomyocytes but in non-cardiomyocytes (Fig. 5C). All together, these results demonstrate that Arg-II are not expressed or at negligible levels in cardiomyocytes but expressed in non-cardiomyocytes. This new experiments with rat heart are included in the method section on page 20, the 1st paragraph. The results are described on page 7, the 1st paragraph, and discussed on page 12, the 2nd paragraph. Legend to Suppl. Fig. 4 is included in the file “Suppl. figure legend_R”.</p><disp-quote content-type="editor-comment"><p>The authors have never investigated the possibility of NO involvement in this mice model.</p></disp-quote><p>As above mentioned, we made great effort and have performed new experiments in human monocyte cell line (THP1) in which iNOS is not expressed and not inducible by LPS and <italic>arg-ii</italic> gene was knocked out by CRISPR technology. Moreover, murine bone-marrow derived macrophages in which <italic>inos</italic> gene was ablated, is also use for this purpose. The results show that Arg-II and iNOS can be upregulated by LPS independent of each other and iNOS slightly reduces Arg-II expression. However, both Arg-II and iNOS are required for IL-1b production upon LPS stimulation. For detailed results and discussion, please see answers to the comments point 2 or point 6 raised by this reviewer.</p><disp-quote content-type="editor-comment"><p>A co-culture system would be appropriate to understand the non-cell-autonomous functions of macrophages.</p></disp-quote><p>We appreciate the suggestion by this reviewer regarding the co-culture system to test the non-cell autonomous role of Arg-II. We think that our current model, which involves treating cells with conditioned media, is a well-established and effective method for demonstrating the non-cell autonomous role of Arg-II. This approach allows us to observe the effects of Arg-II on surrounding cells through the factors present in the conditioned media released from macrophages. The co-culture system could be considered, if the released factor in the conditioned medium is not stable. This is however not the case. Therefore, we are confident that our experimental model with conditioned medium is sufficiently enough to demonstrate a paracrine effect of cell-cell interaction (please also see answers to the comment point 16).</p><disp-quote content-type="editor-comment"><p>The Myocardial infarction data shown in the mice model may not be directly linked to cardiac aging.</p></disp-quote><p>As we have introduced and discussed in the manuscript, aging is a predominant risk factor for cardiovascular disease (CVD). Studies in experimental animal models and in humans provide evidence demonstrating that aging heart is more vulnerable to stressors such as ischemia/reperfusion injury and myocardial infarction as compared to the heart of young individuals. Even in the heart of apparently healthy individuals of old age, chronic inflammation, cardiomyocyte senescence, cell apoptosis, interstitial/perivascular tissue fibrosis, endothelial dysfunction and endothelial-mesenchymal transition (EndMT), and cardiac dysfunction either with preserved or reduced ejection fraction rate are observed. Our study is aimed to investigate the role of Arg-II in cardiac aging phenotype and age-associated cardiac vulnerability to stressors. Therefore, cardiac functional changes and myocardial infarction in response to ischemia/reperfusion injury are suitable surrogate parameters for the purpose.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public Review):</bold></p><p>Summary:</p><p>The results from this study demonstrated a cell-specific role of mitochondrial enzyme arginase-II (Arg-II) in heart aging and revealed a non-cell-autonomous effect of Arg-II on cardiomyocytes, fibroblasts, and endothelial cells through the crosstalk with macrophages via inflammatory factors, such as by IL-1b, as well as a cell-autonomous effect of Arg-II through mtROS in fibroblasts contributing to cardiac aging phenotype. These findings highlight the significance of non-cardiomyocytes in the heart and bring new insights into the understanding of pathologies of cardiac aging. It also provides new evidence for the development of therapeutic strategies, such as targeting the ArgII activation in macrophages.</p></disp-quote><p>We're grateful for the reviewer's positive feedback, acknowledging the significant findings of our study on the role of arginase-II (Arg-II) in cardiac aging. We appreciate this reviewer’s insight into the therapeutic potential of targeting Arg-II activation in macrophages and are excited about the implications for future interventions in age-related cardiac pathologies. Thank you for recognizing the importance of our work in advancing our understanding of cardiac aging and potential therapeutic strategies.</p><disp-quote content-type="editor-comment"><p>Strengths:</p><p>This study targets an important clinical challenge, and the results are interesting and innovative. The experimental design is rigorous, the results are solid, and the representation is clear. The conclusion is logical and justified.</p></disp-quote><p>We thank this reviewer for the positive comment.</p><disp-quote content-type="editor-comment"><p>Weaknesses:</p><p>The discussion could be extended a little bit to improve the realm of the knowledge related to this study.</p></disp-quote><p>We appreciate this comment and have added and revised our discussion on this aspect accordingly at the end of the discussion section on page 19.</p><disp-quote content-type="editor-comment"><p><bold>Recommendations for the authors:</bold></p><p><bold>Reviewer #1 (Recommendations For The Authors):</bold></p><p>I have several critical concerns, specifically about the mechanism of how Arg-II plays a role in cardiac aging.</p><p>My major concerns are:</p><p>(1) The authors have shown non-cell-autonomous effects on aging cardiomyocytes, fibroblasts, and endothelial cells mediated by IL-1b from aging macrophages. A macrophage-specific Arg-II knock-out mouse model is a suitable and necessary control to establish claims.</p></disp-quote><p>We fully agree with this comment of the reviewer. Unfortunately, this macrophage specific <italic>arg-ii</italic> knockout animal model is not available, yet. Future research shall develop the macrophage-specific <italic>arg-ii-/-</italic> mouse model to confirm this conclusion with aging animals. Since Arg-II is also expressed in fibroblasts and endothelial cells and exerts cell-autonomous and paracrine functions, aging mouse models with conditional <italic>arg-ii</italic> knockout in the specific cell types would be the next step to elucidate cell-specific function of Arg-II in cardiac aging. We have pointed out this aspect for future research on page 19, lines 2 to 6.</p><disp-quote content-type="editor-comment"><p>(2) This study suggests that Arg-II exerts its effect through IL-1b in cardiac ageing. However, all experiments performed to demonstrate the link between ArgII and IL-1β are correlative at best. The underlying molecular mechanism, including transcription factors involved in the regulation of IL-1β by <italic>arg-ii</italic>, has not been demonstrated.</p></disp-quote><p>We sincerely appreciate this reviewer’s comment on the aspect! To make it clear, a causal role of Arg-II in promoting IL-1β production in macrophages is evidenced by the experimental results showing that old <italic>arg-ii-/-</italic> mouse heart has lower IL-1β levels than the age-matched <italic>wt</italic> mouse heart (Fig. 6A to 6D). We further showed that the cellular IL-1β protein levels and release are reduced in old <italic>arg-ii-/-</italic> mouse splenic macrophages as compared to the <italic>wt</italic> cells (Fig. 7A, 7C, and 7D). This result is further confirmed with the mouse macrophage cell line RAW264.7 (Suppl. Fig. 5A and suppl. Fig. 5C), in which we demonstrate that silencing <italic>arg-ii</italic> reduces IL-1β levels stimulated with LPS.</p><p>According to this reviewer’s comment (see comment point 6), we made further effort to investigate possible involvement of iNOS in Arg-II-regulated IL-1β production in macrophages stimulated with LPS. We performed new experiments in human monocyte cell line (THP1) in which iNOS is not expressed and not inducible by LPS and <italic>arg-ii</italic> gene was knocked out by CRISPR technology in the cells.</p><p>Moreover, murine bone-marrow derived macrophages in which <italic>inos</italic> gene was ablated, is also use for this purpose. We found that in the human THP1 monocytes in which Arg-II but not iNOS is induced by LPS (100 ng/mL for 24 hours) (Suppl. Fig. 6A), mRNA and protein levels of IL-1b are markedly reduced in <italic>arg-ii</italic> knockout THP1<italic>arg-ii-/-</italic> as compared to the THP1<italic>wt</italic> cells (Suppl. Fig. 6B and 6C), further confirming that Arg-II promotes IL-1b production as also shown in RAW264.7 macrophages (Suppl. Fig. 5A and 5C). The results suggest that Arg-II promotes IL-1b production independently of iNOS. Moreover, the role of iNOS in IL-1b production was also studied in the mouse bone-marrow-derived macrophages in which <italic>inos</italic> gene is ablated. The results demonstrate that LPS-induced IL-1b production is inhibited by <italic>inos</italic> deficiency (BMDM<italic>inos-/-</italic> vs BMDM<italic>wt</italic>) (Suppl. Fig. 6D and 6E), while Arg-II levels are slightly enhanced in the BMDM<italic>inos-/-</italic> cells (Suppl. Fig. 6D and 6F). Since arginase and iNOS share the same metabolic substrate L-arginine, <italic>inos-/-</italic> is expected to increase IL-1b production. This is however not the case. A strong inhibition of IL-1β production in <italic>inos-/-</italic> macrophages is observed. These results implicate that iNOS promotes IL-1β production independently of Arg-II and the inhibiting effect of IL-1β by <italic>inos</italic> deficiency is dominant and able to counteract Arg-II’s stimulating effect on IL-1β production. Hence, our results demonstrate that Arg-II promotes IL-1β production in macrophages independently of iNOS. All together, these results suggest that iNOS slightly reduces Arg-II expression. Arg-II and iNOS can be upregulated by LPS independently. Both Arg-II and iNOS are required for IL-1b production upon LPS stimulation (This concept is illustrated in the Suppl. Fig. 6G). The new results are described on page 8, the last paragraph and page 9, the 1st paragraph, presented in Suppl. Fig.6. The legend to Suppl. Fig. 6 is described in the file “Supplementary figure legend-R”. The related experimental methods are updated on page 23, the last two paragraphs and page 26 the last paragraph. The results are discussed o page 14, the last paragraph and page 15, the first two paragraphs.</p><disp-quote content-type="editor-comment"><p>(3) Figure 2: The authors have not validated the whole-body Arg-II knock-out mice for arg-ii ablation.</p></disp-quote><p>Thanks for pointing out this missing information! We have added the information regarding genotyping of the mice in the method section on page 20, first paragraph. Moreover, Fig. 5C also confirms the genotyping of the non-cardiomyocyte cells isolated from <italic>wt</italic> and <italic>arg-ii-/-</italic> animals.</p><disp-quote content-type="editor-comment"><p>(4) It is unclear why the authors have chosen to focus on IL-1β specifically, among other pro-inflammatory cytokines that were also downregulated in Arg-II-/- mice as demonstrated in Fig. 2A-D.</p></disp-quote><p>We appreciate the reviewer's question, which provides an opportunity to delve deeper into our findings. In our investigation, we observed that aging is accompanied by elevated levels of various proinflammatory markers. Intriguingly, our data revealed that <italic>tnf-α</italic> remained unaffected by the ablation of <italic>arg-ii</italic> during aging in the heart tissues, while <italic>Il-1β</italic> showed a significant reduction in <italic>arg-ii-/-</italic> animals compared to age-matched wild-type (<italic>wt</italic>) mice (Fig. 2). <italic>Mcp1</italic> is however a chemoattractant for macrophages and F4-80 serves as a pan marker for macrophages. Moreover, our previous studies demonstrate a relationship between Arg-II and IL-1β in vascular disease and obesity and age-associated renal and pulmonary fibrosis. Finally, IL-1β has been shown to play a causal role in patients with coronary atherosclerotic heart disease as shown by CANTOS trials. Therefore, we have focused on IL-1β in this study. We have now explained and strengthened this aspect in the manuscript on page 7, the last two lines and page 8, the 1st paragraph as following:</p><p>“Taking into account that our previous studies demonstrated a relationship of Arg-II and IL-1β in vascular disease and obesity (Ming et al., 2012) and in age-associated organ fibrosis such as renal and pulmonary fibrosis (Huang et al., 2021; Zhu et al., 2023), and IL-1β has been shown to play a causal role in patients with coronary atherosclerotic heart disease as shown by CANTOS trials (Ridker et al., 2017), we therefore focused on the role of IL-1β in crosstalk between macrophages and cardiac cells such as cardiomyocytes, fibroblasts and endothelial cells”.</p><disp-quote content-type="editor-comment"><p>(5) Although macrophages are shown to be involved in cardiac ageing in the arg-ii mouse model, the authors have not estimated macrophage infiltration and expression of inflammatory or senescence markers in the hearts of these mice.</p></disp-quote><p>Thank you very much for raising this important point! Taking the comments of the reviewer into account, we have performed new experiments, i.e., multiple immunofluorescent staining to analyze the infiltrated (CCR2<sup>+</sup>/F4-80<sup>+</sup>) and resident (LYVE1<sup>+</sup>/F4-80<sup>+</sup>) macrophage populations and to investigate to which extent that Arg-II affects the infiltrated and resident macrophage populations in the aging heart and whether this is regulated by <italic>arg-ii</italic><sup><italic>-/-</italic></sup>. The results show an age-associated increase in the numbers of F4/80<sup>+</sup> cells in the wt mouse heart, which is reduced in the age-matched <italic>arg-ii</italic><sup><italic>-/-</italic></sup> animals (Fig. 2G). This result is in accordance with the result of <italic>f4/80</italic> gene expression shown in Fig. 2A, demonstrating that <italic>arg-ii</italic> gene ablation reduces macrophage accumulation in the aging heart. Interestingly, resident macrophages as characterized by LYVE1<sup>+</sup>/F4-80<sup>+</sup> cells (Fig. 2E and 2H) are predominant in the aging heart as compared to the infiltrated CCR2<sup>+</sup>/F4-80<sup>+</sup> cells (Fig. 2F and 2I). The increase in both LYVE1<sup>+</sup>/F4-80<sup>+</sup> and CCR2<sup>+</sup>/F4-80<sup>+</sup> macrophages in aging heart is reduced in <italic>arg-ii</italic><sup><italic>-/-</italic></sup> mice (Fig. 2E, 2F, 2H, and 2I). These new results are described on page 6, the 1st paragraph, presented in Fig. 2E to 2I, and discussed on page 13, the 2nd, paragraph. The legend to Fig. 2 is revised. The method for this additional experiment is included on page 22, the 1st paragraph.</p><p>Moreover, the aged-associated accumulation of the senescence cells as demonstrated by p16<sup>ink4</sup> positive cells is significantly reduced in <italic>arg-ii-/-</italic> animals. This new result is incorporated in the Fig. 1 as Fig. 1G and 1H and described / discussed on page 5, the 2nd paragraph and page 14, the 2nd last sentences of the 1st paragraph. The method of p16<sup>ink4</sup> staining is included in the method section on page 22, the 1st paragraph, line 7. The legend to Fig. 1 is revised accordingly.</p><disp-quote content-type="editor-comment"><p>(6) Previously, Arg-II has been reported to serve a crucial role in ageing associated with reduced contractile function in rat hearts by regulating Nitric Oxide Synthase (PMID: 22160208). Elevated NO and superoxide have been shown to play crucial roles in the etiology of cardiovascular diseases (PMID: 24180388). Therefore, it is important to assess whether Nitric Oxide (NO) is involved in the aging-related phenotype in this mouse model.</p></disp-quote><p>Following the reviewer's suggestion, we conducted new experiments to investigate the role of nitric oxide (NO) in the context of the effect of Arg-II-induced IL-1b production in macrophages. We have addressed this question in the response to the comment point 2.</p><disp-quote content-type="editor-comment"><p>(7) Based on the results demonstrated in the study, ablation of Arg-II can be expected to cause a reduction in inflammation-associated phenotypes throughout the body at the multi-organ level. The observed improved cardiac phenotype could be an outcome of whole-body Arg-II ablation. It would be fruitful to develop a cardiac-specific Arg-II knockout mouse model to establish the role of Arg-II in the heart, independent of other organ systems.</p></disp-quote><p>We agree with the comment of the reviewer on this point. Unfortunately, as explained above (see point 1), it is currently not possible for us to perform the requested experiments, due to lack of cardiac specific <italic>arg-ii</italic>-knockout mouse model. Moreover, such an approach is complicated by the absence of Arg-II in cardiomyocytes and the expression of Arg-II in multiple cells including endothelial cells, fibroblasts and macrophage of different origin (resident and monocyte-derived infiltrating cells). It’s thus difficult to generate a cardiac-specific gene knockout mouse. One shall investigate roles of cell-specific Arg-II in cardiac aging by generating cell-specific <italic>arg-ii-/-</italic> mice. We appreciate very this important aspect and have discussed issue on page 19, the lines 2 to 6.</p><disp-quote content-type="editor-comment"><p>(8) Contrary to the findings in this paper, Arg-II has previously been reported to be essential for IL-10-mediated downregulation of pro-inflammatory cytokines, including IL-1β (PMID: 33674584).</p></disp-quote><p>Thank you very much for mentioning this study! We have now discussed thoroughly the controversies as the following on page 15, the last paragraph and page 16, the 1st paragraph;</p><p>“It is of note that a study reported that Arg-II is required for IL-10 mediated-inhibition of IL-1b in mouse BMDM upon LPS stimulation (Dowling et al., 2021), which suggests an anti-inflammatory function of Arg-II. The results of our present study, however, demonstrate that LPS enhances Arg-II and IL-1b levels in macrophages and knockout or silencing Arg-II reduces IL-1b production and release, demonstrating a pro-inflammatory effect of Arg-II. Our findings are supported by the study from another group, which shows decreased pro-inflammatory cytokine production including IL-6 and IL-1b in <italic>arg-ii-/-</italic> BMDM most likely through suppression of NFkB pathway, since <italic>arg-ii-/-</italic> BMDM reveals decreased activation of NFkB and IL-1b levels upon LPS stimulation (Uchida et al., 2023). Most importantly, our previous study also showed that re-introducing <italic>arg-ii</italic> gene back to the <italic>arg-ii-/-</italic> macrophages markedly enhances LPS-stimulated pro-inflammatory cytokine production (Ming et al., 2012), providing further evidence for a pro-inflammatory role of <italic>arg-ii</italic> under LPS stimulation. In support of this conclusion, chronic inflammatory diseases such as atherosclerosis and type 2 diabetes (Ming et al., 2012), inflammaging in lung (Zhu et al., 2023), kidney (Huang et al., 2021) and pancreas (Xiong, Yepuri, Necetin, et al., 2017) of aged animals or acute organ injury such as acute ischemic/reperfusion or cisplatin-induced renal injury are reduced in the <italic>arg-ii-/-</italic> mice (Uchida et al., 2023). The discrepant findings between these studies and that with IL-10 may implicate dichotomous functions of Arg-II in macrophages, depending on the experimental context or conditions. Nevertheless, our results strongly implicate a pro-inflammatory role of Arg-II in macrophages in the inflammaging in aging heart”.</p><disp-quote content-type="editor-comment"><p>(9) The authors have only performed immunofluorescence-based experiments to show fibrotic and apoptotic phenotypes throughout this study. To verify these findings, we suggest that they additionally perform RT-PCR or western blotting analysis for fibrotic markers and apoptotic markers.</p></disp-quote><p>The fibrotic aspect was analyzed not only by microscopy but also by using a quantitative biochemical assay such as hydroxyproline content assessment. Hydroxyproline is a major component of collagen and largely restricted to collagen. Therefore, the measurement of hydroxyproline levels can be used as an indicator of collagen content as previous investigated in the lung (Zhu et al., 2023). We have also measured collagen genes expression by RT-qPCR as suggested by the reviewer and found an age-related decline of collagen mRNA expression levels in both <italic>wt</italic> and <italic>arg-ii-/-</italic> mice, suggesting that the age-associated cardiac fibrosis and prevention in <italic>arg-ii-/-</italic> mice is due to alterations of translational and/or post-translational regulations, including collagen synthesis and/or degradation. The results are in accordance with that reported by other studies published in the literature. We have pointed out this aspect on page 5, the 2nd paragraph:</p><p>“The increased cardiac fibrosis in aging is however, associated with decreased mRNA levels of <italic>collagen-Ia</italic> (<italic>col-Ia</italic>) and <italic>collagen-IIIa</italic> (<italic>col-IIIa</italic>), the major isoforms of pre-collagen in the heart (Suppl. Fig. 2A and 2B), which is a well-known phenomenon in cardiac fibrotic remodelling (Besse et al., 1994; Horn et al., 2016). The results demonstrate that age-associated cardiac fibrosis and prevention in <italic>arg-ii-/-</italic> mice is due to alterations of translational and/or post-translational regulations including collagen synthesis and/or degradation”.</p><p>The results are presented in Suppl. Fig. 2, legend to Suppl. Fig. 2 is included in the file “Suppl. figure legend_R”. Suppl. table 2 for primers is revised accordingly.</p><p>We did not use additional markers to perform apoptotic assays with whole heart, since Fig. 3 shows good evidence that the aging is associated with increased apoptotic cells in the heart and significantly reduced in the <italic>arg-ii-/-</italic> mice. The reduction of TUNEL positive (apoptotic) cells in aged <italic>arg-ii-/-</italic> mice is mainly due to decrease in apoptotic cardiomyocytes. With the histological analysis, the apoptotic cell types can be well analysed. Moreover, biochemical assay for apoptosis such as caspase-3 cleavage with whole heart tissues can not distinguish apoptotic cell types and may not be sensitive enough for aging heart, due to relatively low numbers of apoptotic cells in aging heart as compared to myocardial infarct model.</p><disp-quote content-type="editor-comment"><p>(10) Figure 4: arg-ii has previously been reported to be expressed in rat cardiomyocytes (PMID: 16537391). We strongly suggest the authors verify the expression of Arg-II via immunostaining in isolated cardiomyocytes (using published protocols), and by using multiple different cardiomyocyte-specific markers for colocalization studies to prove the lack of arg-ii expression beyond a reasonable doubt.</p></disp-quote><p>As pointed out by this reviewer, Arg-II was previously reported to be expressed in isolated cardiomyocytes from in rats (PMID: 16537391). Unfortunately, negative controls. i.e., <italic>arg-ii-/-</italic> samples were not included in the study to avoid any possible background signals. We made great effort to investigate whether Arg-II is present in the cardiomyocytes from different species including mice, rats and humans and have included old <italic>arg-ii-/-</italic> mouse samples as a negative control. This allows to validate the antibody specificity and background noises beyond any reasonable doubt. The new experiments in Suppl. Fig. 4 confirms the specificity of the antibody against Arg-II in old mouse kidney which is known to express Arg-II in the S3 proximal tubular cells (Huang J, et al. 2021). To exclude the possible species-specific different expression of Arg-II in the cardiomyocytes, aged mouse and rat heart tissues were used for cellular localization of Arg-II by confocal immunofluorescence staining. As shown in Suppl. Fig. 4B and 4C, both species show Arg-II expression only in non-cardiomyocytes (cells between striated cardiomyocytes) (red arrows) but not in striated cardiomyocytes. Even in the rat myocardial infarction tissues, Arg-II was not found in cardiomyocytes but in endocardium cells (Suppl. Fig. 4B). In isolated cardiomyocytes exposed to hypoxia, a well know strong stimulus for Arg-II protein levels, no Arg-II signals could be detected, while in fibroblasts from the same animals, an elevated Arg-II levels under hypoxia is demonstrated (Fig. 5B). Furthermore, RT-qPCR could not detect <italic>arg-ii</italic> mRNA in cardiomyocytes but in non-cardiomyocytes (Fig. 5C). All together, these results demonstrate that Arg-II are not expressed or at negligible levels in cardiomyocytes but expressed in non-cardiomyocytes. This new experiments with rat heart are included in the method section on page 20, the 1st paragraph. The results are described on page 7, the 1st paragraph, and discussed on page 12, the 2nd paragraph. Legend to Suppl. Fig. 4 is included in the file “Suppl. figure legend_R”.</p><disp-quote content-type="editor-comment"><p>(11) Figure 6G: It may be worthwhile to supplement <italic>arg-ii-/-</italic> old cells with IL-1beta to see if there is an increase in TUNEL-positive cells.</p></disp-quote><p>IL-1b is a well known pro-inflammatory cytokine that causes apoptosis in various cell types including cardiomyocytes (Shen Y., et al., Tex Heart Inst J. 2015;42:109–116. doi: 10.14503/THIJ-14-4254; Liu Z. et. al., Cardiovasc Diabetol 2015;14,125. doi: 10.1186/s12933-015-0288-y; Li. Z., et al., Sci Adv 2020;6:eaay0589. doi: 10.1126/sciadv.aay0589). We appreciate very much the interesting idea of this reviewer to investigate the apoptotic responses of cardiomyocytes from <italic>arg-ii-/-</italic> mice to IL-1b. We agree that it is possible that cardiomyocytes from <italic>wt</italic> from <italic>arg-ii-/-</italic> mice react differently to IL-1b, although the cardiomyocytes do not express Arg-II as demonstrated in our present study. If this is true, it must be due to non-cell autonomous effects of different aging microenvironment in the heart or epigenetic modulations of the myocytes. We found that this is a very interesting aspect and requires further extensive investigation. Since our current study focused on the effect of <italic>wt</italic> and <italic>arg-ii-/-</italic> macrophages on cardiomyocytes and non-cardiomyocytes, we prefer not to include this suggested aspect in our manuscript and would like to explore it in the following study.</p><disp-quote content-type="editor-comment"><p>(12) Figures 4-9: It would be interesting to see if the effect of ArgII in cardiac ageing is gender-specific. It is recommended to include experimental data with male mice in addition to the results demonstrated in female mice.</p></disp-quote><p>As pointed out in the manuscript, we have focused on female mice, because an age-associated increase in <italic>arg-ii</italic> expression is more pronounced in females than in males (Fig. 1A). As suggested by this reviewer, we performed additional experiments investigating effects of <italic>arg-ii</italic> deficiency in male mice during aging, focusing on pathophysiological outcomes of ischemia/reperfusion injury in ex vivo experiments. The ex vivo functional analytic experiments with Langendorff system were performed in aged male mice (see Suppl. Fig. 9). Following ischemia/reperfusion injury, <italic>wt</italic> male mice display reduced left ventricular developed pressure (LVDP), as well as the inotropic and lusitropic states (expressed as dP/dt max and dP/dt min, respectively). As previously reported (Murphy et al., 2007), we also found that old male mice are more prone to I/R injury than age-matched female animals. Specifically, 15 minutes of ischemia are enough to significantly affect the left ventricle contractile function in the male mice (Suppl. Fig. 9). As opposite, age-matched old female mice are relatively resistant to I/R injury, and at least 20 min of ischemia are necessary to induce a significant impairment of the contractile function (Fig. 10). Similar to females, the post I/R recovery of cardiac function is also significantly improved in the male <italic>arg-ii-/-</italic> mice as compared to age-matched <italic>wt</italic> animals. In addition to functional recovery, triphenyl tetrazolium chloride (TTC) staining (myocardial infarction) upon I/R-injury in males is significantly reduced in the age-matched male <italic>arg-ii-/-</italic> animals (Suppl. Fig. 9C and 9D). All together, these results reveal a role for Arg-II in heart function impairment during aging in both genders with a higher vulnerability to stress in the males. These new results are presented in Suppl. Fig. 9, described on page 10, the last paragraph and page 11. The results are discussed on page 18, the 2nd paragraph as following:</p><p>“The fact that aged females have higher Arg-II but are more resistant to I/R injury seems contradictory to the detrimental effect of Arg-II in I/R injury. It is presumable that cardiac vulnerability to injuries stressors depends on multiple factors/mechanisms in aging. Other factors/mechanisms associated with sex may prevail and determine the higher sensitivity of male heart to I/R injury, which requires further investigation. Nevertheless, the results of our study show that Arg-II plays a role in cardiac I/R injury also in males”.</p><p>The information on the experimental methods in the male animals is included on page 20, the last paragraph and page 21, the 1st paragraph. Legend to Suppl. Fig. 9 is included in the file “Suppl. figure legend_R”.</p><disp-quote content-type="editor-comment"><p>(13) Figure 6G: cardiomyocytes from wild-type mice, when treated with macrophages, show 0% TUNEL-positive cells. Since it is unlikely to obtain no TUNEL staining in a cell population, there may be an experimental or analytical error.</p></disp-quote><p>Now it is Fig. 7F and 7G. This is due to our specific experimental procedure. After tissue digestion, cardiomyocytes were plated on laminin-coated dishes. Laminin promotes the adhesion of survived cells. Following plating, we conducted a deep washing process to remove damaged and partially adherent cells. This step ensures that only well-shaped, viable, and strongly adherent cells remain as bioassay cells. These “healthy” cells are then selected for the experiments. the apoptotic cells are removed by washing out, reflecting the high viability of the bioassay cells. We have added this detailed information in the method section on page 24, the 2nd paragraph.</p><disp-quote content-type="editor-comment"><p>(14) Figure 7J: Please assess whether arg-ii depletion also affects the mtROS phenotype.</p></disp-quote><p>According to the suggestion of this reviewer, we performed new experiments which show that human cardiac fibroblasts (HCFs) exposed to hypoxia (1% O<sub>2</sub>, 48 hours), a known physiological trigger of Arg-II up-regulation, exhibit increased mtROS generation, which involves Arg-II (new Fig. 8M to 8P). We found that Arg-II protein level as well as mtROS (assessed by mitoSOX staining) were both enhanced, accompanied by increased levels of HIF1α (Fig 8M). Moreover, mito-TEMPO pre-incubation reduces mtROS, confirming the mitochondrial origin of the ROS. Silencing of <italic>arg-ii</italic> with rAd-mediated shRNA, significantly reduces mtROS levels demonstrating a role of Arg-II in the production of mitochondrial ROS in cardiac fibroblasts (Fig 8M to 8P). We have included these results on page 9, the last paragraph and discussed the results on page 17, the 1st paragraph. The related method is described on page 26, the 2nd paragraph. Legend to Fig. 8 is updated on page 32.</p><disp-quote content-type="editor-comment"><p>(15) Figure 8A-E: The authors have treated human-origin endothelial cells with mice-origin macrophage-conditioned media. It would be more suitable to treat the endothelial cells with human-origin macrophage-conditioned media.</p></disp-quote><p>We acknowledge the concern regarding the use of mouse-origin macrophage-conditioned media on human-origin endothelial cells. It is to note, the biological cross-reactivity of cytokines from one species on cells from a different species has been reported in the literature. It was observed that there is quite a strict threshold of 60% amino acid identity, above which cytokines tend to cross-react and statistically, cytokines would tend to cross-react more often as their % amino acid identity increases (Scheerlinck JPY. Functional and structural comparison of cytokines in different species. Vet Immunol Immunopathol. 1999; 72:39-44. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S0165-2427(99)00115-4">https://doi.org/10.1016/S0165-2427(99)00115-4</ext-link>). Taking IL-1b as an example, the 17.5 kDa mature mouse and human IL-1b share 92% aa sequence identity, suggesting a high cross-reactivity. Indeed, human IL-1b has shown biological cross-reactivity in mouse cells (Ledesma E., et al. Interleukin-1 beta (IL-1β) induces tumor necrosis factor alpha (TNF-α) expression on mouse myeloid multipotent cell line 32D cl3 and inhibits their proliferation. Cytokine. 2004; 26:66-72. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.cyto.2003.12.009">https://doi.org/10.1016/j.cyto.2003.12.009</ext-link>). Moreover, our results also support the reported cross-reactivity between human and mouse IL-1b. The CM from mouse macrophage indeed showed biological function in human endothelial cells. The observed effects of the conditioned media from aged wild-type macrophages on endothelial cells were specifically mediated through IL-1β. This conclusion is supported by our data showing that the upregulation induced by the conditioned media was significantly reduced by the addition of an IL-1β receptor blocker.</p><disp-quote content-type="editor-comment"><p>(16) The co-culture system would be more interesting to test the non-cell autonomous role of Arg II.</p></disp-quote><p>We appreciate the suggestion by this reviewer regarding the co-culture system to test the non-cell autonomous role of Arg-II. We believe that our current model, which involves treating cells with conditioned media, is a well-established and effective method for demonstrating the non-cell autonomous role of Arg-II. This approach allows us to observe the effects of Arg-II on surrounding cells through the factors present in the conditioned media. The co-culture system could be considered, if the released factor in the conditioned medium is not stable. This is however not the case. So we are confident that our experimental model with conditioned medium is good enough to demonstrate a paracrine effect of cell-cell interaction.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations For The Authors):</bold></p><p>Some minor comments may be considered to improve the realm of the knowledge related to this study.</p></disp-quote><p>We appreciate this comment and have added and revised our discussion on this aspect accordingly at the end of the discussion section on page 19, the last 6 lines.</p><disp-quote content-type="editor-comment"><p>(1) The current study showed strong evidence demonstrating the key role of cardiac macrophages in pathologies of cardiac aging, particularly, the macrophages (MФ) from the circulating blood (hematogenous). It is known that the heart is among the minority of organs in which substantial numbers of yolk-sac MФ persist in adulthood and play a crucial role in maintaining cardiac function. Thus, the adult mammalian heart contains two separate and discrete cardiac MФ subgroups, i.e., the resident MФs originated from yolk sac-derived progenitors and the hematogenous MФs recruited from circulating blood monocytes. These two subtypes of MФs may play distinctive roles in the aging heart and the response to cardiac injury. The author could extend the discussion on the possibility of the resident MФs in aging hearts, which could be further investigated in the future.</p></disp-quote><p>We appreciate the suggestion and agree that it provides valuable insight into the study. Taking the comments of the reviewer 1 into account, we have performed new experiments, i.e., co- immunostaining to analyze the infiltrated (CCR2<sup>+</sup>/F4-80<sup>+</sup>) and resident (LYVE1<sup>+</sup>/F4-80<sup>+</sup>) macrophage populations and to investigate to which extent that Arg-II affects infiltrated and resident macrophage populations in the aging heart. We found that in line with the gene expression of <italic>f4/80</italic>, immunofluorescence staining reveals an age-associated increase in the numbers of F4/80<sup>+</sup> cells in the <italic>wt</italic> mouse heart, which is reduced in the age-matched <italic>arg-ii-/-</italic> animals (Fig. 2E, F, G), demonstrating that <italic>arg-ii</italic> gene ablation reduces macrophage accumulation in the aging heart. Interestingly, resident macrophages as characterized by LYVE1<sup>+</sup>/F4-80<sup>+</sup> cells (Fig. 2E and 2H) are predominant in the aging heart as compared to the infiltrated CCR2<sup>+</sup>/F4-80<sup>+</sup> cells (Fig. 2F and 2I). The increase in both LYVE1<sup>+</sup>/F4-80<sup>+</sup> and CCR2<sup>+</sup>/F4-80<sup>+</sup> macrophages in aging heart is reduced in <italic>arg-ii-/-</italic> mice (Fig. 2E, 2F, 2H, and 2I). These new results are described on page 6, the 1st paragraph, presented in Fig. 2E to 2I, and discussed on page 13, the 2nd, paragraph. The legend to Fig. 2 is revised. The method for this additional experiment is included on page 22, the 1st paragraph.</p><disp-quote content-type="editor-comment"><p>(2) It would be beneficial to the readers if the author could provide some explanation about why ArgII could not be detected in VSMCs in the mouse heart and the species difference between humans and mice. In addition, the author may provide an assumption on the possibility that there may also be a cross-talk between macrophages and VSMCs in the aging heart. A little bit more explanation in the Discussion will be helpful.</p></disp-quote><p>We acknowledge and appreciate the suggestion and have discussed these points on page 19 as the following:</p><p>“In this context, another interesting aspect is the cross-talk between macrophages and vascular SMC in the aging heart. In our present study, we could not detect Arg-II in vascular SMC of mouse heart but in that of human heart. This could be due to the difference in species-specific Arg-II expression in the heart or related to the disease conditions in human heart which is harvested from patients with cardiovascular diseases. Indeed, in the <italic>apoe-/-</italic> mouse atherosclerosis model, aortic SMCs do express Arg-II (Xiong et al., 2013). It is interesting to note that rodents hardly develop atherosclerosis as compared to humans. Whether this could be partly contributed by the different expression of Arg-II in vascular SMC between rodents and humans requires further investigation. In our present study, the aspect of the cross-talk between macrophages and vascular SMC is not studied. Since the crosstalk between macrophages and vascular SMC has been implicated in the context of atherogenesis as reviewed (Gong et al., 2025), further work shall investigate whether Arg-II expressing macrophages could interact with vascular SMC in the coronary arteries in the heart and contribute to the development of coronary artery disease and/or vascular remodelling and the underlying mechanisms“.</p><disp-quote content-type="editor-comment"><p>(3) Please clarify the arrows in Figure 9C that indicate the infarct area in each splicing section from one heart.</p></disp-quote><p>The arrows in Figure 9C (now Fig. 10C) are indeed utilized to indicate the sections displaying the infarcted area within each splicing section from one heart. We have explained the arrow in the figure legend (now Fig. 10 and also new Suppl. Fig. 9).</p></body></sub-article></article>